company_name,website_timestamp,preclinical_stage,drug_molecule,target,therapeutic_area,target_type,development_stage,small_molecules,small_molecules_keyword,small_molecules_source_url,peptides,peptides_keyword,peptides_source_url,proteins,proteins_keyword,proteins_source_url,antibodies,antibodies_keyword,antibodies_source_url,antibody_conjugates,antibody_conjugates_keyword,antibody_conjugates_source_url,fusion_proteins,fusion_proteins_keyword,fusion_proteins_source_url,nucleic_acid_therapeutics,nucleic_acid_therapeutics_keyword,nucleic_acid_therapeutics_source_url,gene_cell_therapies,gene_cell_therapies_keyword,gene_cell_therapies_source_url,vaccines,vaccines_keyword,vaccines_source_url,protein_degraders,protein_degraders_keyword,protein_degraders_source_url,other_modalities,other_modalities_keyword,other_modalities_source_url
vanquish oncology inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='vanquishoncology.com', p",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
spectranetics corp,Error: can't compare offset-naive and offset-aware dateti,No,AMT-253; mecbotamab vedotin,"MCAM, Melanoma Cell Adhesion Molecule; AXL, AXL Receptor Tyrosine Kinase",oncology,other; kinases,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nordisk rebalance a/s,"Error: Connection failed - HTTPSConnectionPool(host='se.linkedin.com', port=4",Yes,Semaglutide; Liraglutide,"GLP1R, Glucagon-like Peptide 1 Receptor",metabolic diseases,gpcr,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,postbiotic fermented oat gruel,https://pubmed.ncbi.nlm.nih.gov/36570171/
enveric biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,novel neuroplastogenic small-molecule therapeutics,https://www.linkedin.com/company/envericbio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ananda scientific inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Nantheia A1002; Nantheia ATL5; Nantheia A1002N5S,Disease Name,neuropsychiatric disorders; opioid use disorder; PTSD; social anxiety; neuropathic pain; smoking cessation,Not specified,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Liquid Structure™ Technology,https://anandascientific.com/
dracen pharmaceuticals inc,2023-09-10 00:00:00,No,Not specified,Not specified,oncology,Not specified,Not specified,Yes,leveraging immuno-metabolism to create a potential new treatment paradigm,https://www.linkedin.com/company/dracen-pharmaceuticals-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
clerkenwell health,2025-10-01 08:29:23,No,PCN-101; RL-007; DMT-1002; GRX-917; KUR-101; EMP-01; RLS-01; NN-101; VLS-01,Treatment-resistant depression; Cognitive impairment associated with schizophrenia; Opioid use disorder; Generalized anxiety disorder; Post-traumatic stress disorder; Mild-traumatic brain injury,CNS; psychiatry; mental health disorders,Not specified,Preclinical; Phase 1; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,psychedelics-assisted medical treatments,https://psychedelicalpha.com/news/brain-scanning-technology-to-be-used-for-clinical-psychedelics-trials-in-pioneering-london-start-up-partnership
vasa therapeutics sp zoo,2025-10-13 08:42:49,Yes,VS-041,"MMPs, Matrix Metalloproteinases",cardiovascular; metabolic diseases,enzyme,Phase 1,Yes,"VS-041 is a selective, first-in-class MMP inhibitor for treatment of HFpEF and other cardiovascular indications",https://firstwordpharma.com/story/5968825,Yes,Long acting apelin peptide analogs for combination treatment with incretins in obesity patients,https://www.linkedin.com/company/vasa-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rest therapeutics sas,"Error: Connection failed - HTTPSConnectionPool(host='cordis.europa.eu', port=",Yes,GR-28; Triacsin C,"REST, Repressor Element-1 Silencing Transcription Factor; SCP1, Small C-terminal Domain Phosphatase 1",oncology,enzyme,Preclinical,Yes,RST-01 targets specific NMDA receptors sub-types,https://www.linkedin.com/company/rest-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
island pharmaceuticals ltd,"Error: Connection failed - HTTPSConnectionPool(host='au.linkedin.com', port=4",No,ISLA-101; Galidesivir,Dengue Fever; Marburg Virus,infectious diseases,other,Preclinical,Yes,drug repurposing company,https://www.cnbc.com/quotes/ILPLF,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
signpath pharma inc,2016-02-27 00:00:00,No,LipoCurc; SPP4040,"PD-L1, Programmed Death-Ligand 1; PD-L2, Programmed Death-Ligand 2; B7, B7 Protein; IDO, Indoleamine 2,3-dioxygenase; TNF-alpha, Tumor Necrosis Factor-alpha; IL-1 beta, Interleukin-1 beta; IL-6, Interleukin-6; Interferon gamma",oncology; cardiology,immune checkpoint; cytokine; enzyme,Phase 2,Yes,"SPP4040, a lipid-based drug which is administered orally",https://signpathpharma.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"LipoCurc™, Signpath’s patented Liposomal Curcumin product",https://signpathpharma.com/
promore pharma ab,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,ensereptide,"Disease Name, Scarring on skin",dermatology,Not specified,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
umecrine cognition ab,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,golexanolone,"GABAA receptor, Gamma-Aminobutyric Acid Type A receptor",CNS; neuroinflammation; liver diseases; neurodegenerative diseases,nuclear receptors,Phase 2,Yes,novel small molecule GABAA receptor-modulating steroid antagonist,http://www.umecrinecognition.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
synthorx inc,2020-01-23 00:00:00,Yes,THOR-707,"IL-2, Interleukin-2",oncology; immunology,cytokine,Phase 1,No,,,No,,,Yes,Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair,https://www.linkedin.com/company/synthorx-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair,https://www.linkedin.com/company/synthorx-inc-
inhibitex llc,"Error: Connection failed - HTTPSConnectionPool(host='drug-dev.com', port=443)",No,AdAPT-001; SRK-181; STP 707; SIS 201 CD; IOA-359; Elritercept; ISTH0036; TU-2218; AGMB-129; IO170; ES 014; SHR-1701; HEC585; RO7204239; ESN-Y,"TGF-β, Transforming Growth Factor Beta; ALK5, Activin Receptor-Like Kinase 5",oncology; fibrosis; gastrointestinal diseases,cytokine; enzyme,Phase 3; Phase 2; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
urcc ncorp research base,"Error: Connection failed - HTTPSConnectionPool(host='prevention.cancer.gov', ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
elgan pharma ltd,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,evenamide,Disease Name,CNS,Not specified,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
advantage therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,AD04,Not specified,CNS; neurodegenerative diseases,other,Phase 2,No,,,No,,,Yes,Klotho protein,https://advantagetherapeutics.com/,No,,,No,,,No,,,Yes,mRNA approach,https://advantagetherapeutics.com/,No,,,Yes,vaccine candidate against AD,https://advantagetherapeutics.com/,No,,,Yes,nanocarriers for repeated administration,https://advantagetherapeutics.com/
privo technologies inc,2025-05-25 22:24:33,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,small molecules,https://www.linkedin.com/company/privo-technologies,No,,,No,,,Yes,Monoclonal Antibodies,https://www.linkedin.com/company/privo-technologies,No,,,No,,,No,,,No,,,No,,,No,,,Yes,nanotechnology-based drug delivery platform,https://www.linkedin.com/company/privo-technologies
quadram institute bioscience,"Error: Connection failed - HTTPSConnectionPool(host='uk.linkedin.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vgi health technology limited,Error: Connection failed - HTTPSConnectionPool(host='www.pittstreetresearch.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vgi health technology ltd,Error: Connection failed - HTTPSConnectionPool(host='www.pittstreetresearch.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Exosome-based therapeutics,https://www.marketscreener.com/quote/stock/VGI-HEALTH-TECHNOLOGY-LIM-124598851/
cyclo therapeutics inc,2025-10-13 15:13:11,No,Trappsol Cyclo,Niemann-Pick Type C disease; Alzheimer's disease,rare diseases; CNS,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
duke street bio ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,DSB2455,"PARP1, Poly (ADP-ribose) Polymerase 1; PARP7, Poly (ADP-ribose) Polymerase 7",oncology,enzyme,Preclinical,Yes,highly selective and CNS-penetrant PARP1 inhibitor #DSB2455,https://uk.linkedin.com/company/duke-street-bio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
forbius,2019-11-14 00:00:00,No,AVID200,"TGF-beta 1 and 3, Transforming Growth Factor-beta 1 and 3",oncology; fibrotic diseases,cytokine,Phase 2,No,,,No,,,Yes,protein engineering technologies,https://www.linkedin.com/company/forbius,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
celtic biotech iowa inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,nirogacestat,"Notch, Notch-signaling pathway",oncology,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,specialized receptor binding proteins found in snake venom,https://www.clinicalleader.com/doc/spotlight-innovation-subsidiary-celtic-iowa-cohorts-phase-i-trial-crotoxin-treatment-cancer-0001
resother pharma aps,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,RTP-026,"FPR2, Formyl Peptide Receptor 2",cardiovascular,gpcr,Phase 2,No,,,Yes,peptide-based drugs derived from Annexin A1,https://www.ventureradar.com/organisation/ResoTher%20Pharma%20ApS/c40201a0-626d-45ba-ad04-7048e12f050c,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
longboard pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='www.lundbeck.com', port=",No,LP352,"5-HT2C, 5-Hydroxytryptamine Receptor 2C",CNS; rare neurological diseases,gpcr,Phase 3,Yes,small molecule product candidates,https://www.linkedin.com/company/longboard-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
remegen co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.remegen.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,RC28-E is a VEGF/FGF dual-target fusion protein drug,https://www.prnewswire.com/news-releases/remegen-and-santen-enter-into-exclusive-licensing-agreement-for-ophthalmic-innovative-drug-rc28-e-in-greater-china-and-asian-countries-302532212.html,No,,,No,,,Yes,RC28-E is a VEGF/FGF dual-target fusion protein drug,https://www.prnewswire.com/news-releases/remegen-and-santen-enter-into-exclusive-licensing-agreement-for-ophthalmic-innovative-drug-rc28-e-in-greater-china-and-asian-countries-302532212.html,No,,,No,,,No,,,No,,,No,,
cantargia ab,2025-10-07 12:36:40,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,Cantargia develops antibody based therapies against the target IL1RAP.,https://www.linkedin.com/company/cantargia-ab/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"palvella therapeutics, inc",2025-10-16 00:00:00,No,QTORIN™ rapamycin,PI3K/AKT/mTOR pathway,rare diseases; dermatology,kinases,Phase 3,Yes,QTORIN™ 3.9% rapamycin anhydrous gel,https://www.stocktitan.net/news/PVLA/u-s-food-and-drug-administration-awards-year-two-proceeds-from-uy95g7vt6r8f.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
guangzhou egg biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.newtbdrugs.org', por",No,DX126-262,"HER2, Human Epidermal Growth Factor Receptor 2",oncology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
celtic biotech iowa inc,"Error: Connection failed - HTTPSConnectionPool(host='ie.linkedin.com', port=4",Yes,CB-24,"TRPV6, Transient Receptor Potential Vanilloid 6",oncology,ion channels,Phase 1,No,,,No,,,Yes,specialized receptor binding proteins found in snake venom,https://www.clinicalleader.com/doc/spotlight-innovation-subsidiary-celtic-iowa-cohorts-phase-i-trial-crotoxin-treatment-cancer-0001,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
medivir ab,2025-06-12 14:09:39,Yes,Fostroxacitabine bralpamide; Remetinostat; MIV-711; Birinapant; Xerclear,Not specified,oncology; infectious diseases; rare diseases,enzyme; other; Not specified,Phase 1; Phase 2; Preclinical; Marketed,Yes,Nucleotide DNA polymerase inhibitor (oral),https://www.medivir.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
yaqrit ltd,"Error: Connection failed - HTTPSConnectionPool(host='uk.linkedin.com', port=4",Yes,YAQ006; YAQ007; YAQ005,Hyperammonemia,liver diseases; hepatic encephalopathy,enzyme,Phase 3,Yes,YAQ007 (our oral L-OPA ammonia scavenger),https://uk.linkedin.com/company/yaqrit-ltd,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"toll-like receptor 4 antagonist, YAQ005",https://uk.linkedin.com/company/yaqrit-ltd
strekin ag (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.startupticker.ch', p",No,STR001,Not specified,CNS,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immupharma plc,"Error: Connection failed - HTTPSConnectionPool(host='www.immupharma.co.uk', p",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
antev ltd,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Teverelix,"GnRH, Gonadotropin-Releasing Hormone",oncology; urology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
phoenicis therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,QR 313,Not specified,rare diseases; dermatology,Not specified,Phase 1/II,No,,,No,,,Yes,decorin (a natural protein found in humans),https://cure-eb.org/research-portfolio/fibrx-derm/,No,,,No,,,No,,,Yes,antisense oligonucleotide targeting exon 73 in the COL7A1 gene,https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=600217,No,,,No,,,No,,,No,,
provention bio inc,2023-03-13 00:00:00,Yes,Teplizumab; PRV-3279; PRV-015; PRV-101,"Disease Name, Type 1 Diabetes; CD32B, Cluster of Differentiation 32B; CD79B, Cluster of Differentiation 79B; IL-15, Interleukin-15",immunology; autoimmune diseases,immune checkpoint; cytokine; other,Approved; Phase 2; Phase 3,No,,,No,,,No,,,Yes,CD3-directed antibody,https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367,No,,,No,,,No,,,No,,,No,,,No,,,No,,
lexaria bioscience corp,"Error: Connection failed - HTTPSConnectionPool(host='ca.linkedin.com', port=4",Yes,Semaglutide; FTS,"GLP-1R, Glucagon-Like Peptide-1 Receptor",metabolic diseases; CNS,gpcr,Preclinical,Yes,Lexaria’s DehydraTECH technology improves the way active pharmaceutical ingredients (APIs) enter the bloodstream,https://www.investorbrandnetwork.com/clients/lexaria-bioscience-corp/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Lexaria licenses its fat-soluble active molecule delivery technology to multiple established companies,https://www.investorbrandnetwork.com/clients/lexaria-bioscience-corp/
bionomics ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.iposcoop.com', port=",Yes,BNC210,"α7 nAChR, Alpha-7 Nicotinic Acetylcholine Receptor",CNS,ion channels,Phase 2,Yes,"BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor",https://www.nasdaq.com/articles/bionomics-limited-shareholders-approve-re-domiciliation-united-states-neuphoria,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
novelmed therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.sbir.gov', port=443)",No,NM8074,Not specified,rare diseases,Not specified,Not specified,No,,,No,,,No,,,Yes,"Alternative Pathway-specific antibodies (NM8074, NM5072, and NM8070)",https://www.globenewswire.com/news-release/2025/05/19/3084225/0/en/NovelMed-s-Phase-II-Data-in-Paroxysmal-Nocturnal-Hemoglobinuria-PNH-Patients-Ruxoprubart-Shows-Best-in-Class-Efficacy-as-Monotherapy.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
genzyme corp,2023-07-25 01:18:18,No,Venglustat,Not specified,rare diseases,enzyme,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"vaccines division, rabies and anthrax vaccines",https://www.statnews.com/2022/02/03/sanofi-genzyme-boston-name/,No,,,No,,
cellusion inc,2024-11-06 01:26:58,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Development of cell therapy for bullous keratopathy using iPS cells,https://www.linkedin.com/company/cellusion/,No,,,No,,,No,,
secretome therapeutics,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,Yes,STM-01; STM-21; Dovitinib; Nintedanib,"HFpEF, Heart Failure with Preserved Ejection Fraction; DCM, Dilated Cardiomyopathy; FGFR4, Fibroblast Growth Factor Receptor 4; FLT1, Fms-Related Tyrosine Kinase 1; WNT5A, Wingless-Type MMTV Integration Site Family Member 5A",cardiovascular; oncology,other; kinases,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,neonatal cardiac progenitor cell (nCPC)-derived cell therapy,https://www.cgtlive.com/view/secretome-therapeutics-doses-first-patient-phase-1-trial-heart-failure-cell-therapy-stm-01,No,,,No,,,Yes,"secretomes, naturally occurring molecules that promote healing and regeneration",https://dallasinnovates.com/secretome-therapeutics-appoints-new-chief-medical-officer/
valo therapeutics oy,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,Yes,PeptiCRAd,Disease Name,oncology,other,Preclinical,No,,,Yes,disease-specific peptides,https://www.linkedin.com/company/valo-therapeutics/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,therapeutic vaccination platforms,https://www.linkedin.com/company/valo-therapeutics/,No,,,Yes,oncolytic viruses,https://www.linkedin.com/company/valo-therapeutics/
celonova biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Embozene TANDEM; ONCOZENE; Embozene,"Disease Name, Liver Cancer; Disease Name, Hypervascular Tumors; Disease Name, Uterine Fibroids; Disease Name, Arteriovenous Malformations; Disease Name, Hepatoma",oncology; interventional radiology,other,Investigational,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Drug-eluting microspheres designed to be loaded with chemotherapy drugs for delivery to cancerous tumors,https://news.bostonscientific.com/2015-11-10-Boston-Scientific-To-Acquire-Interventional-Radiology-Business-Of-CeloNova-Biosciences
rubius therapeutics inc,2021-04-16 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,genetically engineer and culture Red Cell Therapeutics™,https://www.linkedin.com/company/rubius-therapeutics,No,,,No,,,Yes,potent cell-cell interaction and tolerance induction,https://www.linkedin.com/company/rubius-therapeutics
bellus health inc,2022-01-14 00:00:00,No,camlipixant,"P2X3, Purinergic Receptor X3",respiratory diseases,ion channels,Phase 3,Yes,twice-daily oral P2X3 receptor antagonist,https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-bellus-health/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
beijing pearl biotechnology llc,"Error: Connection failed - HTTPSConnectionPool(host='www.bioworld.com', port=",No,PLB1001; ANS03,"c-Met, Mesenchymal-Epithelial Transition Factor; ROS1, ROS Proto-Oncogene 1; NTRK, Neurotrophic Tyrosine Receptor Kinase",oncology,kinases,Approved; Phase 1,No,,,No,,,Yes,novel biologics with diverse chemistries,https://www.pearlbio.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,template-directed biomaterials with tunable properties,https://www.pearlbio.com/
h3 biomedicine inc,"Error: Connection failed - HTTPSConnectionPool(host='www.bionity.com', port=4",Yes,H3B-6545,"ERα, Estrogen Receptor Alpha",oncology,nuclear receptors,Phase 2,Yes,advancing drugs from bench to bedside,https://media-us.eisai.com/2021-08-30-Eisai-Announces-New-Executive-Leadership-Team-at-H3-Biomedicine,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tolero pharmaceuticals inc,Error: Connection failed - HTTPSConnectionPool(host='www.sumitomo-pharma.com',No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,targets important biological drivers of blood disorders,https://www.linkedin.com/company/tolero-pharmaceuticals-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arrowhead pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,Plozasiran; ARO-APOC3; Zodasiran; ARO-ANG3,"ApoC3, Apolipoprotein-CIII; ANGPTL3, Angiopoietin-like Protein 3",cardiometabolic; dyslipidemia,enzyme,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNAi technology makes it possible to target the genes that cause disease.,https://arrowheadpharma.com/,No,,,No,,,No,,,No,,
spyre therapeutics inc,2025-10-15 22:11:54,Yes,SPY001; SPY002; SPY003; SPY120; SPY130,α4β7; TL1A; IL-23,gastrointestinal; rheumatological; immune-mediated diseases,cytokine,Phase 2,No,,,No,,,No,,,Yes,Spyre is developing next-generation antibodies that are engineered for prolonged activity in the body,https://www.spyre.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
dicerna pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='www.linkedin.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNAi (ribonucleic acid interference),https://www.linkedin.com/company/dicerna-pharmaceuticals-inc.,No,,,No,,,No,,,No,,
praxis precision medicines inc,2025-10-16 17:43:24,Yes,Not specified,Not specified,CNS,Not specified,Phase 2,Yes,small molecule inhibitor of T-type calcium channels,https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-announces-positive-topline-results-from-jtbxnj5gm2ot.html,No,,,No,,,No,,,No,,,No,,,Yes,"antisense oligonucleotide (ASO) platform, Solidus™",https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-announces-positive-topline-results-from-jtbxnj5gm2ot.html,No,,,No,,,No,,,No,,
crescent biopharma inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,CR-001; CR-002; CR-003,"PD-1, Programmed Death-1; VEGF, Vascular Endothelial Growth Factor",oncology,immune checkpoint; cytokine,Preclinical,No,,,No,,,No,,,Yes,PD-1 x VEGF bispecific antibody,https://www.globenewswire.com/news-release/2025/06/16/3099691/0/en/Crescent-Biopharma-Completes-Closing-of-Merger-with-GlycoMimetics-and-Previously-Announced-Private-Placement-of-200-Million.html,Yes,novel antibody-drug conjugates (ADCs),https://www.globenewswire.com/news-release/2025/06/16/3099691/0/en/Crescent-Biopharma-Completes-Closing-of-Merger-with-GlycoMimetics-and-Previously-Announced-Private-Placement-of-200-Million.html,No,,,No,,,No,,,No,,,No,,,No,,
beijing anshi biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='equalocean.com', port=44",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sichuan kelun botai biomedical co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.globaldata.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
upstream bio inc,2025-10-14 17:39:04,No,verekitug,"TSLP, Thymic Stromal Lymphopoietin receptor",respiratory diseases,cytokine,Phase 2,No,,,No,,,No,,,Yes,clinical-stage monoclonal antibody targeting an upstream driver of inflammatory response,https://www.linkedin.com/company/upstreambio,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sironax ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,SIR2501; SIR4156; SIR9900; SIR2446; SIR8752; SIR0365,"SARM1, Sterile Alpha and TIR Motif Containing 1; NAMPT, Nicotinamide Phosphoribosyltransferase; RIPK1, Receptor-Interacting Serine/Threonine-Protein Kinase 1",neurodegenerative diseases; neuronal and muscular degenerative diseases; inflammation; immunology; CNS,enzyme; enzyme; kinases,Phase 1,Yes,multiple clinical-stage small molecule programs,https://www.sironax.com.cn/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Brain Delivery Module platform,https://www.sironax.com.cn/
abcuro inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,anti-KLRG1 antibody,https://www.linkedin.com/company/abcuro-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nikang therapeutics inc,2025-09-08 12:23:23,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,novel small molecule oncology drug discovery,https://www.linkedin.com/company/nikang-therapeutics-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CDK2 PROTAC Degrader,https://www.linkedin.com/company/nikang-therapeutics-inc,No,,
adarx pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='www.baincapital.com', po",Yes,Not specified,Not specified,neuroscience; immunology; oncology; complement-mediated diseases; cardiovascular diseases; thrombotic diseases; metabolic diseases,other,Preclinical; Phase 1,No,,,No,,,No,,,Yes,AbbVie will contribute its expertise in antibody engineering,https://news.abbvie.com/2025-05-14-AbbVie-and-ADARx-Pharmaceuticals-Announce-Collaboration-and-License-Option-Agreement-to-Develop-Next-Generation-siRNA-Therapies-Across-Multiple-Therapeutic-Areas,Yes,AbbVie will contribute its expertise in antibody drug conjugates (ADCs),https://news.abbvie.com/2025-05-14-AbbVie-and-ADARx-Pharmaceuticals-Announce-Collaboration-and-License-Option-Agreement-to-Develop-Next-Generation-siRNA-Therapies-Across-Multiple-Therapeutic-Areas,No,,,Yes,ADARx's proprietary RNA technology to advance next-generation siRNA therapies,https://news.abbvie.com/2025-05-14-AbbVie-and-ADARx-Pharmaceuticals-Announce-Collaboration-and-License-Option-Agreement-to-Develop-Next-Generation-siRNA-Therapies-Across-Multiple-Therapeutic-Areas,No,,,No,,,No,,,No,,
theras inc,2024-05-02 08:35:54,Yes,ACR-368; ACR-2316,"DNA Damage Response; WEE1, WEE1-like protein kinase; PKMYT1, Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase",oncology,kinases,Phase 2; Preclinical,Yes,developing drugs that target two common cancer genes,https://www.biopharmadive.com/news/bridge-bio-oncology-launch-kras-cancer-drug-theras/714885/,No,,,Yes,protein-protein interaction inhibitor,https://www.biopharmadive.com/news/bridge-bio-oncology-launch-kras-cancer-drug-theras/714885/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
clarity pharmaceuticals ltd,Error: Connection failed - HTTPSConnectionPool(host='www.claritypharmaceutica,No,64 Cu-SAR-bisPSMA,"PSMA, Prostate-Specific Membrane Antigen",oncology,enzyme,Phase 2,No,,,Yes,Antibody and peptide imaging,https://au.linkedin.com/company/clarity-pharmaceuticals,No,,,Yes,Antibody and peptide imaging,https://au.linkedin.com/company/clarity-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Radiopharmaceuticals, Nuclear medicine, Targeted therapy",https://au.linkedin.com/company/clarity-pharmaceuticals
novo holdings as,2025-10-10 01:20:55,No,CagriSema,"GLP-1, Glucagon-Like Peptide-1; Amylin",cardiometabolic; obesity,gpcr; other,Phase 3,Yes,"EXPD-101, a once-daily, oral DPP1 inhibitor",https://www.linkedin.com/company/novo-a-s/,No,,,Yes,biologic product formulation concentrations of 400-500 mg/ml,https://www.linkedin.com/company/novo-a-s/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
urica therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='drug-dev.com', port=443)",No,dotinurad,"URAT1, Uric Acid Transporter 1",metabolic diseases,enzyme,Phase 3,Yes,"Dotinurad, a potentially best-in-class URAT1 inhibitor",https://www.linkedin.com/company/urica-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
crystalys therapeutics inc,2025-09-30 08:00:00,No,dotinurad,"URAT1, Uric Acid Transporter 1",metabolic diseases,enzyme,Phase 3,Yes,"Dotinurad is a next-generation, once daily oral, URAT1 inhibitor",https://www.prnewswire.com/news-releases/crystalys-therapeutics-launches-with-205m-series-a-financing-to-transform-the-treatment-of-gout-302569747.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aviadobio ltd,2024-10-08 09:27:00,No,UGX-202,Retinitis Pigmentosa,CNS; rare diseases,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,AAV-based gene therapy,https://www.prnewswire.com/news-releases/astellas-and-aviadobio-announce-exclusive-option-and-license-agreement-for-gene-therapy-avb-101-targeting-frontotemporal-dementia-and-other-indications-302270158.html,No,,,No,,,No,,
kanglin biotech hangzhou co ltd,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",Yes,KL003,"ß-globin, Beta-globin gene",blood disorders,other,Phase 2,No,,,No,,,No,,,Yes,monoclonal antibodies,https://www.cbinsights.com/company/kanglin-biotec,No,,,No,,,No,,,Yes,lentiviral vector gene therapy,https://www.globenewswire.com/news-release/2024/11/25/2986543/0/en/Kanglin-Biotechnology-Announces-20-Million-Series-A-Financing-to-Advance-the-Development-of-Gene-Therapies.html,No,,,No,,,No,,
acea biosciences inc,2019-04-01 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,Antibody Research,https://www.linkedin.com/company/acea-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Cell-based assays, Cancer research, Drug Screening, Infectious Disease Research, Stem Cell Research",https://www.linkedin.com/company/acea-biosciences
bioinvent international ab,"Error: Connection failed - HTTPSConnectionPool(host='www.globaldata.com', por",Yes,BI-1808; BI-1206; BT-001,"TNFR2, Tumor Necrosis Factor Receptor 2; FcγRIIB, Fc Gamma Receptor IIB; CTLA4, Cytotoxic T-Lymphocyte-Associated Protein 4; GM-CSF, Granulocyte-Macrophage Colony-Stimulating Factor",oncology; hematological cancer; solid tumors; T-cell lymphoma,immune checkpoint; cytokine,Phase 2,No,,,No,,,No,,,Yes,Discovering and developing antibody therapeutics that improve the treatment of cancer,https://www.bioinvent.com/en,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Armed Oncolytic Virus BT-001,https://www.bioinvent.com/en
concentric analgesics inc,2022-02-26 00:00:00,No,Vocacapsaicin; CA-008,"TRPV1, Transient Receptor Potential Vanilloid 1",pain management; CNS,ion channels,Phase 2,Yes,developing breakthrough non-opioid pain therapeutics,https://www.linkedin.com/company/concentric-analgesics-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cue biopharma inc,2025-04-21 01:24:18,No,CUE-401,"FOXP3, Forkhead Box P3",autoimmune diseases,cytokine,Preclinical,No,,,No,,,Yes,engineered biologics are designed to mimic nature’s signals to selectively expand and activate specific immune cells,https://www.cuebiopharma.com/,No,,,No,,,Yes,tolerizing bifunctional molecule for the potential treatment of autoimmune diseases,https://www.linkedin.com/company/cuebiopharma,No,,,No,,,No,,,No,,,Yes,Immuno-STAT® biologics are uniquely designed to mobilize the patient’s immune system to treat serious diseases,https://www.linkedin.com/company/cuebiopharma
codiak biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ardelyx inc,2025-10-16 17:00:24,No,Tenapanor; RDX013; IBSRELA,"NHE3, Sodium-Hydrogen Exchanger 3",renal diseases; gastrointestinal disorders,ion channels,Approved; Phase 2,Yes,IBSRELA® (tenapanor) and XPHOZAH® (tenapanor),https://www.linkedin.com/company/ardelyx-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ocugen inc,2025-10-15 21:07:07,Yes,OCU410ST; OCU400,"RORA, RAR Related Orphan Receptor A; ABCA4, ATP-binding cassette sub-family A member 4",rare diseases; ophthalmology,nuclear receptors; other,Phase 2/3; Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,modifier gene therapy platform,https://www.linkedin.com/company/ocugen,Yes,Inhaled Mucosal Vaccine Platform,https://www.cnbc.com/quotes/OCGN,No,,,No,,
catalyst biosciences inc,2025-06-22 00:00:00,Yes,CB 2679d; CB 2782,"Factor IX, Coagulation Factor IX; Factor XIIa, Coagulation Factor XIIa",rare diseases; hematology,enzyme,Phase 2; Phase 1,No,,,No,,,Yes,SQ administration of recombinant coagulation factors and complement inhibitors,https://www.linkedin.com/company/catalyst-biosciences,No,,,No,,,No,,,No,,,Yes,Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B,https://www.linkedin.com/company/catalyst-biosciences,No,,,No,,,No,,
molecular partners ag,2025-10-13 09:25:44,Yes,MP0712; MP0533,"DLL3, Delta-like Ligand 3; CD33 x CD123 x CD70 x CD3",oncology,other; other,Preclinical; Phase 1/2a,No,,,No,,,Yes,custom-built protein drugs,https://www.swissbiotech.org/listing/molecular-partners-ag/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,DARPins (Designed Ankyrin Repeat Protein),https://www.linkedin.com/company/molecular-partners-ag-zurich-switzerland
xcovery holding co llc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,ENSACOVE; PIQRAY; VIJOICE,"ALK, Anaplastic Lymphoma Kinase; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha",oncology; rare diseases,kinases,Marketed,Yes,small molecule that inhibits anaplastic lymphoma kinase (ALK),https://www.linkedin.com/company/xcovery-holding-co-llc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
beone medicines ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Zanubrutinib; Tislelizumab; Sonrotoclax; Zanidatamab; BGB-16673; Blinatumomab; Pamiparib; BG-68501; BGB-21447; BGB-43395; BGB-A3055; BGB-B455; BG-C9074; BGB-B2033; BG-C137; BGB-53038; BG-C477; BG-89894; BGB-58067,"BTK, Bruton Tyrosine Kinase; PD-1, Programmed Cell Death Protein 1; BCL2, B-cell Lymphoma 2; HER2, Human Epidermal Growth Factor Receptor 2; CD19, Cluster of Differentiation 19; PARP, Poly (ADP-ribose) Polymerase; CDK2, Cyclin-Dependent Kinase 2; CDK4, Cyclin-Dependent Kinase 4; CCR8, C-C Chemokine Receptor 8; CLDN6, Claudin 6; B7-H4, B7 Homolog 4; GPC3, Glypican-3; FGFR2b, Fibroblast Growth Factor Receptor 2b; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; CEA, Carcinoembryonic Antigen; MAT2A, Methionine Adenosyltransferase 2A; PRMT5, Protein Arginine Methyltransferase 5",hematologic malignancies; lung cancers; gastrointestinal cancers; breast/gynecologic cancers; solid tumors,kinases; immune checkpoint; enzyme; other,Approved; Phase 3; Phase 2; Phase 1,Yes,BTK inhibitor,https://www.linkedin.com/company/beonemedicines,No,,,No,,,No,,,Yes,Antibody Drug Conjugates,https://beonemedicines.com/,No,,,No,,,No,,,No,,,Yes,Pioneering Protein Degradation with CDACs,https://beonemedicines.com/,No,,
itabmed co ltd,"Error: Connection failed - HTTPSConnectionPool(host='itabmed.us', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
monopteros therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,MRT-6160; MRT-8102; MRT-2359,"VAV1, Rho-family Guanine Nucleotide Exchange Factor; NEK7, NIMA-related Kinase 7; GSPT1, G1 to S Phase Transition 1",immunology; inflammation; oncology,enzyme; enzyme; other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shenzhen oculgen biomedical technology co ltd,2024-11-30 16:17:42,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,"polypeptide, “peptide” , and “protein” are used interchangeably herein to designate a linear series of amino acid residues connected one to the other by peptide bonds",https://patents.google.com/patent/WO2024114641A1/fr,Yes,"polypeptide includes fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence",https://patents.google.com/patent/WO2024114641A1/fr,Yes,"anti-VEGF antibodies, VEGF Traps, etc.",https://patents.google.com/patent/WO2024114641A1/fr,No,,,Yes,"fusion protein comprising: (a) a complement component 5 (C5) binding domain, (b) a vascular endothelial growth factor (VEGF) binding domain, and (c) a multimerizing component",https://patents.google.com/patent/WO2024114641A1/fr,Yes,"Methods for producing the multi-specific molecules including the processes involving nucleic acids, vectors, expression vectors, and host vector system",https://patents.google.com/patent/WO2024114641A1/fr,No,,,No,,,No,,,No,,
diakonos oncology corp,2025-05-30 08:00:38,Yes,DOC1021,"Disease Name, Glioblastoma",oncology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,double-loaded dendritic cell therapy,https://www.linkedin.com/company/diakonos-oncology,No,,,No,,,Yes,dendritic cell-based treatments,https://www.linkedin.com/company/diakonos-oncology
edgewood oncology inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,Yes,CX-2051; CX-801,"EpCAM, Epithelial Cell Adhesion Molecule; IFN-α2b, Interferon Alpha-2b",oncology,enzyme; cytokine,Phase 1,Yes,BTX-A51—our first-in-class dual CK1α and CDK7/9 inhibitor,https://www.linkedin.com/company/edgewood-oncology,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
imbiologics corp,"Error: Connection failed - HTTPConnectionPool(host='imbiologics.com', port=80",Yes,IMB-101,"OX40L, OX40 Ligand; TNF, Tumor Necrosis Factor",autoimmune diseases; oncology,cytokine,Phase 1,No,,,No,,,No,,,Yes,bispecific antibody targeting OX40L and TNFα,https://www.linkedin.com/company/imbiologics-corp,Yes,ePENDY-ADC Therapeutics Development,https://www.linkedin.com/company/imbiologics-corp,No,,,No,,,No,,,No,,,No,,,Yes,"HLA-G explored in bispecifics, cell therapy, and RNA platforms",https://www.linkedin.com/company/imbiologics-corp
cellestia biotech ag,"Error: Connection failed - HTTPSConnectionPool(host='www.startupticker.ch', p",No,CB-103,Not specified,oncology; autoimmune diseases,Not specified,Phase 2,Yes,Small Molecules,https://www.linkedin.com/company/cellestia-biotech/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ginkgo tree pharmaceutical (suzhou) co ltd,"Error: Connection failed - HTTPSConnectionPool(host='pitchhub.36kr.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
elysium health inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
onyx pharmaceuticals inc,2002-06-09 00:00:00,No,Carfilzomib; Oprozomib,Proteasome,oncology,enzyme,Not specified,Yes,NEXAVAR® (sorafenib) tablets,https://www.europeanpharmaceuticalreview.com/organisations/onyx-pharmaceuticals-inc/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arbutus biopharma corp,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Imdusiran; AB-101,"HBV, Hepatitis B Virus; PD-L1, Programmed Death-Ligand 1",infectious diseases,other; immune checkpoint,Phase 2,Yes,"AB-101, our proprietary oral PD-L1 inhibitor",https://www.linkedin.com/company/arbutus-biopharma-corporation,No,,,No,,,No,,,No,,,No,,,Yes,"GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic",https://www.linkedin.com/company/arbutus-biopharma-corporation,No,,,No,,,No,,,No,,
imcheck therapeutics sas,Error: Connection failed - HTTPSConnectionPool(host='www.boehringer-ingelheim,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,immunotherapeutic antibodies targeting butyrophilins,https://www.linkedin.com/company/imcheck-therapeutics/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
myeloproliferative disorders-research consortium,"Error: Connection failed - HTTPSConnectionPool(host='reports.mountsinai.org',",Yes,Not specified,"JAK2, Janus Kinase 2",oncology; hematologic cancers,kinases,Preclinical,Yes,"MDM2 inhibitors, idasanutlin, navtemadlin",https://touchhaematology.com/podcast/laying-the-groundwork-for-medical-breakthroughs-the-mpn-rc-blueprint/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,haematopoietic stem cell transplantation,https://touchhaematology.com/podcast/laying-the-groundwork-for-medical-breakthroughs-the-mpn-rc-blueprint/,No,,,No,,,Yes,"TGFβ 1/3 trap, AVID200",https://touchhaematology.com/podcast/laying-the-groundwork-for-medical-breakthroughs-the-mpn-rc-blueprint/
phoenix tissue repair inc,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",Yes,AVB-114,Disease Name,rare diseases,other,Phase 2,No,,,No,,,Yes,protein replacement therapy which uses a recombinant collagen type VII (rC7),https://www.prnewswire.com/news-releases/phoenix-tissue-repair-receives-fda-fast-track-designation-for-ptr-01-for-the-treatment-of-dystrophic-epidermolysis-bullosa-deb-and-provides-updates-on-the-phase-12-clinical-study-300840334.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
alterity therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,broad drug discovery platform generating patentable chemical compounds,https://www.linkedin.com/company/alterity-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
angany inc,2024-03-11 13:48:35,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,novel bioparticle-based vaccines,https://nextmune.com/vet/blog-news/nextmune-angany,No,,,Yes,Bioparticle™-based biologics,https://nextmune.com/vet/blog-news/nextmune-angany
carna biosciences inc,2019-06-24 00:00:00,Yes,BMS-986165; Deucravacitinib,"TYK2, Tyrosine Kinase 2; JAK1, Janus Kinase 1",psoriasis; autoimmune diseases,kinases,Approved,Yes,small molecule compounds in immuno-oncology,https://www.gilead.com/news/news-details/2019/gilead-and-carna-biosciences-announce-research-and-development-collaboration-to-develop-novel-immuno-oncology-therapies,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"tranzyme pharma, inc. (formerly neokimia inc.) (inactive)",Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,Yes,TZP-201; TZP-301,Motilin; Ghrelin,gastrointestinal disorders; metabolic diseases,gpcr,Preclinical,Yes,proprietary small molecule macrocyclic template chemistry (MATCH™) technology,https://www.globenewswire.com/news-release/2013/02/08/522082/17400/en/Tranzyme-Pharma-Announces-Exploration-of-Strategic-Alternatives.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
innovative molecules gmbh,Error: Connection failed - HTTPSConnectionPool(host='www.innovativemolecules.,Yes,3BP-6146; NTA-476,"TROP-2, Trophoblast Cell-Surface Antigen 2; PSMA, Prostate-Specific Membrane Antigen; uPAR, Urokinase Plasminogen Activator Receptor",oncology,other,Preclinical; Phase 1,Yes,discovery and development of novel small molecule medicines,https://www.linkedin.com/company/innovative-molecules,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
formosa pharmaceuticals inc,2025-08-22 07:13:00,No,ALM-401; APP13007,"EGFR, Epidermal Growth Factor Receptor; ROR1, Receptor Tyrosine Kinase-like Orphan Receptor 1",oncology; ophthalmology,kinases,Approved; Preclinical,Yes,clobetasol propionate ophthalmic suspension,https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-adalvo-limited-announce-licensing-agreement-for-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-ocular-inflammation-and-pain-302465602.html,No,,,No,,,No,,,Yes,bispecific ADC targeting EGFR/ROR1,https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-adalvo-limited-announce-licensing-agreement-for-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-ocular-inflammation-and-pain-302465602.html,No,,,No,,,No,,,No,,,No,,,Yes,proprietary APNT ® nanoparticle formulation platform,https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-adalvo-limited-announce-licensing-agreement-for-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-ocular-inflammation-and-pain-302465602.html
fab’entech sa,Error: Connection failed - HTTPSConnectionPool(host='european-biotechnology.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
heparegenix gmbh,2025-04-15 00:00:00,Yes,HRX-215,"MKK4, Mitogen-Activated Protein Kinase Kinase 4",liver diseases,kinases,Phase 1,Yes,"HRX-215 is a first-in-class, orally available small molecule inhibitor",https://www.globenewswire.com/news-release/2025/04/15/3061487/0/en/HepaRegeniX-completes-21-5-million-financing-to-support-clinical-advancement-of-HRX-215-for-liver-regeneration.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
avelos therapeutics inc,2024-05-29 08:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"developing small molecule synthetic drugs targeting synthetic lethality, DNA damage response and cell cycle regulation",https://www.prnewswire.com/news-releases/avelos-therapeutics-announces-krw-17-billion-series-b-funding-round-surpassing-krw-30-billion-total-raised-302157710.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aeglea biotherapeutics inc,2023-07-22 00:00:00,No,SPY001; SPY002; SPY003; SPY004,"Integrin α4β7; TL1A, Tumor Necrosis Factor-like Cytokine 1A; IL-23, Interleukin-23",inflammatory bowel disease; ulcerative colitis; Crohn's disease,other; cytokine; cytokine,Phase 1; Preclinical; Preclinical; Preclinical,No,,,No,,,Yes,"human enzymes, and engineering enzymes",https://www.linkedin.com/company/aeglea-biotherapeutics,Yes,best-in-class antibody engineering,https://www.linkedin.com/company/aeglea-biotherapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
iovance biotherapeutics inc,2025-10-08 12:47:43,No,Amtagvi; lifileucel,Not specified,oncology,Not specified,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,tumor-infiltrating lymphocyte (TIL) therapies,https://www.linkedin.com/company/iovance,No,,,No,,,No,,
gossamer bio inc,2025-10-14 14:08:04,No,Seralutinib,"PDGFRα/β, Platelet-Derived Growth Factor Receptor Alpha/Beta; CSF1R, Colony Stimulating Factor 1 Receptor; c-KIT, Proto-Oncogene Receptor Tyrosine Kinase",pulmonary arterial hypertension; pulmonary hypertension associated with interstitial lung disease; rare diseases,kinases,Phase 3,Yes,"Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor",https://www.gossamerbio.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shanghai bao pharmaceuticals co ltd,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,"pharmaceutical recombinant enzymes, human protein hormones",https://www.linkedin.com/company/baopharma/,Yes,"antibodies, including human hyaluronidase PH20 (rhPH20), human chymotrypsin, IgG cleaving enzyme",https://www.linkedin.com/company/baopharma/,No,,,No,,,No,,,Yes,neutralizing antibody reduction and re-dosing potential; #GeneAndCellTherapy,https://www.linkedin.com/company/baopharma/,No,,,No,,,No,,
curevac nv,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,CVnCoV; BNT111; BNT113; BNT327,"PD-L1, Programmed Death-Ligand 1; VEGF-A, Vascular Endothelial Growth Factor A",oncology; infectious diseases,immune checkpoint; cytokine,Not specified,No,,,No,,,Yes,synthesize the desired proteins,https://www.cnbc.com/quotes/CVAC,No,,,No,,,No,,,Yes,"messenger ribonucleic acid, or mRNA",https://www.cnbc.com/quotes/CVAC,No,,,Yes,mRNAs are designed to prevent infections,https://www.cnbc.com/quotes/CVAC,No,,,No,,
goldfinch bio inc (inactive),Error: Connection failed - HTTPSConnectionPool(host='www.startupnetworks.co.u,Yes,GFB-887,"TRPC5, Transient Receptor Potential Canonical Channel 5",kidney diseases,ion channels,Phase 2,Yes,discovery and development of novel compounds,https://www.gilead.com/news/news-details/2019/gilead-sciences-and-goldfinch-bio-announce-strategic-collaboration-to-develop-novel-therapies-for-kidney-disease,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
eyepoint pharmaceuticals inc,2025-10-15 15:34:21,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,tyrosine kinase inhibitor,https://www.linkedin.com/company/eyepointpharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
valneva austria gmbh,2025-10-14 08:30:03,No,Tetravalent Shigella Vaccine Candidate,Shigella,infectious diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases",https://www.linkedin.com/company/valneva,No,,,No,,
asher biotherapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Etakafusp alfa; AB821; AB359,"CD8+ T Cell; IL-2, Interleukin-2; IL-21, Interleukin-21",oncology; infectious diseases,cytokine,Phase 1,No,,,No,,,Yes,"IL-2, a powerful mediator of the immune system",https://asherbio.com/,No,,,No,,,No,,,No,,,Yes,Cis-targeted Cytokine Augmentation of Cell Therapies,https://asherbio.com/,No,,,No,,,Yes,T cell engagers (TCEs),https://www.linkedin.com/company/asher-biotherapeutics
immunomedics inc,2020-09-13 00:00:00,No,Trodelvy; Sacituzumab Govitecan,"Trop-2, Trophoblast Cell Surface Antigen 2",oncology,other,Approved,No,,,No,,,No,,,Yes,next-generation antibody-drug conjugate (ADC) technology,https://www.gilead.com/news/news-details/2020/gilead-sciences-to-acquire-immunomedics,Yes,antibody-drug conjugate (ADC),https://www.gilead.com/news/news-details/2020/gilead-sciences-to-acquire-immunomedics,No,,,No,,,No,,,No,,,No,,,No,,
pharmacyclics llc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Ibrutinib,"BTK, Bruton's Tyrosine Kinase",oncology,kinases,Marketed,Yes,covalent-inhibitor technologies,https://www.linkedin.com/company/pharmacyclics,No,,,No,,,Yes,bispecific antibodies,https://www.linkedin.com/company/pharmacyclics,Yes,antibody-drug conjugates (ADCs),https://www.linkedin.com/company/pharmacyclics,No,,,No,,,No,,,No,,,No,,,No,,
synlogic inc,2023-10-29 00:00:00,No,SYNB2081; SYNB1353,"Disease Name, Gout; Disease Name, Homocystinuria",metabolic diseases; immunology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Synthetic Biotics are novel biotherapeutics designed to address the underlying drivers of disease,https://www.synlogictx.com/
aileron therapeutics inc,2025-10-16 15:21:08,Yes,LTI-03; ALRN-6924; LTI-01,"Cav1, Caveolin-1; MDM2, Mouse Double Minute 2; MDMX, Mouse Double Minute X",pulmonary fibrosis; oncology; orphan pulmonary diseases,other; other; other,Phase 1; Preclinical; Phase 2,No,,,Yes,stapled peptide therapeutics,https://www.stocktitan.net/news/ALRN/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
onconova therapeutics inc,2021-10-24 00:00:00,No,Narazaciclib; Rigosertib; Tivoxavir marboxil; Ratutrelvir,"CDK4/6, Cyclin-Dependent Kinase 4/6; Ark5, AMP-Activated Protein Kinase; Mpro, Main Protease (3CL Protease); KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog",oncology; respiratory viral diseases,kinases; enzyme; other,Phase 3; Phase 2; Phase 1,Yes,"narazaciclib, and rigosertib",https://www.linkedin.com/company/onconova,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
eg 427,2025-10-08 11:53:38,Yes,EG110A,Type-C Sensory Neurons,neurology; urology,other,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,Yes,DNA medicine,https://www.globenewswire.com/news-release/2025/10/06/3161387/0/en/EG-427-Receives-U-S-FDA-Fast-Track-Designation-for-EG110A-DNA-Medicine-in-Neurogenic-Bladder-Patients.html,Yes,gene therapy,https://fr.linkedin.com/company/eg427,No,,,No,,,No,,
aerorx therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='vcnewsdaily.com', port=4",No,AERO-007,"Disease Name, Chronic Obstructive Pulmonary Disease",respiratory diseases,other,Phase 2,Yes,long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA),https://www.geneonline.com/aerorx-therapeutics-secures-21-million-for-late-stage-trials-of-copd-drug-aero-007/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aerorx therapeutics llc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,AERO-007,Not specified,respiratory diseases,gpcr,Phase 3,Yes,Liquid formulations of indacaterol,https://patents.google.com/patent/US20220096456A1/en,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shanghai biotroy biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biotroy.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bio-thera solutions ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.bio-thera.com', port",No,BAT2506; BAT2206,"TNF-α, Tumor Necrosis Factor Alpha; IL-12 and IL-23, Interleukin-12 and Interleukin-23",autoimmune diseases; inflammatory diseases,cytokine,Approved,No,,,No,,,No,,,Yes,innovative enhanced monoclonal antibodies,https://www.linkedin.com/company/bio-thera-solutions-ltd/,Yes,antibody-drug conjugates,https://www.linkedin.com/company/bio-thera-solutions-ltd/,No,,,No,,,No,,,No,,,No,,,No,,
nerviano medical sciences srl,"Error: Connection failed - HTTPSConnectionPool(host='www.novaquest.com', port",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,discovering and clinically developing small molecule NCEs for oncology,https://it.linkedin.com/company/nerviano-medical-sciences-s.r.l.,No,,,No,,,No,,,Yes,payload-linker platform further enhances our pipeline by enabling next-generation ADC production,https://it.linkedin.com/company/nerviano-medical-sciences-s.r.l.,No,,,No,,,No,,,No,,,No,,,No,,
memo therapeutics ag,2025-09-02 07:04:23,Yes,potravitug,"BKPyV, BK Polyomavirus",infectious diseases,other,Phase 3,No,,,No,,,No,,,Yes,development of best-in-class antibodies to treat viral infections and cancer,https://www.swissbiotech.org/listing/memo-therapeutics-ag/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
polarityte inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,SkinTE,Disease Name,chronic wounds,Not specified,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,regenerative tissue products and biomaterials,https://www.prnewswire.com/news-releases/polarityte-announces-entry-into-a-letter-of-intent-for-acquisition-of-the-company-301710003.html
regenetp inc,2025-04-16 16:10:47,No,REGN1908; REGN1909; REGN5713; REGN5715,Cat Allergy; Birch Allergy,immunology,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,regenerative tissue products and biomaterials,"https://stockanalysis.com/quote/otc/RGTPQ/company/#:~:text=RegenETP%2C%20Inc.%2C%20a%20clinical,sciences%20in%20the%20United%20States."
indapta therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,Yes,IDP-023,Not specified,oncology; autoimmune diseases,cytokine,Phase 1,No,,,No,,,No,,,Yes,FDA-approved tumor-targeting antibodies,https://indapta.com/,Yes,"ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules",https://www.linkedin.com/company/indapta-therapuetics,No,,,No,,,Yes,allogeneic FcRγ-deficient natural killer (G-NK) cell therapy,https://indapta.com/,No,,,No,,,Yes,immune cell engagers,https://www.linkedin.com/company/indapta-therapuetics
genenta science spa,"Error: Connection failed - HTTPSConnectionPool(host='genenta.gcs-web.com', po",No,Temferon,Not specified,oncology,Not specified,Phase 1/2a,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,lentivirus-based gene and cell therapies in cancer,https://www.cnbc.com/quotes/GNTA,No,,,No,,,No,,
immune biosolutions inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,Not specified,"B1R, Bradykinin Receptor B1; NTSR1, Neurotensin Receptor 1",oncology,gpcr,Preclinical,No,,,No,,,No,,,Yes,discovery and engineering of avian and human antibodies for therapeutic applications,https://ca.linkedin.com/company/immune-biosolutions-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kymab ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.devex.com', port=443",Yes,KY1005; KY1044,"OX40L, OX40-Ligand; ICOS, Inducible T-cell Co-Stimulator",immunology; oncology,cytokine; immune checkpoint,Phase 2; Phase 1/2,No,,,No,,,No,,,Yes,fully human monoclonal antibody targeting key immune system regulator OX40L,https://www.sanofi.com/en/media-room/press-releases/2021/2021-04-09-05-00-00-2207173,No,,,No,,,No,,,No,,,Yes,to develop vaccines and therapeutic antibodies to pathogens of infectious diseases,https://www.gatesfoundation.org/about/committed-grants/2016/11/inv-009620,No,,,No,,
fibrogen inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Roxadustat; FG-3246; Pamrevlumab,"HIF-PH, Hypoxia-Inducible Factor Prolyl Hydroxylase; CD46; Not specified",oncology; hematology; fibrotic diseases,enzyme; other; other,Phase 3; Phase 2; Phase 3,Yes,"Roxadustat, is an oral small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase",https://www.fibrogen.com/our-company,No,,,No,,,Yes,"Pamrevlumab, an anti-CTGF human monoclonal antibody",https://www.linkedin.com/company/fibrogen,Yes,FG-3246 is a potential first-in-class fully human antibody-drug conjugate (ADC),https://www.fibrogen.com/r-d-pipeline,No,,,No,,,No,,,No,,,No,,,No,,
disc medicine inc,"Error: Connection failed - HTTPSConnectionPool(host='www.globaldata.com', por",No,Bitopertin; DISC-0974; DISC-3405,"GlyT1, Glycine Transporter 1; HJV, Hemojuvelin; TMPRSS6, Transmembrane Serine Protease 6",hematology; rare diseases,enzyme; other; enzyme,Phase 3; Phase 2; Phase 1,Yes,orally administered inhibitor of glycine transporter 1 (GlyT1),https://www.globenewswire.com/news-release/2025/10/16/3168389/0/en/Disc-Medicine-Announces-Receipt-of-FDA-Commissioner-s-National-Priority-Voucher-CNPV-for-Bitopertin-in-Erythropoietic-Protoporphyria-EPP.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
centessa pharmaceuticals plc,2025-10-08 11:30:06,Yes,ORX750; ORX142; ORX489,"OX2R, Orexin Receptor 2",neurological disorders; neurodegenerative disorders; neuropsychiatric disorders; sleep-wake disorders,gpcr,Phase 2; Phase 1; Preclinical,Yes,Orexin Receptor 2 Agonist Program,https://centessa.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,LockBody® Technology Platform,https://centessa.com/
viridian therapeutics inc,2025-10-16 14:44:23,No,veligrotug; VRDN-001; VRDN-003; VRDN-006; VRDN-008,"FcRn, Neonatal Fc receptor; Thyroid Eye Disease",rare diseases; autoimmune diseases,other,Phase 3,No,,,No,,,Yes,protein engineering,https://www.linkedin.com/company/viridiantx,Yes,antibody discovery,https://www.linkedin.com/company/viridiantx,No,,,Yes,neonatal Fc receptor (FcRn) inhibitors,https://www.linkedin.com/company/viridiantx,No,,,No,,,No,,,No,,,No,,
altrubio inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,ALTB-268; ALTB-168,"PSGL-1, P-selectin glycoprotein ligand-1",immunology; inflammatory diseases,immune checkpoint,Phase 2,No,,,No,,,No,,,Yes,PSGL-1 agonist antibody,https://www.globenewswire.com/news-release/2025/06/23/3103244/0/en/AltruBio-Presents-New-Preclinical-Data-at-FOCIS-2025-Demonstrating-ALTB-268-s-Efficacy-in-T-Cell-Mediated-Inflammatory-Models.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
annexon inc,2025-01-08 00:00:00,Yes,ANX005; ANX007; ANX1502; ANX009,"C1q, Complement Component 1q",autoimmune diseases; neurodegenerative diseases; ophthalmic diseases,other,Phase 3,Yes,"ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications",https://www.tipranks.com/stocks/annx,No,,,No,,,Yes,"ANX005, a monoclonal antibody, which is in Phase II/III clinical trials",https://www.tipranks.com/stocks/annx,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cellectis sa,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,lasme-cel; UCART22,"Disease Name, Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",oncology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,allogeneic CAR-T cells capable of recognizing and combating cancer cells,https://www.linkedin.com/company/cellectis,No,,,No,,,No,,
xbrane biopharma ab,"Error: Connection failed - HTTPSConnectionPool(host='xbrane.com', port=443): ",No,Ximluci; Lucamzi,"VEGF-A, Vascular Endothelial Growth Factor-A",ophthalmology,cytokine,Approved,No,,,No,,,Yes,high-yield protein expression technology for the development of biosimilars,https://www.tipranks.com/news/company-announcements/xbrane-biopharma-announces-reverse-share-split,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
medicinova inc,2025-10-14 18:20:33,No,MN-166; MN-001,"PDE4, Phosphodiesterase Type-4; MIF, Macrophage Migration Inhibitory Factor",neurodegenerative diseases; oncology; respiratory diseases; substance use disorders,enzyme; cytokine,Phase 2b/3,Yes,small-molecule therapeutics,https://www.home.saxo/markets/stocks/mnov-xnas,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
quince therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,TransCon PTH; Baxdrostat; Miransertib; Setrusumab,Hypoparathyroidism; Uncontrolled Hypertension; Various cancers with specific genetic mutations; Osteogenesis Imperfecta,rare diseases; cardiovascular; oncology; bone diseases,enzyme; other; kinases; other,Phase 2; Preclinical; Preclinical; Phase 3,Yes,small molecules,https://www.home.saxo/markets/stocks/qncx-xnas,Yes,peptides,https://www.home.saxo/markets/stocks/qncx-xnas,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells,https://www.linkedin.com/company/quincetx-inc
omeros corp,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,Zaltenibart; Narsoplimab,"MASP-3, Mannan-binding lectin-associated serine protease-3; MASP-2, Mannan-binding lectin-associated serine protease-2",rare diseases; blood disorders; kidney diseases,enzyme,Phase 3; Approved,Yes,"discovering, developing, and commercializing small-molecule therapeutics",https://www.linkedin.com/company/omeros-corporation,No,,,Yes,"discovering, developing, and commercializing protein therapeutics",https://www.linkedin.com/company/omeros-corporation,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gaba therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,GRX-917,"GABAa receptor; NLRP3, NLR Family Pyrin Domain Containing 3",CNS; psychiatric disorders; neurological disorders; auto-immune disorders,ion channels; enzyme,Phase 1,Yes,GRX-917 is a deuterated analog of an established anxiety medication,https://gabarx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nbe-therapeutics ag,"Error: Connection failed - HTTPSConnectionPool(host='ch.linkedin.com', port=4",Yes,Not specified,Not specified,oncology,Not specified,Preclinical,No,,,No,,,No,,,Yes,monoclonal antibodies,https://ch.linkedin.com/company/nbe-therapeutics-ag,Yes,antibody drug conjugates (ADCs),https://www.swissbiotech.org/listing/nbe-therapeutics-ag/,No,,,No,,,No,,,No,,,No,,,No,,
neutrolis inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,immunology,Not specified,Not specified,No,,,No,,,Yes,analogs of naturally occurring enzymes that disassemble NETs,https://www.globenewswire.com/news-release/2024/12/18/2999013/0/en/Neutrolis-Expands-Senior-Leadership-Team-to-Drive-Development-of-Growing-Pipeline-of-Non-Immunosuppressive-Therapies-for-NET-mediated-Autoimmune-Diseases.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,exDNASE™ platform powers the development of analogs of naturally occurring enzymes that disassemble NETs,https://www.globenewswire.com/news-release/2024/12/18/2999013/0/en/Neutrolis-Expands-Senior-Leadership-Team-to-Drive-Development-of-Growing-Pipeline-of-Non-Immunosuppressive-Therapies-for-NET-mediated-Autoimmune-Diseases.html
emulate therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,ultra-low radio frequency energy technology (ulRFE®) to specifically regulate signaling and metabolic pathways on the molecular and genetic levels,https://stockanalysis.com/stocks/emtx/company/
applied genetic technologies corp,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,SPINRAZA; ThecaFlex DRx,"SMN, Survival Motor Neuron Protein",neurology; rare diseases,other,Marketed; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,AAV-based gene therapies,https://www.labiotech.eu/trends-news/syncona-acquiring-applied-genetic-technologies-corporation/,No,,,No,,,No,,
sellas life sciences group inc,2025-10-03 18:48:17,Yes,Galinpepimut-S; SLS009,"WT1, Wilms Tumor 1; CDK9, Cyclin-Dependent Kinase 9",oncology,other; kinases,Phase 3; Phase 2,Yes,highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor,https://sellaslifesciences.com/,Yes,"galinpepimut-S, or GPS, a cancer immunotherapeutic agent",https://sellaslifesciences.com/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Cancer Vaccine platform,https://www.linkedin.com/company/sellas-life-sciences,No,,,No,,
blueberry therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,Not specified,Not specified,dermatology; skin diseases,Not specified,Preclinical,Yes,"potent selective and safe molecules (peptides, antibodies, small molecules)",https://uk.linkedin.com/company/blueberry-therapeutics-ltd,Yes,"potent selective and safe molecules (peptides, antibodies, small molecules)",https://uk.linkedin.com/company/blueberry-therapeutics-ltd,No,,,Yes,"potent selective and safe molecules (peptides, antibodies, small molecules)",https://uk.linkedin.com/company/blueberry-therapeutics-ltd,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ablynx nv,2017-11-30 00:00:00,Yes,caplacizumab; vobarilizumab,Not specified,rare diseases; hematology; immunology,Not specified,Approved; Phase 3,No,,,No,,,Yes,proprietary therapeutic proteins based on single-domain antibody fragments,https://www.nanotechnologyworld.org/companydirectory-1/ablynx-nv.,Yes,"Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments",https://www.nanotechnologyworld.org/companydirectory-1/ablynx-nv.,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gi innovation co ltd,"Error: Connection failed - HTTPSConnectionPool(host='convention.bio.org', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cogent biosciences inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,Yes,Bezuclastinib; CGT4859; CGT4255; CGT6297,"KIT, Receptor Tyrosine Kinase; FGFR2, Fibroblast Growth Factor Receptor 2; FGFR3, Fibroblast Growth Factor Receptor 3; ErbB2, Receptor Tyrosine Kinase; PI3Kα, Phosphoinositide 3-Kinase Alpha; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog",oncology; rare diseases,kinases; other,Phase 3; Phase 2; Phase 1; Preclinical,Yes,small molecule therapeutics,https://www.cogentbio.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
enliven therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,ELVN-001; ELVN-002; ELV-3111,"BCR::ABL1, Breakpoint Cluster Region-Abelson 1; HER2, Human Epidermal Growth Factor Receptor 2; NRAS, Neuroblastoma RAS Viral Oncogene Homolog; BRAF, B-Raf Proto-Oncogene Serine/Threonine Kinase",oncology,kinases,Phase 1,Yes,small molecule inhibitors,https://www.linkedin.com/company/enliventherapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zai lab ltd,2025-10-13 17:45:04,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"product discovery, development and commercialization",https://www.cnbc.com/quotes/ZLAB,No,,,No,,,Yes,IL-13/IL-31R bispecific antibody,https://www.linkedin.com/company/zai-lab,Yes,DLL3-targeted antibody-drug conjugate (ADC),https://www.linkedin.com/company/zai-lab,No,,,No,,,No,,,No,,,No,,,No,,
sanifit therapeutics sa,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,Yes,SAR445877,"PD1, Programmed Cell Death Protein 1; IL-15, Interleukin-15",oncology,immune checkpoint; cytokine,Phase 3,Yes,INS-3001 is a subcutaneously applied calcification inhibitor based on the natural compound inositol hexaphosphate (IP6),"https://newsroom.csl.com/2021-11-22-Vifor-Pharma-to-spearhead-development-of-vascular-calcification-field,-through-acquisition-of-Sanifit-Therapeutics-and-Inositec-AG",No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
amicogen inc,2022-02-01 00:00:00,No,STRO-003,"ROR1, Receptor Tyrosine Kinase-Like Orphan Receptor 1",oncology,kinases,Preclinical,No,,,No,,,Yes,Head of Enzyme/Biopharmaceuticals Business Division,https://www.linkedin.com/company/amicogen-inc/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zentalis pharmaceuticals inc,2025-10-13 20:09:19,No,azenosertib; ZN-c3; ZN-d6; ZN-a1,"WEE1, WEE1 G2 checkpoint kinase; BAP1, BRCA1-associated protein 1; HER2, Human Epidermal Growth Factor Receptor 2",oncology,kinases; enzyme; other,Phase 1,Yes,Developing small molecule therapeutics targeting fundamental biological pathways of cancers,https://www.linkedin.com/company/zentalis-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
revolution medicines inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Daraxonrasib,"RAS, Rat Sarcoma Viral Oncogene Homolog",oncology,kinases,Phase 3,Yes,multi-selective inhibitor for RAS-addicted cancers,https://www.quiverquant.com/news/Revolution+Medicines+Receives+FDA+Voucher+for+Daraxonrasib+Under+National+Priority+Voucher+Pilot+Program,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
morphosys ag,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Pelabresib; Tulmimetostat,"BET, Bromodomain and Extra-Terminal domain proteins; EZH1, Enhancer of Zeste Homolog 1; EZH2, Enhancer of Zeste Homolog 2",oncology; hematology,other; enzyme,Phase 3; Phase 1,Yes,Pelabresib (CPI-0610) is an investigational small molecule designed to promote anti-tumor activity,https://www.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash,No,,,No,,,Yes,"MorphoSys’ pipeline includes a broad portfolio of partnered assets of which some are in partnership with Novartis, including ianalumab (VAY736) which is studied across multiple immunological diseases and in hematology",https://www.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Epigenetics,https://www.linkedin.com/company/morphosys
shanghai novamab biopharmaceuticals co ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,LQ036,"IL-4Rα, Interleukin-4 Receptor Alpha",respiratory diseases,cytokine,Phase 2,No,,,No,,,Yes,IL-18 surrogate cytokine agon,https://www.linkedin.com/company/novamab/,Yes,bispecific VHH antibody structure,https://www.linkedin.com/company/novamab/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Synthetic cytokine agonist,https://www.linkedin.com/company/novamab/
biogenomics llc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Clofazimine; Haloperidol; Bacampicillin; Benzocaine; Ciclopirox; Ciclosporin; Co-dergocrine mesilate; Dicycloverine; Fludrocortisone; Fluticasone; Isoxicam; Lansoprazole; Levopropoxyphene; Lomustine; Metixene; Myricetin; Niclosamide; Nocodazole; Pentoxifylline; Sirolimus; Thiamazole; Tocainide; Tretinoin; Valproic acid; Zuclopenthixol,Not specified,infectious diseases,Not specified,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"advanced stem cells, exosomes and biostimulator technologies",https://www.linkedin.com/company/thebiogenomics,No,,,No,,,Yes,advanced exosome formulations,https://thebiogenomics.com/
epics therapeutics sa,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,EP102,"METTL3, Methyltransferase-like Protein 3",oncology,enzyme,Phase 1,Yes,small molecule drugs targeting RNA epigenetic mechanisms,https://be.linkedin.com/company/epics-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aston sci co ltd,2025-09-11 07:35:44,No,AST-201; AST-301,Not specified,oncology,Not specified,Phase 2,No,,,Yes,Peptide,https://www.linkedin.com/company/astonsci,No,,,No,,,No,,,No,,,Yes,mRNA,https://www.linkedin.com/company/astonsci,No,,,Yes,therapeutic cancer vaccines,https://www.linkedin.com/company/astonsci,No,,,No,,
allecra therapeutics gmbh,2016-07-15 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,cefepime/enmetazobactam,https://www.linkedin.com/company/allecra-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
medikine inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
dizal (jiangsu) pharmaceutical co ltd,2025-09-09 11:38:21,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,sunvozertinib (targeted oral treatment for EGFR exon20ins NSCLC),https://www.linkedin.com/company/dizal-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
dizal pharmaceutical co,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations,https://www.prnewswire.com/news-releases/dizal-showcases-robust-portfolio-of-lung-cancer-studies-at-2025-wclc-302550606.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
dizal pharmaceutical co ltd,2025-09-09 11:38:21,No,Sunvozertinib; DZD9008,"EGFR, Epidermal Growth Factor Receptor",oncology,kinases,Approved,Yes,non-covalent blood-brain barrier (BBB) penetrant LYN/BTK dual inhibitor,"https://www.linkedin.com/company/dizal-pharma#:~:text=Dizal%20Pharmaceutical%20Co.%2C%20Ltd%20(,of%20cancer%20and%20immunological%20diseases.",No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
atriva therapeutics gmbh,"Error: Connection failed - HTTPSConnectionPool(host='www.eib.org', port=443):",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,MEK inhibitors,https://www.linkedin.com/company/atriva-therapeutics-gmbh,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
respirion pharmaceuticals pty ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immuneoncia therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.bioworld.com', port=",Yes,IMC-001,"PD-L1, Programmed Death-Ligand 1",oncology; rare cancers,immune checkpoint,Not specified,No,,,No,,,No,,,Yes,ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 Phase I study was completed in Feb 2019 and its Phase 2 study is being prepared.,https://www.linkedin.com/company/immuneoncia,No,,,No,,,No,,,No,,,No,,,No,,,No,,
fortunerock (china) ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,ABO2011; ABO2102,"KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog",oncology,enzyme,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
veralox therapeutics inc,2025-01-10 16:48:58,Yes,VLX-1005;cGAS inhibitors,"12-LOX, 12-Lipoxygenase;cGAS, Cyclic GMP-AMP Synthase",cardiovascular;autoimmune diseases;inflammatory diseases;rare diseases;neurodegenerative diseases;metabolic diseases,enzyme;other,Phase 2;Preclinical,Yes,small molecule drug discovery & development company,https://members.mdtechcouncil.com/lifesciencesdirectory/Details/veralox-therapeutics-654838,No,,,No,,,No,,,No,,,No,,,Yes,cGAS inhibitors,https://www.prnewswire.com/news-releases/veralox-therapeutics-expands-its-pipeline-with-the-exclusive-option-to-acquire-nudge-therapeutics-302347548.html,No,,,No,,,No,,,No,,
adaptimmune therapeutics plc,2025-07-11 14:56:06,Yes,TECELRA; Uzatresgene autoleucel; Lete-cel; Afami-cel; ADP-A2M4CD8,"MAGE-A4, Melanoma-associated antigen A4; NY-ESO, New York Esophageal Squamous Cell Carcinoma-1; Mesothelin; CD19, Cluster of Differentiation 19; CD70, Cluster of Differentiation 70",oncology,immune checkpoint,Approved; Phase 2; Failed,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline",https://www.cnbc.com/quotes/ADAP,No,,,No,,,No,,
evelo biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biopharmadive.com', ",No,VYN201; Upadacitinib; Ritlecitinib; FB102; TEV-53408,"Small Intestinal Axis; JAK1, Janus Kinase 1; JAK3, Janus Kinase 3; IL-2Rβ, Interleukin-2 Receptor Beta Subunit; IL-15, Interleukin 15",inflammatory diseases; autoimmune diseases; dermatology,other; kinases; kinases; cytokine; cytokine,Phase 3; Phase 3; Phase 3; Phase 1; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles (EVs),https://www.flagshippioneering.com/companies/evelo-biosciences
tilt biotherapeutics ltd,2025-05-13 07:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,cytokines (TNF and IL-2),https://www.globenewswire.com/news-release/2025/05/13/3079780/0/en/TILT-Biotherapeutics-Announces-Closing-of-USD-25-Million-Series-B-Financing.html,No,,,No,,,No,,,No,,,Yes,"CAR-T cells, tumor infiltrating lymphocytes (TILs)",https://fi.linkedin.com/company/tilt-biotherapeutics-ltd,No,,,No,,,Yes,oncolytic viruses,https://www.globenewswire.com/news-release/2025/05/13/3079780/0/en/TILT-Biotherapeutics-Announces-Closing-of-USD-25-Million-Series-B-Financing.html
nanocarrier co ltd,2015-10-18 00:00:00,Yes,Doxil; Abraxane,"CD47, Cluster of Differentiation 47; PECAM-1, Platelet Endothelial Cell Adhesion Molecule-1; TNF, Tumor Necrosis Factor",oncology; cardiovascular; CNS,immune checkpoint; cytokine; other,Approved,Yes,NanoCarrier technology can deliver small molecules,https://www.linkedin.com/company/nanocarrier-ltd-,No,,,Yes,NanoCarrier technology can deliver proteins,https://www.linkedin.com/company/nanocarrier-ltd-,No,,,No,,,No,,,Yes,NanoCarrier technology can deliver siRNA,https://www.linkedin.com/company/nanocarrier-ltd-,No,,,No,,,No,,,Yes,micellar nanoparticles technology,https://www.linkedin.com/company/nanocarrier-ltd-
polyactiva pty ltd,"Error: Connection failed - HTTPSConnectionPool(host='au.linkedin.com', port=4",No,PA5108; Latanoprost FA SR Ocular Implant; Levofloxacin Ocular Implant,"Disease Name, Primary Open-Angle Glaucoma; Disease Name, Ocular Hypertension; Disease Name, Endophthalmitis",ophthalmology,other,Phase 2,Yes,investigational new chemical entity,https://polyactiva.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,biodegradable implants with sustained drug delivery,https://polyactiva.com/
pharmatrophix inc,"Error: Connection failed - HTTPSConnectionPool(host='www.alzdiscovery.org', p",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gid group inc,2020-09-18 00:00:00,No,AdAPT-001; SRK-181; STP 707; SIS 201 CD; IOA-359; Elritercept; ISTH0036; TU-2218; AGMB-129; IO170; ES 014; SHR-1701; HEC585; RO7204239; ESN-Y,"TGF-β, Transforming Growth Factor Beta; TPX2, Microtubule Nucleation Factor",oncology; fibrosis,cytokine; other,Phase 3; Phase 2; Phase 1; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cell therapy company with significant trial results,https://www.linkedin.com/company/the-gid-group-inc.,No,,,No,,,No,,
tc biopharm ltd,2025-06-11 12:44:26,No,GTB-3650; GTB-5550; GTB-7550,"CD33, Cluster of Differentiation 33; B7H3, B7 Homolog 3",oncology; autoimmune diseases,cytokine; other,Phase 1; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer,https://uk.linkedin.com/company/tc-biopharm-limited,No,,,No,,,No,,
calypso biotech sa,"Error: Connection failed - HTTPSConnectionPool(host='www.startupticker.ch', p",No,CALY-002,"IL-15, Interleukin-15",immunology; auto-immune diseases,cytokine,Phase 1,No,,,No,,,No,,,Yes,anti-IL-15 antibody CALY-002,https://www.swissbiotech.org/listing/calypso-biotech-sa/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
modis therapeutics inc,2019-08-26 11:00:00,Yes,GLM101,"PMM2, Phosphomannomutase 2",rare diseases,enzyme,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,Yes,investigational deoxynucleoside combination therapy,https://www.globenewswire.com/news-release/2019/08/26/1906376/35369/en/Zogenix-Announces-Acquisition-of-Modis-Therapeutics-Inc.html,No,,,No,,,No,,,No,,
lexicon pharmaceuticals inc,2025-10-14 14:11:11,Yes,Sotagliflozin; Lx9211; Telotristat Ethyl,Not specified,cardiovascular; metabolic diseases; CNS,Not specified,Phase 3; Phase 2; Phase 1,Yes,All of our drug candidates are new molecular entities discovered internally,https://www.linkedin.com/company/lexicon-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
apcintex ltd,2021-02-17 00:00:00,No,Not specified,Not specified,rare diseases,Not specified,Not specified,No,,,No,,,Yes,specific inhibitor of the anticoagulant protease activated protein C (APC),https://www.ipgroupplc.com/news-and-events/ip-group-news/2021/2021-02-17,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sichuan nofit biopharmaceutical technology co ltd,2025-06-05 22:54:07,Yes,Sacituzumab Tirumotecan; Tagitanlimab,"TROP2, Trophoblast Cell-Surface Antigen 2; PD-L1, Programmed Death-Ligand 1",oncology,other; immune checkpoint,Phase 2,Yes,small molecule drugs,https://www.prnewswire.com/news-releases/kelun-biotech-announces-approximately-us250-million-placement-302475045.html,No,,,No,,,No,,,Yes,"ADC platforms, OptiDC™, ADC project approved for marketing",https://www.prnewswire.com/news-releases/kelun-biotech-announces-approximately-us250-million-placement-302475045.html,No,,,No,,,No,,,No,,,No,,,No,,
emalex biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.baincapital.com', po",No,ecopipam,"D1 receptor, Dopamine receptor D1",CNS,gpcr,Phase 3,Yes,dopamine D1 receptor antagonist,https://www.linkedin.com/company/emalex-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sichuan kelun biotech biopharmaceutical co ltd,2025-06-05 22:54:07,Yes,sac-TMT; Trastuzumab Botidotin; SKB315; SKB410; SKB571; SKB518; SKB535; SKB445; SKB500; SKB501; SKB107; Tagitanlimab; Cetuximab N01; A400; SKB378; SKB336; A296,"TROP2, Trophoblast Cell Surface Antigen 2; HER2, Human Epidermal Growth Factor Receptor 2; CLDN18.2, Claudin 18.2; Nectin-4; PD-L1, Programmed Death-Ligand 1; EGFR, Epidermal Growth Factor Receptor; RET, Rearranged during Transfection; FXI, Factor XI; STING, Stimulator of Interferon Genes; TSLP, Thymic Stromal Lymphopoietin",oncology; autoimmune disorders; inflammation; metabolic diseases,immune checkpoint; enzyme; other,Marketed; Phase 3; Phase 2; Phase 1; Preclinical,Yes,small molecule drugs,https://www.prnewswire.com/news-releases/kelun-biotech-announces-approximately-us250-million-placement-302475045.html,No,,,No,,,No,,,Yes,"ADC platforms, OptiDC™, ADC project approved for marketing",https://www.prnewswire.com/news-releases/kelun-biotech-announces-approximately-us250-million-placement-302475045.html,No,,,No,,,No,,,No,,,No,,,No,,
sichuan kelun bio-tech pharmaceutical co ltd,2025-06-05 22:54:07,Yes,Sac-TMT; Tagitanlimab; Cetuximab N01; Trastuzumab Botidotin; SKB315; SKB410; SKB571; SKB518; SKB535; SKB445; SKB500; SKB501; SKB107; A400,"TROP2, Trophoblast Cell-Surface Antigen 2; PD-L1, Programmed Death-Ligand 1; EGFR, Epidermal Growth Factor Receptor; HER2, Human Epidermal Growth Factor Receptor 2; CLDN18.2, Claudin-18 Isoform 2; Nectin-4, Nectin Cell Adhesion Molecule 4; RET, Rearranged during Transfection",oncology; autoimmune; metabolic diseases; inflammatory diseases,immune checkpoint; enzyme; other,Marketed; NDA; Phase 3; Phase 2; Phase 1; Preclinical,Yes,small molecule drugs,https://www.prnewswire.com/news-releases/kelun-biotech-announces-approximately-us250-million-placement-302475045.html,No,,,No,,,No,,,Yes,"ADC platforms, OptiDC™, ADC project approved for marketing",https://www.prnewswire.com/news-releases/kelun-biotech-announces-approximately-us250-million-placement-302475045.html,No,,,No,,,No,,,No,,,No,,,No,,
dimension therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='drug-dev.com', port=443)",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
blade therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,BLD-0409,Autotaxin,lung diseases; liver diseases; cardiovascular diseases,enzyme,Phase 2,Yes,"differentiated pipeline of oral, small-molecule therapies",https://globalgenes.org/raredaily/blade-therapeutics-reverse-mergers-into-spac-to-become-a-public-company/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cerecin pte ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Aducanumab; AGB101; AR1001; AVP-786; AXS-05; Blarcamesine; BPDO-1603; Brexpiprazole; Caffeine; Donanemab; Donepezil; E2814; Escitalopram; Fosgonimeton; Gantenerumab; Guanfacine; Hydralazine hydrochloride; Icosapent ethyl,"Aβ, Amyloid Beta; SV2A, Synaptic Vesicle Glycoprotein 2A; Neurotransmitter receptors; Tau, Microtubule-associated protein tau; Synaptic plasticity/neuroprotection; Oxidative stress; Inflammation",CNS; Alzheimer's disease,enzyme; other; other; other; other; other; other,Phase 3,Yes,"Cerecin's lead compound, tricaprilin",https://www.prnewswire.com/news-releases/accera-closes-new-investment-led-by-asias-leading-agribusiness-group-wilmar-and-rebrands-as-cerecin-300724328.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
imv inc,2022-01-20 00:00:00,No,Maveropepimut-S; IGV-001; IEC-001; IHC-001; IUC-001; IOC-001,"Survivin, Tumor-associated antigen; Glioblastoma; Endometrial Cancer; Hepatocellular carcinoma; Urothelial Cancer; Ovarian Cancer",oncology,other,Phase 2; IND-enabling; IND-enabling; IND-enabling; IND-enabling; IND-enabling,No,,,Yes,antigenic peptides of survivin,https://www.linkedin.com/company/imv-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gamida cell ltd,2025-08-29 15:43:11,No,Omisirge; GDA-201,Hematologic Malignancies; Non-Hodgkin Lymphoma,oncology,other,Approved; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Our proprietary nicotinamide (NAM) technology expands the number of cells while maintaining their intrinsic properties to create potentially curative cell therapy products and candidates for patients with cancer.,https://www.linkedin.com/company/gamida-cell-ltd-,No,,,No,,,No,,
gliknik inc,"Error: Connection failed - HTTPSConnectionPool(host='www.pfizer.com', port=44",Yes,GL-2045; GL-0817,Not specified,autoimmune diseases; oncology,other,Preclinical; Phase 2,No,,,Yes,Two peptide immune modulators are in dose rising studies in patients with advanced Head and Neck Squamous Cell Carcinoma.,https://members.mdtechcouncil.com/lifesciencesdirectory/details/gliknik-inc-3229382,Yes,GL-2045 acts by presenting highly ordered multimers of normal human IgG Fc to its receptors.,https://www.pfizer.com/news/press-release/press-release-detail/gliknik-enters-licensing-agreement-pfizer-drug-candidate,Yes,"Gliknik is also conducting research on stradobodiesTM, modified monoclonal antibodies for cancer.",https://members.mdtechcouncil.com/lifesciencesdirectory/details/gliknik-inc-3229382,No,,,No,,,No,,,No,,,No,,,No,,,No,,
dren bio inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,DR-0201; SAR448501; DR-01,"CD20, Cluster of Differentiation 20",immunology; oncology; autoimmune diseases,other,Phase 1,No,,,No,,,No,,,Yes,novel first-in-class antibody therapeutics,https://www.globenewswire.com/news-release/2025/03/20/3045945/0/en/Press-Release-Sanofi-to-acquire-Dren-Bio-s-bispecific-myeloid-cell-engager-for-deep-B-cell-depletion-broadening-immunology-pipeline.html,No,,,No,,,No,,,No,,,No,,,No,,,Yes,targeted myeloid engager and phagocytosis platform,https://www.globenewswire.com/news-release/2025/03/20/3045945/0/en/Press-Release-Sanofi-to-acquire-Dren-Bio-s-bispecific-myeloid-cell-engager-for-deep-B-cell-depletion-broadening-immunology-pipeline.html
basilea pharmaceutica ltd,"Error: Connection failed - HTTPSConnectionPool(host='ch.linkedin.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
actinium pharmaceuticals inc,2025-06-23 16:27:25,Yes,ATNM-400; Actimab-A; Iomab-ACT; Iomab-B,"Prostate Cancer; CD33, Cluster of Differentiation 33; Myeloid Derived Suppressor Cells (MDSCs); Not specified",oncology; hematology; cell and gene therapy,other; immune checkpoint; other; other,Preclinical; Phase 2/3; Preclinical; Not specified,No,,,No,,,No,,,Yes,Indium-111-labeled antibody,https://bit.ly/41OmjPt,Yes,Actinium-225 antibody radioconjugate,https://bit.ly/41OmjPt,No,,,No,,,Yes,Commercial CAR-T Trial,https://bit.ly/3RQW8lu,No,,,No,,,No,,
c4 therapeutics inc,2025-10-07 13:34:20,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,small-molecule medicines,https://www.linkedin.com/company/c4-therapeutics-inc.,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,targeted protein degradation,https://www.linkedin.com/company/c4-therapeutics-inc.,No,,
inovio pharmaceuticals inc,2025-10-14 14:39:03,No,INO-3107,"HPV-6 and HPV-11, Human Papillomavirus Types 6 and 11",infectious diseases; rare diseases,other,Phase 1/2,No,,,No,,,No,,,Yes,dMAb (DNA-encoded monoclonal antibodies),https://www.linkedin.com/company/inovio-pharmaceuticals,No,,,No,,,Yes,"DNA medicines, DNA plasmids",https://www.linkedin.com/company/inovio-pharmaceuticals,No,,,Yes,DNA vaccines,https://www.linkedin.com/company/inovio-pharmaceuticals,No,,,No,,
tenax therapeutics inc,2025-10-10 13:03:01,No,Not specified,"PH-HFpEF, Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction",cardiovascular,Not specified,Phase 3,Yes,"imatinib mesylate, a kinase inhibitor",https://www.cnbc.com/quotes/TENX,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nordic nanovector asa,2022-01-19 00:00:00,No,ATX-101; Betalutin; Humalutin; Alpha37,"PCNA, Proliferating Cell Nuclear Antigen; CD37",oncology; haematological cancers; autoimmune diseases,other; immune checkpoint,Phase 2; Preclinical,No,,,No,,,No,,,Yes,CD37-targeting antibody,https://www.inderes.dk/en/releases/nordic-nanovector-asa-key-information-regarding-potential-subsequent-offering,Yes,antibody-radionuclide-conjugate,https://www.inderes.dk/en/releases/nordic-nanovector-asa-key-information-regarding-potential-subsequent-offering,No,,,No,,,No,,,No,,,No,,,Yes,radionuclide-based anti-cancer therapies,https://www.prnewswire.com/news-releases/nordic-nanovector-announces-agreement-to-acquire-thor-medical-an-emerging-producer-of-alpha-emitters-for-radiopharmaceuticals-to-treat-cancer-301844109.html
t7 therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.bioworld.com', port=",Yes,Not specified,"p97, AAA-ATPase",infectious diseases,enzyme,Preclinical,No,,,No,,,No,,,Yes,first-in-class monoclonal antibody targeting a broad set of autoimmune diseases,https://www.linkedin.com/posts/catellosomma_lifesciencevc-activity-6866343521742290944-iTrV,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cystetic medicines inc,"Error: Connection failed - HTTPSConnectionPool(host='medicine.illinois.edu', ",Yes,VX-121; VX-561; ETD001; Brensocatib; ELX-02; S1226,"CFTR, Cystic Fibrosis Transmembrane Conductance Regulator; DPP1, Dipeptidyl Peptidase I; G542X mutation; Not specified",rare diseases; respiratory diseases,enzyme; other,Phase 3; Phase 2,Yes,small molecule channels that serve as molecular prosthetics,https://www.prnewswire.com/news-releases/cystetic-medicines-doses-first-person-with-cystic-fibrosis-in-phase-1-trial-of-investigational-therapy-cm001-designed-to-form-ion-channels-to-help-restore-airway-function-301971270.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
mozart therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,MTX-101,"CD8, Cluster of Differentiation 8; KIR2DL, Killer Cell Immunoglobulin-like Receptor 2DL",autoimmune diseases; inflammatory diseases,immune checkpoint,Phase 1,No,,,No,,,No,,,Yes,bispecific antibodies to restore endogenous CD8 Treg function,https://www.linkedin.com/company/mozart-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
topelia aust ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Not specified,"JAK, Janus Kinase; AKT, Protein Kinase B",oncology,kinases,Preclinical,Yes,ivermectin and doxycycline—medications with long-standing safety profiles,https://au.linkedin.com/company/topelia,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
angiex inc,2021-05-09 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,Antibody drug conjugates are an exciting drug modality,https://www.globenewswire.com/news-release/2024/08/07/2926298/0/en/Angiex-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-AGX101-a-novel-TM4SF1-Directed-Antibody-Drug-Conjugate-for-the-Treatment-of-Solid-Tumors.html,Yes,Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs),https://www.linkedin.com/company/angiex-inc,No,,,No,,,No,,,No,,,No,,,No,,
immune onc therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Iberdomide; Mezigdomide,Not specified,oncology,other,Phase 3,No,,,No,,,No,,,Yes,"antagonist antibody targeting LILRB2 (also known as ILT4), IO-202, a first-in-class antagonist antibody targeting LILRB4",https://www.linkedin.com/company/immune-onc-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,Yes,novel bispecific antibody targeting LILRB4 and CD3,https://www.linkedin.com/company/immune-onc-therapeutics
rona therapeutics inc,2025-09-15 12:00:06,Yes,RN3161; RN026; RN1871,"INHBE, Inhibin Beta E; Lipoprotein(a); AGT, Angiotensinogen",obesity; cardiometabolic diseases; hypertension,other; other; enzyme,Phase 1; Preclinical; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"nucleic acid therapeutics company to discover, develop and deliver transformative modular RNA medicines",https://www.linkedin.com/company/ronatherapeutics/,No,,,No,,,No,,,No,,
zucara therapeutics inc,2025-05-01 07:30:34,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"ZT-01, a first-in-class SST receptor 2 antagonist",https://www.prnewswire.com/news-releases/zucara-therapeutics-announces-second-and-final-closing-of-us25-million-series-b-financing-302441949.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bionova pharmaceuticals ltd,2020-11-20 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
renibus therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pathios therapeutics ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,"GPR65, G Protein-Coupled Receptor 65",oncology,gpcr,Preclinical,Yes,"oral, highly potent, and selective small molecule inhibitor of GPR65",https://www.prnewswire.com/news-releases/pathios-therapeutics-announces-dosing-of-first-patient-in-phase-12-clinical-study-of-gpr65-inhibitor-ptt-4256-in-patients-with-advanced-solid-cancers-302310915.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vittoria biotherapeutics inc,2024-11-12 11:30:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"gene-edited, autologous, dual-population CAR-T therapy",https://www.globenewswire.com/news-release/2025/05/28/3089461/0/en/Vittoria-Biotherapeutics-to-Share-Trials-in-Progress-Presentation-from-Phase-1-Study-of-VIPER-101-at-ASCO-2025-Annual-Meeting.html,No,,,No,,,No,,
rallybio corp,2025-09-25 12:00:00,Yes,RLYB116; RLYB332; RLYB114,"C5, Complement component 5; Matriptase-2; Not specified",rare diseases; complement dysregulation; hematology; iron overload; severe anemias; ophthalmological diseases,enzyme; other; enzyme,Phase 1; Preclinical; Preclinical,Yes,"REV102, a potential first-in-class oral ENPP1 inhibitor",https://www.stocktitan.net/news/RLYB/,No,,,Yes,engineered proteins,https://www.stocktitan.net/news/RLYB/,Yes,antibodies,https://www.stocktitan.net/news/RLYB/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
atrogi ab,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,ATR-258,"β2-AR, Beta-2 Adrenergic Receptor",metabolic diseases; obesity; diabetes; muscle-wasting conditions,gpcr,Phase 2,Yes,harnessing the potential of small molecules with distinct and novel signaling profiles,https://se.linkedin.com/company/atrogi,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bacainn therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,ADS051; ADS032; ADS024,"Not specified; NLRP1, NLR Family Pyrin Domain Containing 1; NLRP3, NLR Family Pyrin Domain Containing 3; LPAR3, Lysophosphatidic Acid Receptor 3",inflammatory diseases; ulcerative colitis; respiratory inflammation; dermal inflammation; neurodegenerative diseases; neuroinflammatory diseases,Not specified; other; gpcr,Phase 2; Preclinical; Not specified,Yes,small molecule neutrophil modulator,https://pubmed.ncbi.nlm.nih.gov/37392453/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pyc therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='au.linkedin.com', port=4",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,Yes,creating a new generation of ribonucleic acid (RNA) therapies,"https://www.cnbc.com/quotes/PYCXF#:~:text=PYC%20Therapeutics%20Limited%20is%20an,of%20patients%20with%20genetic%20diseases.",No,,,No,,,No,,,No,,
oncosynergy inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,DB102; Tofacitinib; VT1021; Varlilumab; Debio 0123; PRT3645,"PKC beta, Protein Kinase C beta; PI3K, Phosphoinositide 3-kinase; AKT, AKT serine/threonine kinase; Jak family, Janus Kinase family; CD47, Cluster of Differentiation 47; CD36, Cluster of Differentiation 36; CD27, Cluster of Differentiation 27; Wee1, Wee1-like protein kinase; CDK4/6, Cyclin-dependent kinases 4 and 6",oncology,kinases; immune checkpoint; other; kinases; kinases,Phase 3; Phase 3; Phase 2/3; Phase 2; Phase 1/2; Phase 1,Yes,synthetic small molecule invented by Drs. Nicolas Winssinger and Martin Karplus,https://www.prnewswire.com/news-releases/dandrit-biotech-usa-inc-announces-the-purchase-of-oncosynergy-inc-300246291.html,No,,,No,,,Yes,"anti-CD29 monoclonal antibody, OS2966",https://www.prnewswire.com/news-releases/dandrit-biotech-usa-inc-announces-the-purchase-of-oncosynergy-inc-300246291.html,No,,,No,,,No,,,No,,,Yes,"MCV, a dendritic cell cancer vaccine",https://www.prnewswire.com/news-releases/dandrit-biotech-usa-inc-announces-the-purchase-of-oncosynergy-inc-300246291.html,No,,,No,,
chordia therapeutics inc,2019-05-01 00:00:00,No,CTX-712,"CLK, CDC-like Kinase",oncology,kinases,Phase 1/2,Yes,first in class cancer drugs,https://www.linkedin.com/company/chordia-therapeutics-inc/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
minoryx therapeutics sl,"Error: Connection failed - HTTPSConnectionPool(host='www.minoryx.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
squarex pharmaceutical corp,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Squarex; squaric acid dibutyl ester,Herpes Simplex Virus 1; Herpes Simplex Virus 2,infectious diseases,other,Phase 2,Yes,immunomodulator squaric acid dibutyl ester,https://www.linkedin.com/company/squarex-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cardurion pharmaceuticals inc,2024-07-16 12:21:00,No,CRD-750,"PDE9, Phosphodiesterase-9",cardiovascular,enzyme,Phase 2,Yes,developing groundbreaking clinical programs in PDE9 and CaMKII inhibition,https://www.linkedin.com/company/cardurion,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cardurion pharmaceuticals llc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,CRD-750,"PDE9, Phosphodiesterase-9",cardiovascular,enzyme,Phase 2,Yes,developing groundbreaking clinical programs in PDE9 and CaMKII inhibition,https://www.linkedin.com/company/cardurion,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sonoma biotherapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
suzhou connect biopharmaceuticals ltd,2023-04-11 20:05:00,Yes,FB704A,"TSLP, Thymic Stromal Lymphopoietin",immunology; respiratory diseases,cytokine,Phase 2,Yes,proprietary small molecules,https://www.globenewswire.com/news-release/2023/04/11/2644919/0/en/Connect-Biopharma-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,No,,,No,,,Yes,"antibodies, using functional T cell assays, to screen and discover potent product candidates",https://www.globenewswire.com/news-release/2023/04/11/2644919/0/en/Connect-Biopharma-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
betagenon ab,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,ATX-304,"AMPK, AMP-activated Protein Kinase",metabolic diseases; cardiovascular diseases; kidney diseases; oncology,enzyme,Phase 1,Yes,PAN-AMPK activator O304,https://pmc.ncbi.nlm.nih.gov/articles/PMC6124394/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
alnylam pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Zilebesiran,"AGT, Angiotensinogen",cardiovascular,enzyme,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNA interference (RNAi) therapeutics,https://www.linkedin.com/company/alnylam-pharmaceuticals,No,,,No,,,No,,,No,,
vironexis biotherapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,VNX-101; VNX-202,"CD19, Cluster of Differentiation 19; CD3, Cluster of Differentiation 3",oncology; immunology,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,AAV-delivered T-cell immunotherapy,https://www.linkedin.com/company/vironexis,Yes,cancer vaccine,https://www.linkedin.com/company/vironexis,No,,,No,,
alyssum therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,AT-1965,Disease Name,oncology,Not specified,Phase 1; Phase 2,Yes,"A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTITUMOR ACTIVITY OF AT-1965",https://www.honorhealth.com/clinical-trials/cancer/cancer-alyssum-therapeutics-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,next-generation immunotherapies to modulate B cells,https://www.linkedin.com/company/alyssum-therapeutics
ixchelsis ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",Yes,Zanzalintinib; XB010; XL309; XB371; Xb628; XL495; Pembrolizumab; Olaparib,"VEGFR, Vascular Endothelial Growth Factor Receptor; MET, Mesenchymal-Epithelial Transition Factor; TAM kinases, TYRO3/AXL/MER; 5T4, Tumor Antigen; USP1, Ubiquitin-Specific Peptidase 1",oncology,kinases; other; enzyme,Phase 1; Phase 2/III; Phase III,Yes,oxytocin receptor antagonist,https://www.prnewswire.com/news-releases/tvm-life-science-ventures-vii-announces-investment-in-ixchelsis-ltd-218489011.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bobcatbio inc,"Error: Connection failed - HTTPSConnectionPool(host='www.fundz.net', port=443",No,Not specified,Not specified,oncology,Not specified,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biotyx medical (shenzhen) co ltd,2024-04-02 15:13:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,iron bioresorbable scaffold,https://pubmed.ncbi.nlm.nih.gov/39537105/
jhm biopharmaceutical (hangzhou) co ltd,2024-05-07 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cortendo ab,2014-12-01 00:00:00,No,COR-003; ATL1103,"GHr, Growth Hormone Receptor",rare diseases; endocrine disorders,other,Phase 3; Phase 2,Yes,COR-003 (levoketoconazole) currently being studied in the Phase 3 global SONICS trial for the treatment of Cushing’s syndrome,https://www.locustwalk.com/cortendo-ab-raises-up-to-27-5m-in-additional-private-placement-with-leading-u-s-and-eu-healthcare-investors/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
metriopharm ag,2021-10-12 00:00:00,Yes,MP1032,"ROS, Reactive Oxygen Species",inflammatory diseases; infectious diseases; autoimmune diseases; rare diseases,other,Phase 2,Yes,platform of oral small molecules,https://www.linkedin.com/company/metriopharm/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arctic therapeutics ehf,2025-01-22 20:51:38,No,AT-001; AT-004,Amyloid Proteins; Acne Vulgaris,neurology; dermatology,other,Phase 2,Yes,an oral treatment designed to prevent the aggregation of harmful amyloid proteins in the brain,https://globalgenes.org/raredaily/arctic-therapeutics-announces-27-6-million-financing/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nerre therapeutics ltd,2025-06-05 08:55:08,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
synendos therapeutics ag,No timestamp found,Yes,SYT-510,Endocannabinoid System,CNS; neuropsychiatric disorders; anxiety disorders; PTSD,other,Phase 1,Yes,first-in-class inhibitors (small molecules),https://www.linkedin.com/company/synendos/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
genelux corp,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,oncolytic viruses,https://www.linkedin.com/company/genelux
bill & melinda gates medical research institute,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,M72/AS01E; MAM01; L9LS; TBA-7371; RSM01,Mycobacterium tuberculosis; Plasmodium falciparum; Respiratory Syncytial Virus,infectious diseases,other,Phase 3; Phase 2a,Yes,research and test potential therapeutics to treat or eliminate mild COVID-19,https://www.gatesfoundation.org/about/committed-grants/2020/11/inv023708,No,,,Yes,human monoclonal antibody MAM01,https://www.linkedin.com/company/gates-medical-research-institute,Yes,human monoclonal antibody MAM01,https://www.linkedin.com/company/gates-medical-research-institute,No,,,No,,,Yes,"ActCRISPR-TB, an early-stage CRISPR-based test",https://www.linkedin.com/company/gates-medical-research-institute,No,,,Yes,M72/AS01E vaccine candidate,https://www.linkedin.com/company/gates-medical-research-institute,No,,,No,,
mural oncology inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Nemvaleukin; MURA-8518; MURA-7012,"IL-2R, Intermediate-Affinity Interleukin-2 Receptor; IL-18, Interleukin-18; IL-12, Interleukin-12",oncology,cytokine,Phase 3; Preclinical,No,,,No,,,Yes,protein engineering platform,https://www.linkedin.com/company/mural-oncology,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
springworks therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.linkedin.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"nirogacestat, mirdametinib",https://www.merckgroup.com/en/news/springworks-acquisition-completed-01-07-2025.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arca biopharma inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,ORKA-001; ORKA-002,"IL-23p19, Interleukin-23p19; IL-17A/F, Interleukin-17A/F",dermatology; inflammatory diseases,cytokine,Preclinical,Yes,Gencaro™ (bucindolol hydrochloride) is an investigational compound,https://www.linkedin.com/company/arca-biopharma?trk=ppro_cprof,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pardes biosciences inc,2021-08-26 21:43:00,Yes,PBI-0451,"3CL Protease, Coronavirus Main Protease",infectious diseases,enzyme,Phase 2,Yes,"structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery",https://www.foresitecapital.com/pardes-biosciences-legend/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ventyx biosciences inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,discovery of differentiated small molecule therapeutics,https://www.linkedin.com/company/ventyx-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
selecxine inc,"Error: Connection failed - HTTPConnectionPool(host='www.selecxine.com', port=",Yes,SLC-3010,"IL-2, Interleukin-2; TCB2, Anti-human IL-2 antibody",oncology; immunology,cytokine,Preclinical,No,,,No,,,Yes,cytokine-antibody complexes,https://www.probiocdmo.com/GenScript-and-Selecxine-Enter-Into-Strategic-Cooperation-Agreement.html,Yes,monoclonal antibodies using platform technology,https://www.probiocdmo.com/GenScript-and-Selecxine-Enter-Into-Strategic-Cooperation-Agreement.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
antabio sas,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"Antibacterial drug discovery, Drug development",https://www.linkedin.com/company/antabio-sas,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
jacobio pharmaceuticals group co ltd,2025-10-15 14:59:48,Yes,Pan-KRAS inhibitor,"KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog",oncology,kinases,Not specified,Yes,"KRAS G12C inhibitor (Glecirasib), SHP2 inhibitor (Sitneprotafib)",https://www.linkedin.com/company/jacobio-pharma,No,,,No,,,No,,,Yes,iADC Platform,https://www.linkedin.com/company/jacobio-pharma,No,,,No,,,No,,,No,,,No,,,Yes,Induced Allosteric Drug Discovery Platform (IADDP),https://www.linkedin.com/company/jacobio-pharma
oncoresponse inc,2023-05-18 08:00:00,Yes,OR2805,CD163,oncology,cytokine,Phase 1,No,,,No,,,No,,,Yes,fully human monoclonal antibody identified from an Elite Responder using OncoResponse's proprietary B-cell discovery platform,https://www.prnewswire.com/news-releases/oncoresponse-awarded-13-million-in-funding-from-cprit-and-raises-14-million-in-added-funds-from-investors-to-advance-cancer-immunotherapy-301828055.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
guangzhou bebetter medicine technology co ltd,2020-05-26 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
march biosciences,2024-10-23 12:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CAR-T cell therapy,https://www.linkedin.com/company/march-biosciences,No,,,No,,,No,,
lipocine inc,2021-02-26 00:00:00,Yes,LPCN 1154; LPCN 2101; LPCN 2203; LPCN 2401; LPCN 1148; LPCN 1107; LPCN 1144; TLANDO,"GABA receptor, Gamma-Aminobutyric Acid receptor",CNS; epilepsy; essential tremor; obesity; liver cirrhosis; metabolic diseases,gpcr,Phase 3,Yes,oral delivery solutions for existing drugs,https://www.home.saxo/markets/stocks/lpcn-xnas,No,,,Yes,oral versions of several hormones,https://www.linkedin.com/company/lipocine-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules,https://www.linkedin.com/company/lipocine-inc-
spyryx biosciences inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sotio biotech as,"Error: Connection failed - HTTPSConnectionPool(host='www.ppf.eu', port=443): ",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,modified IL-15 (RLI) acting as a potent stimulant of NK cells and cytotoxic T cells,https://pmc.ncbi.nlm.nih.gov/articles/PMC5360142/,No,,,Yes,a new generation of potent and stable antibody-drug conjugates (ADCs),https://www.linkedin.com/company/sotio,No,,,No,,,Yes,proprietary technology designed to improve on the efficacy of CAR T therapies,https://www.linkedin.com/company/sotio,No,,,No,,,Yes,combining ACI treatment with oncolytic viruses,https://pmc.ncbi.nlm.nih.gov/articles/PMC5360142/
lb pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,LB-102,"D2, Dopamine Receptor D2",CNS; neuropsychiatric disorders; schizophrenia,gpcr,Phase 3,Yes,"investigational oral small molecule, LB-102",https://www.linkedin.com/company/lbpharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pliant therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,PLN-101095; PLN-74809; PLN-1474; PLN-101325,"αvβ8, Integrin αvβ8; αvβ1, Integrin αvβ1; TGF-β, Transforming Growth Factor-beta; Integrin α7β1",oncology; fibrosis; muscular dystrophies,other; other; cytokine; other,Phase 1; Phase 2b; Phase 1; Preclinical,Yes,discovery and development of integrin-based therapeutics,https://www.linkedin.com/company/pliantrx,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,integrin biology and TGF-β modulation,https://www.linkedin.com/company/pliantrx
mineralys therapeutics inc,2025-10-03 18:05:45,No,Lorundrostat,"CYP11B2, Aldosterone Synthase",cardiovascular; renal; metabolic diseases,enzyme,Phase 3,Yes,"lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI)",https://mineralystx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
acadia pharmaceuticals inc,2025-10-16 21:23:05,Yes,ACP-101; DAYBUE; ACP-204; pimavanserin,Not specified,CNS; rare diseases; neurodegenerative diseases,Not specified,Phase 3; Approved,Yes,developing the next wave of therapeutic advancements with a robust and diverse pipeline,https://acadia.com/en-us,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
peplin inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
dianthus therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,DNTH212; DNTH103,"BDCA2, Blood Dendritic Cell Antigen 2; BAFF/APRIL, B-cell Activating Factor/A Proliferation-Inducing Ligand; C1s, Complement Protein C1s",immunology; autoimmune diseases; neuromuscular diseases,cytokine; other,Phase 1; Phase 2,No,,,No,,,Yes,bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2,https://dianthustx.com/,Yes,monoclonal antibody engineered to selectively target the classical pathway,https://dianthustx.com/,No,,,Yes,bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2,https://dianthustx.com/,No,,,No,,,No,,,No,,,No,,
brii biosciences ltd,2025-08-21 11:02:00,Yes,BRII-179; Elebsiran; Tobevibart; BRII-732; BRII-753; Soralimixin,"HBV, Hepatitis B Virus; HDV, Hepatitis D Virus",infectious diseases,other,Phase 2,Yes,soralimixin (BRII-693),https://www.prnewswire.com/apac/news-releases/brii-biosciences-provides-corporate-updates-and-reports-2025-interim-financial-results-302535357.html,No,,,Yes,"BRII-179, a recombinant protein-based HBV immunotherapeutic",https://www.prnewswire.com/apac/news-releases/brii-biosciences-provides-corporate-updates-and-reports-2025-interim-financial-results-302535357.html,Yes,"tobevibart, a broadly neutralizing monoclonal antibody targeting HBV",https://www.prnewswire.com/news-releases/brii-biosciences-provides-corporate-update-and-reports-full-year-2024-financial-results-302407811.html,No,,,No,,,Yes,"elebsiran, an HBV-targeting siRNA",https://www.prnewswire.com/apac/news-releases/brii-biosciences-provides-corporate-updates-and-reports-2025-interim-financial-results-302535357.html,No,,,No,,,No,,,No,,
cara therapeutics inc,2025-04-15 20:05:15,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
teitur trophics aps,2025-10-15 00:00:00,Yes,TT-P34,"SorCS2, Sortilin-related Vps10p domain containing receptor",CNS; neurodegenerative diseases,other,Phase 2,No,,,Yes,first-in-class cyclic peptides,https://www.teiturtrophics.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
trefoil therapeutics llc,Error: Connection failed - HTTPSConnectionPool(host='www.exsightventures.com',No,TTHX1114,Not specified,ophthalmology,Not specified,Not specified,No,,,No,,,Yes,regenerative therapies,https://www.linkedin.com/company/trefoiltherapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
palladio biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Tolvaptan; Lixivaptan,Not specified,rare diseases; cardiovascular,Not specified,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zephyrm biotechnologies co ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,CAStem,Not specified,respiratory diseases; immunology; musculoskeletal diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,development of innovative cell therapy products derived from pluripotent stem cells (PSC),https://thebambooworks.com/increasing-losses-prompt-zephyrm-bioscience-to-seek-funds-through-ipo/,No,,,No,,,No,,
aboleris pharma,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,ABO21009,"CD45RC, Cluster of Differentiation 45RC",autoimmune diseases; inflammatory diseases,other,Phase 1,No,,,No,,,No,,,Yes,humanized anti-CD45RC monoclonal antibody,https://www.prnewswire.com/news-releases/aboleris-pharma-announces-first-cohort-dosed-in-phase-1-study-of-abo21009-a-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis-302447848.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
beijing zhidao biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,DX126-262,"HER2, Human Epidermal Growth Factor Receptor 2",oncology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vyriad inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Voyager-V1,Not specified,oncology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,in vivo CAR-T cell therapies,https://www.prnewswire.com/news-releases/vyriad-announces-strategic-collaboration-with-novartis-to-develop-in-vivo-car-t-cell-therapies-302310717.html,No,,,No,,,Yes,oncolytic viruses,https://www.linkedin.com/company/vyriad
hebei senlang biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sichuan zhishan weixin biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
genfit sa,2025-10-06 16:30:02,Yes,VS-02,Disease Name,metabolic diseases; rare diseases,other,Preclinical,Yes,"capacity to develop high potential assets, from early-stages to late development",https://www.linkedin.com/company/genfit,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
light chain bioscience,2025-10-13 12:39:02,Yes,Not specified,"CD47, Cluster of Differentiation 47",oncology,immune checkpoint,Phase 3,No,,,No,,,No,,,Yes,bispecific and multispecific antibody platform,https://www.swissbiotech.org/listing/lightchainbio/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
novimmune sa,2025-10-13 12:39:02,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities.,https://www.linkedin.com/company/novimmune/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
prokidney corp,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells,https://www.linkedin.com/company/prokidney-corp,No,,,No,,,No,,
suzhou ribo life sciences co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,RBD4059; RBD5044; RBD7022; RBD1016,Not specified,cardiovascular; metabolic diseases; liver diseases; kidney diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"RNAi technologies, oligonucleotide therapeutics, siRNA, ASO, Aptamer",https://www.linkedin.com/company/suzhou-ribo-life-science-ltd-co/,No,,,No,,,No,,,No,,
laurent pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='ca.linkedin.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
maggie''s pearl llc,"Error: Connection failed - HTTPSConnectionPool(host='www.maggiespearl.com', p",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,epalrestat,https://www.maggiespearl.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immunicom inc,2022-07-14 00:00:00,No,Atebimetinib; IMM-6-415,"MEK, Mitogen-Activated Protein Kinase Kinase",oncology,kinases,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,non-drug-based cancer therapy,https://www.linkedin.com/company/immunicom
inhalon biopharma inc,2022-12-08 00:00:00,Yes,IN-002; IN-006; IN-007; IN-003,Respiratory Syncytial Virus; SARS-CoV-2; Human Metapneumovirus,infectious diseases,other,Phase 1,No,,,No,,,No,,,Yes,inhaled antibodies to trap pathogens,https://www.linkedin.com/company/inhalon-biopharma,No,,,No,,,No,,,No,,,No,,,No,,,Yes,muco-trapping antibodies bind to pathogens and crosslink them to mucins,https://www.linkedin.com/company/inhalon-biopharma
trevena inc,2024-08-08 00:00:00,Yes,TRV045,Not specified,CNS; pain management,gpcr,Preclinical,Yes,drug discovery & development,https://www.linkedin.com/company/trevena-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"anesiva, inc.",2009-07-04 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nextcure inc,2025-07-16 00:00:00,Yes,SIM0505; LNCB74,"CDH6, Cadherin-6; B7-H4, B7 Homolog 4",oncology,other,Phase 1,No,,,No,,,No,,,Yes,immunomedicines to treat cancer and other immune-related diseases,https://www.linkedin.com/company/nextcure-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vbi vaccines inc,2024-05-09 00:00:00,No,BRII-179; VBI-2601; PreHevbri; VBI-1901,"HBV, Hepatitis B Virus; CMV, Cytomegalovirus",infectious diseases; oncology,other; other,Phase 2; Approved; Phase 2b,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,VBI develops vaccine candidates that mimic the natural presentation of viruses,https://www.linkedin.com/company/vbi-vaccines-inc,No,,,No,,
zyversa therapeutics inc,2025-09-10 11:55:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
proda biotech llc,Error: Connection failed - 403 Client Error: Forbidden for url: https://news.,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
attgeno ab,2022-07-05 09:22:09,No,Supernitro,Not specified,cardiovascular,Not specified,Phase 2,Yes,nitric oxide-donating drugs,https://www.linkedin.com/company/attgeno,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biomimetix jv llc,"Error: Connection failed - HTTPSConnectionPool(host='www.linkedin.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
defence therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.newsfilecorp.com', p",Yes,111In-AccuTOX-Trastuzumab,"HER2, Human Epidermal Growth Factor Receptor 2",oncology,other,Preclinical,No,,,No,,,No,,,Yes,antibody drug conjugates targeting various cancers,https://simplywall.st/stocks/ca/pharmaceuticals-biotech/cse-dtc/defence-therapeutics-shares,Yes,antibody drug conjugates (ADC) products using its proprietary platform,https://www.cnbc.com/quotes/DTC-FF,No,,,No,,,No,,,Yes,"ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; mRNA vaccination program",https://simplywall.st/stocks/ca/pharmaceuticals-biotech/cse-dtc/defence-therapeutics-shares,No,,,Yes,"AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma",https://simplywall.st/stocks/ca/pharmaceuticals-biotech/cse-dtc/defence-therapeutics-shares
rocky mountain ms research group llc,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",Yes,Frexalimab; IMU-838; Foralumab; Orelabrutinib; JPH034; CC-97540; PB018,CD40 ligand; Dihydroorotate dehydrogenase; CD3 antigen; Agammaglobulinaemia tyrosine kinase; LAT1; Immunologic cytotoxicity; Antibody-dependent cell cytotoxicity,CNS; immunology,immune checkpoint; enzyme; other; kinases; other; other; other,Phase 3; Phase 3; Phase 2; Phase 2; Phase 1; Phase 1; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biodonostia health research institute,Error: Connection failed - HTTPSConnectionPool(host='innovation-radar.ec.euro,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cann group ltd,Error: Connection failed - HTTPSConnectionPool(host='www.canngrouplimited.com,Yes,CGX-926,"MC4R, Melanocortin 4 Receptor",genetic obesity,gpcr,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,medicinal cannabis for both medicinal and research purposes,https://www.latrobe.edu.au/industry-and-community/la-trobe-industry/case-studies/cann-group
wihuri research institute,"Error: Connection failed - HTTPSConnectionPool(host='wihurinrahasto.fi', port",No,ONO-4059; Doxorubicin; Gefitinib; Bosutinib; Docetaxel,"NRP1, Neuropilin 1",infectious diseases; cardiovascular; neurocognitive disorders,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
theravitae co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,stem cells,https://www.theravitae.com/,No,,,No,,,Yes,platelet rich plasma,https://www.theravitae.com/
thiogenesis therapeutics corp,2025-10-17 00:00:00,Yes,TTI-0102,Not specified,rare diseases; metabolic diseases,Not specified,Phase 2,Yes,developing sulfur-containing prodrugs that act as precursors,https://ca.linkedin.com/company/thiogenesis-therapeutics-corp,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
anthos therapeutics inc,2025-02-11 14:46:26,No,Abelacimab,"FXI, Factor XI",cardiovascular,enzyme,Phase 3,No,,,No,,,No,,,Yes,monoclonal antibody targeting the FXI inhibition pathway,https://www.novartis.com/news/media-releases/novartis-bolsters-late-stage-cardiovascular-pipeline-agreement-acquire-anthos-therapeutics-usd-925-million-upfront,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nighthawk biosciences inc,Error: Connection failed - HTTPSConnectionPool(host='nighthawkbio.chadbaucom.,No,PTX-35,Not specified,immunology,Not specified,Not specified,No,,,No,,,Yes,large molecule biomanufacturing,https://www.scorpiusbiologics.com/news/nighthawk-biosciences-completes-name-change-to-scorpius-holdings,No,,,No,,,No,,,No,,,Yes,rapidly advancing biologic and cell therapy programs,https://www.scorpiusbiologics.com/news/nighthawk-biosciences-completes-name-change-to-scorpius-holdings,No,,,No,,,No,,
translate bio inc,Error: can't compare offset-naive and offset-aware dateti,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,Yes,mRNA therapeutics,https://www.drugtargetreview.com/news/97380/sanofi-acquires-translate-bio-for-mrna-therapeutic-development/,No,,,Yes,mRNA vaccines,https://www.drugtargetreview.com/news/97380/sanofi-acquires-translate-bio-for-mrna-therapeutic-development/,No,,,No,,
chinook therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.novartis.com', port=",Yes,nedosiran; lumasiran,"LDHA, Lactate Dehydrogenase A",rare diseases; metabolic diseases,enzyme,Approved,Yes,"atrasentan, an oral endothelin A receptor antagonist",https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-medicines-strategy-and-renal-pipeline-agreement-acquire-chinook-therapeutics-usd-32bn-upfront-usd-40-share,No,,,No,,,Yes,"zigakibart, an anti-APRIL monoclonal antibody",https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-medicines-strategy-and-renal-pipeline-agreement-acquire-chinook-therapeutics-usd-32bn-upfront-usd-40-share,No,,,No,,,No,,,No,,,No,,,No,,,No,,
realta life sciences inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,RLS-0071,"C1, Complement Component 1; MPO, Myeloperoxidase; NETs, Neutrophil Extracellular Traps",rare diseases; acute inflammatory diseases,enzyme; cytokine; other,Phase 2,No,,,Yes,engineered peptides with potential for treating conditions in many therapeutic areas through its unique dual targeting mechanism,https://realtalifesciences.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ascelia pharma ab,2025-10-01 06:19:08,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,Oncoral is a novel oral irinotecan tablet in development.,https://www.linkedin.com/company/asceliapharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
trellis bioscience llc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='carb-x.org', port=443): ",No,TRL 1068,Biofilm,infectious diseases,other,Phase 1,No,,,No,,,No,,,Yes,native human monoclonal antibodies,https://www.linkedin.com/company/trellis-bioscience,No,,,No,,,No,,,No,,,No,,,No,,,No,,
atlas molecular pharma sl,2022-03-02 00:00:00,Yes,ATL-001,Not specified,rare diseases; ultra-rare diseases; metabolic disorders,enzyme,Phase 1,Yes,developing new pharmacological chaperones for the treatment of rare metabolic diseases,https://biotech-spain.com/en/articles/atlas-molecular-pharma-closes-a-eur-3-million-round-of-funding-to-advance-clinical-development-of-a-drug-to-treat-congenital-erythropoietic-porphyria/,No,,,Yes,"stabilising and recovering the function of UROIIIS, the protein which, when defective due to inherited mutations, causes the accumulation of toxic porphyrins",https://biotech-spain.com/en/articles/atlas-molecular-pharma-closes-a-eur-3-million-round-of-funding-to-advance-clinical-development-of-a-drug-to-treat-congenital-erythropoietic-porphyria/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
imunon inc,2025-10-15 14:54:06,Yes,IMNN-101; IMNN-001,SARS-CoV-2 Omicron XBB1.5 spike antigen variant; Advanced ovarian cancer,infectious diseases; oncology,other; cytokine,Phase 1; Phase 3,No,,,No,,,Yes,gene-based delivery of cytokines and other therapeutic proteins,https://www.globenewswire.com/news-release/2025/10/17/3168591/0/en/IMUNON-Invited-to-Present-PlaCCine-DNA-Technology-Proof-of-Concept-Data-in-Platform-Presentations-at-Leading-Vaccine-Conferences.html,No,,,No,,,No,,,Yes,non-viral DNA technology,https://www.globenewswire.com/news-release/2025/10/17/3168591/0/en/IMUNON-Invited-to-Present-PlaCCine-DNA-Technology-Proof-of-Concept-Data-in-Platform-Presentations-at-Leading-Vaccine-Conferences.html,No,,,Yes,PlaCCine platform for the development of nucleic acid vaccines,https://www.linkedin.com/company/imunon,No,,,No,,
matinas biopharma holdings inc,2025-03-13 00:00:00,Yes,MAT2203; MAT2501,Fungal Infections; Bacterial Infections,infectious diseases; orphan indications,other,Phase 3; Phase 1,Yes,improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology,https://www.linkedin.com/company/matinas-biopharma,No,,,No,,,No,,,No,,,No,,,Yes,"Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides",https://www.linkedin.com/company/matinas-biopharma,No,,,Yes,"Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines",https://www.linkedin.com/company/matinas-biopharma,No,,,Yes,lipid nanocrystal (LNC) platform technology,https://www.linkedin.com/company/matinas-biopharma
oncosynergy inc,2025-08-07 16:30:04,No,OS2966,Not specified,oncology,other,Phase 1,No,,,No,,,No,,,Yes,anti-PD1 antibody,https://www.linkedin.com/company/oncosynergy,No,,,No,,,No,,,No,,,No,,,No,,,No,,
monta biosciences aps,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,MBS8,"TLR7, Toll-like Receptor 7",oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,TLR7 agonist formulated in micelles,https://dk.linkedin.com/company/monta-biosciences
keranetics llc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,KeraStat,Disease Name,oncology,Not specified,Phase N/A,No,,,No,,,Yes,"purified, human-derived keratin",https://www.linkedin.com/company/keranetics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
apeptico research and development ltd,Error: Connection failed - HTTPSConnectionPool(host='www.lifesciencesdirector,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
phost''in sas,"Error: Connection failed - HTTPSConnectionPool(host='www.phostin.com', port=4",No,TALZENNA; XTANDI; PADCEV; mevrometostat; disitamab vedotin; sasanlimab,"EZH2, Enhancer of Zeste Homolog 2; PD-1, Programmed Death-1; HER2, Human Epidermal Growth Factor Receptor 2",oncology; genitourinary cancers; prostate cancer; bladder cancer,enzyme; immune checkpoint; other,Phase 3; Approved; Phase 1; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
follicum ab,2022-02-02 23:00:00,Yes,FOL-005,"Disease Name, Alopecia",dermatology,other,Phase 2,No,,,Yes,novel tissue repair peptides,https://www.marketscreener.com/quote/stock/FOLLICUM-AB-PUBL-120972169/,Yes,"drug candidate for hair growth inhibition, FOL-005, is based on an endogenous protein",https://www.marketscreener.com/quote/stock/FOLLICUM-AB-PUBL-120972169/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
89bio inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,pegozafermin,"FGF21, Fibroblast Growth Factor 21",metabolic diseases; liver diseases; cardiovascular diseases,cytokine,Phase 3,No,,,No,,,Yes,glycoPEGylated analog of FGF21,https://www.linkedin.com/company/89bio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kairos pharma ltd,2025-10-17 13:26:12,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma",https://www.home.saxo/markets/stocks/kapa-xase,No,,,No,,,Yes,"antibodies for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma",https://www.home.saxo/markets/stocks/kapa-xase,No,,,No,,,No,,,No,,,No,,,No,,,No,,
idera pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
principia biopharma inc,"Error: Connection failed - HTTPSConnectionPool(host='www.sanofi.com', port=44",No,Wayrilz; rilzabrutinib; tolebrutinib,"BTK, Bruton Tyrosine Kinase",immunology; autoimmune diseases; rare diseases,kinases,Approved,Yes,reversible and irreversible covalent small molecule inhibitors,https://www.linkedin.com/company/principia-biopharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
human genome sciences inc,2012-07-27 00:00:00,No,Albutropin,Not specified,endocrinology,Not specified,Not specified,No,,,No,,,No,,,Yes,mAb,https://www.linkedin.com/company/human-genome-sciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ludwig institute for cancer research ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
syntara ltd,2025-10-16 21:48:33,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,oral and topical pan-LOX inhibitors,https://au.linkedin.com/company/syntara-tx,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
montreal clinical research institute,"Error: Connection failed - HTTPSConnectionPool(host='leadiq.com', port=443): ",Yes,TransCon CNP; TYRA-300; VOXZOGO; Infigratinib; RBM-007; SAR-442501; Recombinant human growth hormone; BMN 111,"FGFR3, Fibroblast Growth Factor Receptor 3; CNP, C-type Natriuretic Peptide",rare diseases; oncology,kinases; cytokine,Phase 2; Phase 3; Approved,Yes,new class of drugs that can reduce bad cholesterol levels by up to 70%,https://ca.linkedin.com/company/ircm,No,,,Yes,"Everyday biological processes, like digestion, immune response and memory, depend on certain proteins.",https://ca.linkedin.com/company/ircm,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neurizon therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,Preclinical Characterization of NUZ-001: A Brain-Penetrant Small Molecule That Reduces TDP-43 Aggregation in ALS Models,https://au.linkedin.com/company/neurizon,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
chemocentryx inc,2022-10-20 09:05:36,Yes,Avacopan,"C5aR1, Complement Component 5a Receptor 1",immunology; rare diseases,gpcr,Phase 3,Yes,"TAVNEOS (avacopan), approved by the FDA as an adjunctive treatment of ANCA-associated vasculitis, is a first-in-class, orally administered small molecule",https://www.prnewswire.com/news-releases/amgen-successfully-completes-acquisition-of-chemocentryx-301654916.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
athersys inc,2023-05-18 00:00:00,No,MultiStem,Not specified,neurological; inflammatory & immune; cardiovascular,other,Phase 3,Yes,pharmaceuticals,https://www.linkedin.com/company/athersys,No,,,No,,,No,,,No,,,No,,,No,,,Yes,stem cell therapy,"https://www.athersys.com/home/default.aspx#:~:text=Athersys%20is%20a%20clinical%2Dstage,the%20quality%20of%20human%20life.",No,,,No,,,No,,
everimmune sa,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Oncobax® AK,Not specified,oncology,Not specified,Phase 1; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Live Biotherapeutic Product (LBP),https://www.linkedin.com/company/everimmune/
immorna biotherapeutics inc,No timestamp found,Yes,JCXH-211,"IL-12, Interleukin-12",oncology,cytokine,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,Yes,mRNA-based therapeutics,https://www.linkedin.com/company/immorna,No,,,Yes,mRNA-based vaccines,https://www.linkedin.com/company/immorna,No,,,Yes,"lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery",https://www.linkedin.com/company/immorna
phoenicia biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.sbir.gov', port=443)",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
levicept ltd,2025-10-14 11:00:09,No,LEVI-04,"NT-3, Neurotrophin-3",osteoarthritis; chronic pain,cytokine,Phase 2,No,,,No,,,Yes,p75 neurotrophin receptor fusion protein (p75NTR-Fc),https://uk.linkedin.com/company/levicept-ltd,No,,,No,,,Yes,p75 neurotrophin receptor fusion protein (p75NTR-Fc),https://uk.linkedin.com/company/levicept-ltd,No,,,No,,,No,,,No,,,No,,
abvance therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,ABV100,Not specified,diabetes,other,Preclinical,No,,,Yes,"ABV100: A titratable, fixed ratio combination of two FDA-approved peptides to control glycemia while mitigating the threat of hypoglycemia.",https://www.linkedin.com/company/abvance-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
elpida therapeutics,"Error: Connection failed - HTTPSConnectionPool(host='blog.cirm.ca.gov', port=",No,ELP-02,"FIG4, FIG4 Gene",rare diseases; neurodegenerative disorders,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Gene Therapies,https://www.linkedin.com/company/elpidatx,No,,,No,,,No,,
elpida llc,2025-09-26 19:11:17,No,ELP-02,"FIG4, FIG4 Gene",rare diseases; neurodegenerative disorders,other,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Gene Therapies,https://www.linkedin.com/company/elpidatx,No,,,No,,,No,,
yap therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",Yes,VT-107; K-975; IK-930,"TEAD, TEA Domain Transcription Factor; YAP, Yes-Associated Protein; TAZ, Transcriptional Coactivator with PDZ-binding Motif",oncology,other,Preclinical; Phase 1,No,,,No,,,No,,,No,,,Yes,drug-antibody conjugates (ADCs),https://www.northstarnm.com/northstar-medical-radioisotopes-and-yap-therapeutics-enter-into-collaboration-agreement-for-the-development-and-production-of-radiopharmaceutical-products/,No,,,No,,,Yes,targeted AAV-based gene therapy for regenerative medicines,https://www.northstarnm.com/northstar-medical-radioisotopes-and-yap-therapeutics-enter-into-collaboration-agreement-for-the-development-and-production-of-radiopharmaceutical-products/,No,,,No,,,Yes,radio-labeled biopharmaceuticals aimed at treating life-threatening cancers,https://www.northstarnm.com/northstar-medical-radioisotopes-and-yap-therapeutics-enter-into-collaboration-agreement-for-the-development-and-production-of-radiopharmaceutical-products/
celularity inc,2025-10-14 14:17:04,No,gedatolisib,"PI3K, Phosphatidylinositol-4,5-biphosphate 3-kinase; mTOR, Mechanistic Target of Rapamycin",oncology,kinases,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"placenta-derived T cells, NK cells, and pluripotent stem cells",https://www.linkedin.com/company/celularity,No,,,No,,,Yes,"placental-derived cell therapies, mesenchymal-like adherent stromal cells",https://www.marketscreener.com/quote/stock/CELULARITY-INC-124927370/company/
diamedica therapeutics inc,2025-10-16 18:43:02,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,Recombinant Protein,https://www.linkedin.com/company/diamedica,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
corvus pharmaceuticals inc,2025-10-10 14:16:57,Yes,Soquelitinib,"ITK, Interleukin-2-Inducible T-cell Kinase",immunology; dermatology,kinases,Phase 1,Yes,developing product candidates that precisely target proteins,https://www.home.saxo/markets/stocks/crvs-xnas,No,,,Yes,"product candidate, soquelitinib, is designed to bind specifically to a protein",https://www.home.saxo/markets/stocks/crvs-xnas,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
isa pharmaceuticals bv,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,ISA101b,"HPV16, Human Papillomavirus Type 16",oncology,other,Phase 2,No,,,Yes,Synthetic Long Peptide (SLP®) concept,https://www.linkedin.com/company/isa-pharmaceuticals/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,therapeutic vaccine technology,https://www.labiotech.eu/more-news/isa-pharmaceuticals-amplivant-adjuvant-boosts-immune-response-in-slp-immunotherapy/,No,,,No,,
vandria sa,"Error: Connection failed - HTTPSConnectionPool(host='hevolution.com', port=44",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"We are developing small molecules to treat unmet medical need in the areas of CNS, lung, liver, and muscle disease.",https://www.swissbiotech.org/listing/vandria-sa/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
apogee therapeutics inc,No timestamp found,Yes,APG777,Not specified,immunology; inflammatory disorders,Not specified,Phase 1,No,,,No,,,No,,,Yes,"monoclonal antibody (mAb), APG777, APG990, APG333, APG808",https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apge/apogee-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
4d molecular therapeutics inc,2025-10-17 14:32:57,No,4D-150; 4D-710; 4D-175; 4D-725; 4D-310; 4D-110; 4D-125,Wet Age-Related Macular Degeneration; Diabetic Macular Edema; Cystic Fibrosis; Geographic Atrophy; Alpha-1 Antitrypsin Deficiency; Fabry Disease Cardiomyopathy; Choroideremia; X-Linked Retinitis Pigmentosa,ophthalmology; pulmonology; cardiology; rare diseases,Not specified,Phase 2; Phase 1/2; Phase 1; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Gene Therapy, Adeno-Associated Virus",https://4dmoleculartherapeutics.com/,No,,,No,,,No,,
corixa corp,"Error: Connection failed - HTTPSConnectionPool(host='www.seattletimes.com', p",No,Bexxar; Melacine; MPL; PVAC,Not specified,oncology; immunology; infectious diseases; autoimmune diseases,other,Approved; Phase 3; Marketed; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,immunotherapeutics,https://www.clearygottlieb.com/news-and-insights/news-listing/glaxosmithkline-in-%24300-million-corixa-acquisition128,No,,,No,,
tizona therapeutics inc,2020-07-21 00:00:00,Yes,NBTXR-3; mRNA-4157; HB-200; MCLA-158; HFB-301001,"PD-1, Programmed Death-1; EGFR, Epidermal Growth Factor Receptor; LGR5, Leucine-rich Repeat Containing G-protein-coupled Receptor 5; OX-40, Tumor Necrosis Factor Receptor Superfamily Member 4",oncology,immune checkpoint; other; gpcr; other,Phase 3; Phase 2/III; Phase II; Phase I/II; Phase I,No,,,No,,,No,,,Yes,"TTX-080, an anti-HLA-G antibody",https://www.gilead.com/news/news-details/2020/gilead-sciences-secures-exclusive-option-to-acquire-tizona-therapeutics-for-300-million,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ascendis pharma as,2025-10-14 12:00:56,No,TransCon CNP; TransCon hGH,"CNP, C-type Natriuretic Peptide; FGFR3, Fibroblast Growth Factor Receptor 3",rare diseases,cytokine; kinases,Phase 2,No,,,No,,,Yes,growth hormone,https://www.linkedin.com/company/ascendis-pharma-a-s,No,,,No,,,Yes,TransCon technology platform,https://www.linkedin.com/company/ascendis-pharma-a-s,No,,,No,,,No,,,No,,,No,,
iveric bio inc,2022-12-30 00:00:00,No,Avacincaptad pegol,"C5, Complement Component 5",ophthalmology,enzyme,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapy,https://www.linkedin.com/company/ivericbio,No,,,No,,,No,,
jade biosciences inc,2024-10-31 12:18:00,Yes,JADE101; JADE201; JADE-003,"APRIL, A Proliferation-Inducing Ligand",autoimmune diseases,cytokine,Preclinical,No,,,No,,,No,,,Yes,anti-APRIL monoclonal antibody,"https://www.linkedin.com/company/jade-biosciences#:~:text=About%20us,Industry%20Biotechnology%20Research",No,,,No,,,No,,,No,,,No,,,No,,,No,,
zenas biopharma (usa) llc,2025-10-08 09:07:07,No,Orelabrutinib; Obexelimab; IL-17AA/AF inhibitor; TYK2 inhibitor,"BTK, Bruton’s Tyrosine Kinase; CD19, Cluster of Differentiation 19; FcγRIIb, Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b; IL-17AA/AF, Interleukin-17AA/AF; TYK2, Tyrosine Kinase 2",neurology; immunology; autoimmune diseases,kinases; immune checkpoint; cytokine; other,Phase 3; Phase 2; Preclinical,No,,,No,,,No,,,Yes,bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb,https://www.linkedin.com/company/zenas-biopharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,
uniquity bio inc,Error: can't compare offset-naive and offset-aware dateti,No,Solrikitug; MK-8226,"TSLP, Thymic Stromal Lymphopoietin",immunology; inflammation; respiratory diseases; gastrointestinal diseases,cytokine,Phase 2,No,,,No,,,No,,,Yes,monoclonal antibody targeting thymic stromal lymphopoietin (TSLP),https://www.blackstone.com/news/press/blackstone-life-sciences-launches-uniquity-bio-to-develop-novel-medicines-in-immunology-inflammation/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
acelyrin inc,2025-05-21 13:05:17,Yes,Izokibep; Lonigutamab; SLRN-517,"IL-17A, Interleukin-17A; IGF-1R, Insulin-like Growth Factor 1 Receptor; c-KIT, Proto-Oncogene c-KIT",immunology; thyroid eye disease; chronic urticaria,cytokine; other; other,Phase 3; Phase 1; Preclinical,Yes,oral tyrosine kinase 2 inhibitors,https://www.nasdaq.com/articles/alumis-inc-completes-merger-acelyrin-inc-strengthen-pipeline-immune-mediated-disease,No,,,Yes,anti–insulin-like growth factor 1 receptor therapy,https://www.nasdaq.com/articles/alumis-inc-completes-merger-acelyrin-inc-strengthen-pipeline-immune-mediated-disease,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
apellis pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Empaveli; Syfovre,"C3, Complement Component 3",rare diseases; ophthalmology,other,Approved,No,,,Yes,pegcetacoplan,https://www.marketscreener.com/news/apellis-pharmaceuticals-shares-rise-after-wells-fargo-upgrade-ce7d5adfda8ef120,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
athira pharma inc,2024-11-08 09:50:03,Yes,ATH-1105; Fosgonimeton,"HGF, Hepatocyte Growth Factor",CNS; neurodegenerative diseases,other,Phase 1,Yes,trying to develop small molecule drugs that help regenerate nerve cells,https://www.biopharmadive.com/news/athira-strategic-alternatives-earnings-alzheimers-neuroscience/732405/,No,,,Yes,"Athira’s research specifically revolves around hepatocyte growth factor, or HGF, a protein involved in protecting, growing and repairing brain cells",https://www.biopharmadive.com/news/athira-strategic-alternatives-earnings-alzheimers-neuroscience/732405/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kiadis pharma nv,"Error: Connection failed - HTTPSConnectionPool(host='www.sanofi.com', port=44",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
synageva biopharma corp,2015-02-05 00:00:00,No,SBC-103; Kanuma; SBC-105,"NAGLU, Alpha-N-Acetyl-Glucosaminidase; ENPP1, Ectonucleotide Pyrophosphatase/Phosphodiesterase-1",rare diseases; metabolic diseases,enzyme,Phase 1/2; Approved; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
eutilex co ltd,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
crucell nv (inactive),Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,No,CR8020; CR6261; Quinvaxem,"Hemagglutinin, Influenza A Virus Surface Protein",infectious diseases,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,centre for vaccines within Johnson & Johnson's pharmaceuticals group,https://www.prnewswire.com/news-releases/johnson--johnson-launches-recommended-public-offer-to-acquire-crucell-111510254.html,No,,,No,,
occurx pty ltd,2024-12-19 00:00:00,Yes,Asengeprast; FT011; OCX063; CTA382,"GPR68, G Protein-Coupled Receptor 68",fibrotic diseases; systemic sclerosis; chronic kidney disease; focal segmental glomerulosclerosis; diabetic nephropathy,gpcr,Phase 2,Yes,"third-generation series of pre-clinical GPR68 antagonists, based on a different chemical backbone",https://certatherapeutics.com/certa-therapeutics-expands-gpr68-platform-through-acquisition-of-occurx/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zz biotech llc,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,3K3A-APC,Not specified,cardiovascular,enzyme,Phase 3,No,,,No,,,Yes,"3K3A-APC, a genetically engineered variant of human activated protein C (APC), a serine protease, that has been optimized for human therapeutic use",https://www.linkedin.com/company/zz-biotech,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
mediwound ltd,2025-09-30 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,next-generation protein-based therapies for burn and wound care,"https://www.cnbc.com/quotes/MDWD#:~:text=Mediwound%20Ltd%20is%20an%20Israel,for%20tissue%20repair%20and%20regeneration.",No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
galera therapeutics inc,2023-03-15 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,small molecule superoxide dismutase mimetics,https://www.globenewswire.com/news-release/2024/12/31/3003077/0/en/Galera-Therapeutics-completes-acquisition-of-Nova-Pharmaceuticals.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cognition therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,small molecule therapeutics,https://www.cnbc.com/quotes/CGTX,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
flexion therapeutics inc,2015-09-04 00:00:00,No,ZILRETTA,"Disease Name, Osteoarthritis Knee Pain",musculoskeletal disorders,Not specified,Marketed,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
jasper therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,briquilimab,"KIT, CD117",immunology; respiratory diseases,other,Preclinical,No,,,No,,,No,,,Yes,"briquilimab, a humanized antibody designed to stop KIT signaling",https://www.linkedin.com/company/jaspertherapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cytonics corp,2025-08-17 20:35:28,Yes,TG-C; LNA043; SAR446959,Not specified,osteoarthritis,Not specified,Phase 3; Phase 2; Phase 1,No,,,No,,,Yes,CYT-108 is a recombinant protease inhibitor therapy with potential disease-modifying effects,https://www.prnewswire.com/news-releases/cytonics-announces-that-last-patient-completes-last-visit-in-first-in-human-phase-1-clinical-trial-for-cyt-108-as-a-treatment-for-osteoarthritis-302415007.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
lin bioscience inc,"Error: Connection failed - HTTPSConnectionPool(host='www.linbioscience.com', ",Yes,LBS-007; LBS-008; LBS-009; LBS-002,"CDC7, Cell Division Cycle 7",oncology; ophthalmology; metabolic diseases,kinases,Phase 1,Yes,LBS-007 has demonstrated very potent activity against leukemia and multiple solid tumors in preclinical studies.,https://www.globenewswire.com/news-release/2024/11/27/2987977/0/en/Lin-BioScience-Receives-U-S-FDA-Fast-Track-Designation-For-LBS-007.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rigerna therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,VMT01/02; VMT-α-NET; PSV359; PSV4XX,"MC1R, Melanocortin 1 Receptor; SSTR2, Somatostatin Receptor 2; FAP-α, Fibroblast Activation Protein-alpha; PSMA, Prostate-Specific Membrane Antigen",oncology; melanoma; neuroendocrine tumors; solid tumors; prostate cancer,gpcr; gpcr; enzyme; other,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,Yes,siRNA,https://www.linkedin.com/company/rigerna-therapeutics,No,,,No,,,No,,,No,,
oncoverity inc (inactive),Error: Connection failed - HTTPSConnectionPool(host='www.pharmaceutical-techn,No,CLP002; BT5528; SAR408701; RAYZ-8009; 177 Lu-FAP-2286,"PD-L1, Programmed Death-Ligand 1; EphA2, Ephrin Type-A Receptor 2; CEACAM5, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; GPC3, Glypican-3; FAP, Fibroblast Activation Protein",oncology,immune checkpoint; other; other; other; other,Phase 2; Phase 1/2; Phase 2; Phase 1/1b; Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
afasci inc,"Error: Connection failed - HTTPSConnectionPool(host='convention.bio.org', por",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,small molecule drugs,https://conductscience.com/supplier/afasci/?srsltid=AfmBOorr0DAW6YB0FmyrXSGSl8dVw4B9NtqSTY6uO7KPW_u_W-P0sIbQ,Yes,peptide drugs,https://conductscience.com/supplier/afasci/?srsltid=AfmBOorr0DAW6YB0FmyrXSGSl8dVw4B9NtqSTY6uO7KPW_u_W-P0sIbQ,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
botanic healthcare pvt ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.entrepreneur.com', p",No,Not specified,Not specified,oncology,Not specified,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sitryx therapeutics ltd,2025-10-15 11:08:33,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"novel, oral MTHFD2 inhibitor",https://uk.linkedin.com/company/sitryx-therapeutics-limited,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
hangzhou sumgen biotech co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.sumgenbio.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sensei biotherapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,Yes,solnerstotug; SNS-101; SNS-102; SNS-103; SNS-20,"VISTA, V-domain Ig suppressor of T cell activation",oncology,immune checkpoint,Phase 1/2,No,,,No,,,No,,,Yes,conditionally active antibodies,https://www.senseibio.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aldena therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,ALY-101; ALD-102,"JAK1, Janus Kinase 1",dermatology; autoimmune diseases,kinases,Phase 2; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,Yes,siRNA-based therapies,https://pci.com/aldena-therapeutics-selects-pci/,No,,,No,,,No,,,No,,
nammi therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='themmrf.org', port=443):",No,QXL138AM; SLNP-IC1; NTI-121,"CD138, Syndecan-1",oncology; immunology,cytokine,Phase 1,No,,,No,,,Yes,Interferon alpha 2 is a potent anti-cancer therapeutic,https://www.prnewswire.com/news-releases/nammi-therapeutics-inc-announces-first-patient-dosed-with-qxl138am-in-a-phase-1-study-evaluating-advanced-solid-tumors-and-multiple-myeloma-302299498.html,Yes,tumor antigen targeting antibody fused to a masked cytokine,https://www.nammirx.com/,Yes,Masked ImmunoCytokines (MICs): A tumor antigen targeting antibody fused to a masked cytokine,https://www.nammirx.com/,No,,,No,,,No,,,No,,,No,,,Yes,Nammisomes: Prodrugs of Immune modulators formulated as combinations in lipid-based nanoparticles,https://www.nammirx.com/
abm therapeutics corp,"Error: Connection failed - HTTPSConnectionPool(host='www.vivabiotech.com', po",Yes,ABM-1310,Not specified,oncology; CNS,Not specified,Phase 1,Yes,small molecule targeted therapy,https://www.linkedin.com/company/abm-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
abm therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.vivabiotech.com', po",Yes,ABM-1310,Not specified,oncology; CNS,Not specified,Phase 1,Yes,small molecule targeted therapy,https://www.linkedin.com/company/abm-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
certa therapeutics pty ltd,2024-12-19 09:00:00,Yes,FT011; OCX063; CTA382,"GPR68, G Protein-Coupled Receptor 68",fibrotic diseases; autoimmune diseases; kidney diseases,gpcr,Phase 2,Yes,advanced clinical pipeline of innovative small molecule candidate drugs that target GPR68,https://www.globenewswire.com/news-release/2024/12/19/2999579/0/en/Certa-Therapeutics-Expands-GPR68-Platform-through-Acquisition-of-OccuRx.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
xalud therapeutics inc,2021-09-24 00:00:00,Yes,XT-150,"IL-10, Interleukin-10",musculoskeletal; CNS; chronic inflammatory diseases,cytokine,Phase 2,No,,,No,,,Yes,"interleukin-10 (IL-10), a potent cytokine",https://www.xaludthera.com/,No,,,No,,,No,,,Yes,non-viral plasmid DNA (pDNA)-delivered gene therapy platform,https://www.xaludthera.com/,Yes,non-viral plasmid DNA (pDNA)-delivered gene therapy platform,https://www.xaludthera.com/,No,,,No,,,No,,
lyvgen biopharma ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,LVGN-6051,"CD137, 4-1BB",oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,Yes,agonist therapeutic antibodies for cancer,https://www.linkedin.com/company/lyvgen-biopharma?trk=similar-pages_result-card_full-click,No,,,No,,,No,,,No,,,No,,,No,,,No,,
atox bio ltd,2022-11-21 07:41:21,No,RBT-1; OCE-205,Not specified,acute kidney injury; cardiovascular diseases,Not specified,Phase 3; Not specified,No,,,Yes,Reltecimod (AB103) is a rationally designed peptide,https://www.integra-holdings.com/news/atox-bio-closes-30-million-investment/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
incarda therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Inrhythm,Disease Name,cardiovascular,Not specified,Not specified,Yes,"developing novel drugs designed for rapid, safe, and effective cardioversion of atrial fibrillation (AF)",https://www.linkedin.com/company/incarda-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nutrinia ltd (inactive),Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,No,SER-109; ridinilazole; Blautix; B244,Clostridium difficile; Irritable Bowel Syndrome; Acne Vulgaris,infectious diseases; gastrointestinal; dermatology,enzyme; other; other,Pre-registration; Phase 2; Phase II/III,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
intersect ent inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,PROPEL; SINUVA,Nasal Polyps; Chronic Rhinosinusitis,"Ear, Nose, and Throat (ENT)",other,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,bioabsorbable steroid-eluting sinus implants,https://news.medtronic.com/2022-05-13-Medtronic-completes-acquisition-of-Intersect-ENT
lutris pharma,2025-01-28 07:03:34,No,LUT014,"B-Raf, B-Raf Protein",oncology; dermatology,kinases,Phase 2,Yes,small molecule,https://www.prnewswire.com/news-releases/lutris-pharma-secures-30-million-financing-to-advance-the-development-of-biopharmaceutical-to-improve-anti-cancer-drug-effectiveness-302361244.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
advanced biodesign,2025-10-14 13:06:52,No,ABD-3001,Disease Name,oncology,Not specified,Preclinical,Yes,development of small-molecule that will selectively inhibit specific ALDH enzyme,https://fr.linkedin.com/company/advanced-biodesign,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
canary foundation for health research,No timestamp found,Yes,CCT-217,Not specified,metabolic diseases,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"molecular imaging, proteomics, chemistry, cell and molecular biology, and bioinformatics",https://med.stanford.edu/canarycenter/history.html
multidisciplinary association for psychedelic studies,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,MDMA,"PTSD, Post-Traumatic Stress Disorder",CNS,other,Phase 3,Yes,Developing psychedelics and marijuana into prescription medicines,https://www.linkedin.com/company/mapsnews,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"MDMA-Assisted Therapy for Posttraumatic Stress Disorder (PTSD), MDMA-Assisted Therapy for Social Anxiety in Autistic Adults, MDMA-Assisted Therapy for Life-Threatening Illness",https://www.linkedin.com/company/mapsnews
"diobex, inc. (inactive)","Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
changchun baike biotech co ltd,"Error: Connection failed - HTTPConnectionPool(host='www.bchtpharm.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shanton pharma co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.shantonpharma.com', ",No,HR091506; Febuxostat; IG3018,Not specified,metabolic diseases,enzyme,Phase 3; Phase 2/3; Phase 1/2,Yes,advanced and innovative drug research and developmental approaches,https://www.linkedin.com/company/shanton-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shanton pharma holdings ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.shantonpharma.com', ",No,SAP-001,Not specified,metabolic diseases,enzyme,Phase 2,Yes,advanced and innovative drug research and developmental approaches,https://www.linkedin.com/company/shanton-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
9 meters biopharma inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.rttnews.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
synklino aps,"Error: Connection failed - HTTPSConnectionPool(host='eirventures.eu', port=44",Yes,SYN002,"CMV, Cytomegalovirus",infectious diseases,other,Preclinical,No,,,No,,,Yes,fusion protein that targets US28 for CMV infections,https://www.linkedin.com/company/synklino/,No,,,No,,,Yes,fusion protein that targets US28 for CMV infections,https://www.linkedin.com/company/synklino/,No,,,No,,,No,,,No,,,No,,
lianbio,2020-11-29 00:00:00,No,Infigratinib; TP-03; BBP-398,"FGFR1-3, Fibroblast Growth Factor Receptor 1-3; Demodex; SHP2, Src Homology 2 Domain Containing Protein Tyrosine Phosphatase",oncology; ophthalmology,kinases; other; enzyme,Phase 2; Phase 3; Phase 1,Yes,marketing rights to the heart medicine mavacamten,https://www.biopharmadive.com/news/lianbio-shut-down-return-cash-dividend/707451/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
fred hutchinson cancer research center,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,STEAP1,"STEAP1, Six Transmembrane Epithelial Antigen of the Prostate 1",oncology,other,Preclinical,No,,,No,,,No,,,Yes,immunotherapy,https://bigtencrc.org/member-institutions/fred-hutch-cancer-center/,No,,,No,,,No,,,Yes,bone marrow transplantation,https://bigtencrc.org/member-institutions/fred-hutch-cancer-center/,Yes,COVID-19 vaccines,https://bigtencrc.org/member-institutions/fred-hutch-cancer-center/,No,,,No,,
shanghai hexaell biotech co ltd,2025-02-11 00:00:00,Yes,Not specified,Not specified,oncology,Not specified,Not specified,No,,,No,,,Yes,"secretion of liver-specific proteins such as ALB, AAT and TRF",https://golden.com/wiki/Hexaell_Biotech-REK9JE8,No,,,No,,,No,,,No,,,Yes,focusing on developing novel cell therapies and regenerative medicines for severe liver diseases,https://golden.com/wiki/Hexaell_Biotech-REK9JE8,No,,,No,,,No,,
tiburio therapeutics inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,TBR-760; TBR-065,Not specified,rare diseases; neuroendocrine tumors; endocrine diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,dopamine-somatostatin chimeric molecule,https://blog.zymewire.com/post/tiburio-therapeutics-a-map-for-selling-to-this-stealth-biotech-startup
preglem sa,2008-01-04 00:00:00,No,Donanemab; Evobrutinib; Tolebrutinib; Fitusiran; Marstacimab; Concizumab; Rocatinlimab; PRA023; Bimekizumab; Zolbetuximab; Datopotamab deruxtecan; Imetelstat; Ensifentrine,"Amyloid-beta; BTK, Bruton Tyrosine Kinase; TFPI, Tissue Factor Pathway Inhibitor; IL17, Interleukin-17; Claudin18.2; TROP2, Trophoblast Cell Surface Antigen 2; Telomerase; PDE 3/4, Phosphodiesterase 3/4",neurology; immunology; hematology; oncology; respiratory,immune checkpoint; kinases; enzyme; cytokine; other; other; enzyme; enzyme,Pre-reg; Phase III; Phase III; Pre-reg; Pre-reg; Pre-reg; Phase III; Phase III; Pre-reg; Pre-reg; Phase III; Pre-reg; Pre-reg,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ultimovacs as,2025-03-17 13:43:22,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,"UV1, a peptide-based vaccine inducing a specific T cell response",https://www.linkedin.com/company/ultimovacs-as/,No,,,No,,,No,,,No,,,No,,,Yes,pioneering the development of 'off the shelf' T Cell Receptor Natural Killer (TCR-NK) cell therapies,https://www.globenewswire.com/news-release/2024/12/17/2998486/0/en/ULTIMOVACS-ANNOUNCES-AGREEMENT-TO-COMBINE-ITS-BUSINESS-WITH-ZELLUNA-IMMUNOTHERAPY-AND-INTENTION-TO-LAUNCH-FULLY-COMMITTED-PRIVATE-PLACEMENT.html,Yes,UV1 is being developed as a therapeutic cancer vaccine,https://www.linkedin.com/company/ultimovacs-as/,No,,,No,,
ultimovacs asa,2025-03-17 13:43:22,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,peptide-based vaccine inducing a specific T cell response,https://www.linkedin.com/company/ultimovacs-as/,No,,,No,,,No,,,No,,,No,,,Yes,T Cell Receptor Natural Killer (TCR-NK) cell therapies,https://www.globenewswire.com/news-release/2024/12/17/2998486/0/en/ULTIMOVACS-ANNOUNCES-AGREEMENT-TO-COMBINE-ITS-BUSINESS-WITH-ZELLUNA-IMMUNOTHERAPY-AND-INTENTION-TO-LAUNCH-FULLY-COMMITTED-PRIVATE-PLACEMENT.html,Yes,therapeutic cancer vaccine,https://www.linkedin.com/company/ultimovacs-as/,No,,,No,,
lohocla research corp,"Error: Connection failed - HTTPSConnectionPool(host='taggs.hhs.gov', port=443",Yes,Not specified,Not specified,chronic pain; neurologic disorders,Not specified,Not specified,Yes,developing medications to treat chronic pain and addictions,https://www.linkedin.com/company/lohocla-research-corporation,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
amal therapeutics sa,2018-12-12 00:00:00,Yes,ATP128,"Disease Name, Colorectal Cancer",oncology,other,Preclinical,No,,,Yes,"KISIMA®, a novel peptide/protein-based immunisation technology platform",https://www.swissbiotech.org/listing/amal-therapeutics/,Yes,"KISIMA®, a novel peptide/protein-based immunisation technology platform",https://www.swissbiotech.org/listing/amal-therapeutics/,No,,,No,,,Yes,assembly within one chimeric fusion protein of 3 elements essential to generate potent immunity,https://www.swissbiotech.org/listing/amal-therapeutics/,No,,,No,,,Yes,developing therapeutic vaccines,https://www.swissbiotech.org/listing/amal-therapeutics/,No,,,No,,
kriya therapeutics inc,2025-09-12 11:08:54,Yes,KRIYA-748; KRIYA-825,"Engineered Ion Channel; C3, Complement Component 3; C5, Complement Component 5",neurology; ophthalmology,ion channels; other,Clinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapies,https://kriyatherapeutics.com/,No,,,No,,,No,,
morphotek inc,2025-03-25 08:51:57,Yes,AVZO-103,Nectin4; TROP2,oncology,other,Phase 1/2,No,,,No,,,Yes,protein therapeutics,https://media-us.eisai.com/2012-08-14-Morphotek-Inc-Opens-60-000-square-foot-Manufacturing-Plant,Yes,therapeutic monoclonal antibodies,https://www.flagshippioneering.com/companies/morphotek,No,,,No,,,No,,,No,,,No,,,No,,,No,,
effector therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.sfgate.com', port=44",No,eFT508; eFT226,"MNK1/2, Mitogen-Activated Protein Kinase-Interacting Kinase 1 and 2; eIF4A, Eukaryotic Initiation Factor 4A",oncology,kinases; other,Phase 2,Yes,small molecule STRI product candidates,https://www.cnbc.com/quotes/EFTR,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
azura ophthalmics pty ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,AZR-MD-001,Meibomian Gland Dysfunction,ophthalmology,other,Phase 3,Yes,Our internally discovered pipeline of new chemical entities,https://il.linkedin.com/company/azura-ophthalmics-limited,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
surge therapeutics inc,2023-08-19 00:00:00,No,GTB-3650; GTB-5550,CD33; B7H3,oncology,immune checkpoint; other,Phase 1; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,intraoperative immunotherapy,https://www.linkedin.com/company/surge-therapeutics
crescendo biologics ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.anderapartners.com',",Yes,CB213; CB307,"PD-1, Programmed Death-1; LAG-3, Lymphocyte Activation Gene-3; CD137, Cluster of Differentiation 137; PSMA, Prostate-Specific Membrane Antigen",oncology,immune checkpoint,Phase 1; Preclinical,No,,,No,,,No,,,Yes,Humabody® therapeutics,https://uk.linkedin.com/company/crescendo-biologics-ltd,No,,,No,,,No,,,No,,,No,,,No,,,Yes,multi-functional Humabody therapeutics,https://uk.linkedin.com/company/crescendo-biologics-ltd
zhejiang boyiao biopharmaceutical co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.reuters.com', port=4",Yes,CN201; GLP-1 receptor agonists,"PD-1, Programmed Cell Death Protein 1; VEGF, Vascular Endothelial Growth Factor; GLP-1, Glucagon-Like Peptide-1",oncology; cardiovascular; metabolic diseases,immune checkpoint; cytokine; other,Phase 1; Preclinical,Yes,Small Molecules,https://apicule.com/api-suppliers/zhejiang-boxiao-biopharmaceutical-co-ltd/,Yes,Peptides,https://apicule.com/api-suppliers/zhejiang-boxiao-biopharmaceutical-co-ltd/,Yes,Recombinant Proteins,https://apicule.com/api-suppliers/zhejiang-boxiao-biopharmaceutical-co-ltd/,Yes,Monoclonal Antibodies,https://apicule.com/api-suppliers/zhejiang-boxiao-biopharmaceutical-co-ltd/,Yes,Antibody-Drug Conjugates (ADCs),https://apicule.com/api-suppliers/zhejiang-boxiao-biopharmaceutical-co-ltd/,No,,,Yes,mRNA Production,https://apicule.com/api-suppliers/zhejiang-boxiao-biopharmaceutical-co-ltd/,Yes,Cell & Gene Therapy,https://apicule.com/api-suppliers/zhejiang-boxiao-biopharmaceutical-co-ltd/,No,,,No,,,No,,
cidara therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,CD388,Influenza Virus,infectious diseases,other,Phase 3,Yes,targeted small molecules,https://www.linkedin.com/company/cidara-therapeutics,Yes,peptides coupled to a proprietary human antibody fragment,https://www.linkedin.com/company/cidara-therapeutics,No,,,Yes,proprietary human antibody fragment,https://www.linkedin.com/company/cidara-therapeutics,Yes,Drug–Fc Conjugate (DFC),https://www.linkedin.com/company/cidara-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,
veru inc,2025-09-23 12:40:33,No,Enobosarm; VERU-111; VERU-100,"AR, Androgen Receptor; Alpha and Beta Tubulin Subunits; GnRH, Gonadotropin-Releasing Hormone",oncology,nuclear receptors; other; other,Phase 3; Phase 2; Phase 2,Yes,"two late-stage novel small molecules, enobosarm and sabizabulin",https://www.linkedin.com/company/veru-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"apex bioscience, inc. (inactive)",2002-06-14 14:09:48,No,Bezuclastinib; CGT4859; CGT4255; CGT6297,"KIT, KIT Activation Loop Mutations; FGFR2, Fibroblast Growth Factor Receptor 2; FGFR3, Fibroblast Growth Factor Receptor 3; ErbB2, Epidermal Growth Factor Receptor 2; PI3Kα, Phosphoinositide 3-Kinase Alpha; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog",oncology; immunology,kinases; kinases; kinases; kinases; kinases; other,Phase 3; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neurocrine biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,INGREZZA; valbenazine,"VMAT2, Vesicular Monoamine Transporter 2",neurology; movement disorders,other,Marketed,Yes,INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor,https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-kinect-4-post-hoc-analysis-demonstrating-rapid-and-sustained-therapeutic-efficacy-of-ingrezza-valbenazine-40-mg-capsules-302586928.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
axcella health inc,2022-11-13 00:00:00,Yes,AXA1665; AXA1125; AXA1957,"Hepatic Encephalopathy; NAFLD, Non-Alcoholic Fatty Liver Disease; NASH, Nonalcoholic Steatohepatitis",liver diseases,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,endogenous metabolic modulators (EMMs),https://axcellahealth.com/
impact therapeutics inc,2024-12-15 00:00:00,No,Iberdomide; Mezigdomide,"CRBN, Cereblon",oncology,enzyme,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
otonomy inc,2021-05-07 00:00:00,Yes,OTO-413,"BDNF, Brain-Derived Neurotrophic Factor",CNS; hearing loss,cytokine,Phase I/II,Yes,drug candidate OTO-413 for hearing loss,https://www.biopharmadive.com/news/otonomy-liquidate-dissolve-shut-down/639179/,No,,,Yes,Brain-Derived Neurotrophic Factor (BNDF),https://www.prnewswire.com/news-releases/spiral-therapeutics-acquires-otonomy-assets-to-boost-inner-ear-disorders-pipeline-and-appoints-industry-leaders-to-board-301782910.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,drug delivery technology to the ear,https://www.linkedin.com/company/otonomy-inc
uniqure biopharma bv,2025-10-16 21:00:38,No,AMT-130; AMT-240; AMT-061; AMT-191; AMT-162; AMT-260,"HTT, Huntingtin Protein; APOE4, Apolipoprotein E4; SOD1, Superoxide Dismutase 1",neurology; rare diseases; hematology,other; other; enzyme,Phase 2; Preclinical; Phase 3; Preclinical; Preclinical; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"gene therapy, AAV vectors",https://www.linkedin.com/company/uniqure,No,,,No,,,No,,
uniqure nv,2025-10-16 21:00:38,No,AMT-130; AMT-260; AMT-240; etranacogene dezaparvovec; AMT-191; AMT-162,"HTT, Huntingtin; GRIK2, Glutamate Ionotropic Receptor Kainate Type Subunit 2; APOE4, Apolipoprotein E4; Disease Name; Disease Name; SOD1, Superoxide Dismutase 1",neurology; rare diseases; CNS,other; ion channels; other; other; other; enzyme,Phase 1; Phase 1/2; Preclinical; Approved; Preclinical; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapy,https://www.linkedin.com/company/uniqure,No,,,No,,,No,,
mirati therapeutics inc,2023-09-08 00:00:00,No,Adagrasib,"KRASG12C, Kirsten Rat Sarcoma Viral Oncogene Homolog G12C",oncology,kinases,Phase 3,Yes,breakthrough therapies that target the genetic drivers of cancer,https://www.linkedin.com/company/mirati-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gemma biotherapeutics inc,2024-12-23 10:00:55,Yes,GM1 gangliosidosis; Krabbe disease; metachromatic leukodystrophy,Disease Name,rare diseases; central nervous system,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"gene therapy research, AAV vectors, genome editing",https://www.linkedin.com/company/gemmabiotx,No,,,No,,,No,,
kandy therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='adventls.com', port=443)",Yes,Not specified,Not specified,women's health,Not specified,Phase 2,Yes,KRAS G12D inhibitor,https://www.bayer.com/media/en-us/bayer-completes-acquisition-of-uk-based-biotech-company-kandy-therapeutics-ltd/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
enyo pharma sa,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
dermbiont inc,2023-11-19 00:00:00,No,DBI-002,Not specified,infectious diseases; dermatology,other,Phase 2,Yes,targeted small molecule therapeutics,https://www.linkedin.com/company/dermbiont,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,biotherapeutics that repair an imbalance of the microbiome,https://www.linkedin.com/company/dermbiont
abalos therapeutics gmbh,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,arenavirus-based immuno-virotherapy,https://de.linkedin.com/company/abalos-the
autolus therapeutics plc,2025-09-19 14:31:36,Yes,AUTO4; AUTO1; AUCATZYL,"TRBC1, T Cell Receptor Beta Constant 1; CD19, Cluster of Differentiation 19",oncology,other; immune checkpoint,Phase 1; Approved,No,,,No,,,No,,,Yes,tumor recognition domain of an antibody,https://www.autolus.com/,No,,,No,,,No,,,Yes,CAR T cell therapy company,https://uk.linkedin.com/company/autolus-ltd-,No,,,No,,,No,,
nanjing legend biotech co ltd,2025-10-15 13:31:03,No,LCAR-B38M,"BCMA, B-cell Maturation Antigen",oncology,immune checkpoint,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"CAR-T, CAR-T Manufacturing, Cell Therapy",https://www.linkedin.com/company/legendbiotechco.,No,,,No,,,No,,
janux therapeutics inc,2025-09-24 14:46:03,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
knopp biosciences llc,"Error: Connection failed - HTTPSConnectionPool(host='www.baincapital.com', po",Yes,Dexpramipexole,Eosinophils,inflammatory diseases; neurological diseases; eosinophilic disorders; asthma,other,Phase 3,Yes,"clinical-stage oral small molecule, dexpramipexole",https://knoppbio.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kolon tissuegene inc,2025-10-11 11:26:48,No,Not specified,Disease-modifying osteoarthritis drugs (DMOADs),Musculoskeletal diseases,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cell and gene therapy for osteoarthritis,https://www.prnewswire.com/news-releases/kolon-tissuegene-highlights-long-term-safety-data-and-potential-us-fda-pathway-for-tg-c-at-oarsi-world-congress-302439695.html,No,,,No,,,No,,
apexigen inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,APX005M,"PD-1, Programmed Cell Death-1 Receptor",oncology,immune checkpoint,Not specified,No,,,No,,,No,,,Yes,discovering and developing a new generation of antibody therapeutics,https://www.linkedin.com/company/apexigen,No,,,No,,,No,,,No,,,No,,,No,,,No,,
orexigen therapeutics inc (inactive),2018-03-12 10:01:35,No,Contrave; Empatic,Not specified,obesity; metabolic diseases,Not specified,Marketed; Phase 2,Yes,"naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine",https://www.takeda.com/newsroom/newsreleases/2016/orexigen-and-takeda-jointly-announce-orexigens-acquisition-of-all-rights/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
epygenix therapeutics inc,2024-04-30 07:00:00,Yes,EPX-100,"5-HT, Serotonin Signaling Pathways",CNS; rare diseases,other,Phase 2,Yes,"clemizole hydrochloride (EPX-100), a potent, oral, centrally acting serotonin (5HT2) agonist",https://www.prnewswire.com/news-releases/harmony-biosciences-acquires-epygenix-therapeutics-inc-adding-late-stage-epilepsy-franchise-to-growing-pipeline-of-innovative-cns-assets-302131000.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,proprietary phenotype-based zebrafish drug screening platform,https://www.prnewswire.com/news-releases/harmony-biosciences-acquires-epygenix-therapeutics-inc-adding-late-stage-epilepsy-franchise-to-growing-pipeline-of-innovative-cns-assets-302131000.html
sling therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,oral small molecule linsitinib,https://www.prnewswire.com/news-releases/sling-therapeutics-announces-positive-topline-results-from-phase-2b3-lids-clinical-trial-of-oral-small-molecule-linsitinib-in-patients-with-thyroid-eye-disease-302350327.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tavotek biotherapeutics,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,oncology; immunology; autoimmune diseases; inflammatory diseases,immune checkpoint,Preclinical,No,,,No,,,No,,,Yes,Bispecific antibody generation is actively pursued for therapeutic and research antibody development.,https://www.linkedin.com/in/chiu-mark-35174b33,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"novel multispecific antibodies that simultaneously target epidermal growth factor receptor (EGFR), cMET, and either programmed death-ligand 1 (PD-L1) or vascular endothelial growth factor (VEGF).",https://www.linkedin.com/company/tavotek
alucent biomedical inc,No timestamp found,No,AlucentNVS,Arteriovenous Fistula,cardiovascular; renal diseases,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Natural Vascular Scaffolding (NVS) technology,https://www.stradlinglaw.com/experience/alucent-biomedical-closes-series-b-financing.html
inversago pharma inc,"Error: Connection failed - HTTPSConnectionPool(host='forbion.com', port=443):",No,INV-202,"CB1, Cannabinoid Receptor 1",metabolic diseases; obesity,gpcr,Phase 2,Yes,"INV-202, an oral CB1 inverse agonist",https://www.globenewswire.com/news-release/2023/08/10/2722413/0/en/Novo-Nordisk-to-acquire-Inversago-Pharma-to-develop-new-therapies-for-people-living-with-obesity-diabetes-and-other-serious-metabolic-diseases.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cullgen inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,CG001419,"TRK, Tropomyosin receptor kinase",pain,kinases,Phase 1,Yes,highly active small molecule designed to selectively degrade both mutant and wild-type TRK proteins,https://www.prnewswire.com/news-releases/pulmatrix-and-cullgen-announce-proposed-merger-302303818.html,No,,,Yes,targeting of historically 'undruggable' proteins for selective destruction,https://www.prnewswire.com/news-releases/astellas-and-cullgen-enter-into-strategic-collaboration-and-option-agreement-to-advance-innovative-targeted-protein-degraders-301851639.html,No,,,No,,,No,,,No,,,No,,,No,,,Yes,targeted protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins,https://www.linkedin.com/company/cullgen,No,,
vivace therapeutics inc,2025-03-12 06:00:39,No,VT3989,"Merlin, Tumor Suppressor Protein",oncology; rare diseases,other,Preclinical,Yes,Vivace Therapeutics is a small molecule drug discovery and development company,https://www.prnewswire.com/news-releases/vivace-therapeutics-raises-35-million-in-series-d-financing-to-support-clinical-development-of-first-in-class-cancer-drug-targeting-the-hippo-pathway-302397707.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sairopa bv,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,ADU-1805; ADU-1604; SIRPα-PD-L1 bispecific antibody,"SIRPα, Signal Regulatory Protein Alpha; CTLA4, Cytotoxic T-Lymphocyte-Associated Protein 4; PD-L1, Programmed Death-Ligand 1",oncology,immune checkpoint,Phase 1; Phase 2; Preclinical,No,,,No,,,No,,,Yes,portfolio of therapeutic antibodies,https://www.linkedin.com/company/sairopa-b-v/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
salubris biotherapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas",https://www.linkedin.com/company/salubris-biotherapeutics,No,,,No,,,Yes,"Antibody Engineering, Bi-Specific Antibodies",https://www.linkedin.com/company/salubris-biotherapeutics,Yes,Antibody-Drug Conjugates,https://www.linkedin.com/company/salubris-biotherapeutics,Yes,investigational fusion protein for the treatment of heart failure,https://www.linkedin.com/company/salubris-biotherapeutics,No,,,No,,,No,,,No,,,No,,
anokion sa,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,Yes,ANK-700,Not specified,neurology; autoimmune diseases,other,Phase 1,No,,,No,,,Yes,Protein engineering,https://www.linkedin.com/company/anokion-sa,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
deutsches zentrum fur diabetesforschung ev,"Error: Connection failed - HTTPSConnectionPool(host='de.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
alpha tau medical ltd,2025-04-30 00:00:00,Yes,Alpha DaRT,"Disease Name, Solid Tumors",oncology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy),https://www.alphatau.com/
oramed pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Diabetes,metabolic diseases,Not specified,Phase 3,No,,,No,,,Yes,oral insulin and POD™ platform,https://www.prnewswire.com/news-releases/oramed-pharmaceuticals-issues-letter-to-shareholders-302391492.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biotie therapies ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,No,Tozadenant; SYN120,Not specified,CNS; Parkinson's disease,Not specified,Phase 3; Phase 2,Yes,Selincro (nalmefene) for alcohol dependence,https://www.linkedin.com/company/biotie-therapies-corp.,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
akero therapeutics inc,2024-04-05 00:00:00,No,efruxifermin,Not specified,metabolic diseases,Not specified,Phase 3,No,,,No,,,Yes,FGF21 analogue efruxifermin (EFX),https://www.ropesgray.com/en/news-and-events/news/2025/10/novo-nordisk-enters-agreement-to-acquire-akero-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
e-star biotech llc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,VGA039,Protein S,bleeding disorders,enzyme,Phase 3,No,,,Yes,"novel peptides designed to treat cardiovascular, metabolic, and kidney diseases",https://www.globenewswire.com/news-release/2025/02/05/3021131/0/en/E-Star-BioTech-Announces-Dosing-of-First-Patient-in-Phase-2-Clinical-Trials-of-MANP-in-Resistant-Hypertension.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aer therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,AERO-007; fexlamose,Chronic Obstructive Pulmonary Disease,respiratory diseases,Not specified,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aer therapeutics inc (inactive),2025-10-17 13:32:24,Yes,AERO-007; fexlamose,Chronic Obstructive Pulmonary Disease,respiratory diseases,Not specified,Phase 2,Yes,novel inhaled small molecule mucolytic drug,https://innovation.ucsf.edu/news/aer-therapeutics-closes-36-million-series-advance-development-aer-01-innovative-mucolytic,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ab2 bio ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Tadekinig alfa,"IL-18, Interleukin-18",immunology; rare diseases,cytokine,Phase 3,No,,,No,,,Yes,"Tadekinig alfa is a novel, recombinant human interleukin-18 Binding Protein (IL-18 BP)",https://www.globenewswire.com/news-release/2025/01/27/3015292/0/en/AB2-Bio-signs-U-S-option-and-licensing-agreement-with-Nippon-Shinyaku-for-Tadekinig-alfa-for-an-ultra-rare-autoimmune-disease.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
curateq biologics gmbh (inactive),2025-10-01 00:00:00,No,DAZUBLYS,"HER2, Human Epidermal Growth Factor Receptor 2",oncology,other,Approved,No,,,No,,,No,,,Yes,"trastuzumab biosimilar, DAZUBLYS, specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein",https://www.goodwinlaw.com/en/insights/blogs/2025/04/curateq-biologics-trastuzumab-biosimilar-receives-positive-opinion-in-europe,No,,,No,,,No,,,No,,,No,,,No,,,No,,
anthera pharmaceuticals inc (inactive),"Error: Connection failed - ('Connection aborted.', RemoteDisconnected('Remote",No,ICT 1&2; ICT 3; liprotamase; blisibimod,Colorectal Cancer; Tumor Source; Autoimmune Diseases,oncology; autoimmune diseases,other,Phase 3; Preclinical,Yes,developing drugs to treat serious diseases associated with inflammation and autoimmune disorders,https://www.prnewswire.com/news-releases/anthera-halts-vista-16-clinical-study-due-to-lack-of-efficacy-following-recommendation-by-the-independent-data-safety-monitoring-board-142116083.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
axial therapeutics inc,Error: Connection failed - 404 Client Error: Not Found for url: https://www.l,Yes,AB-2004,Not specified,CNS; Autism Spectrum Disorder,Not specified,Phase 2,Yes,small molecule therapies,https://www.linkedin.com/company/axial-biotherapeutics-inc.,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
g2gbio inc,"Error: Connection failed - HTTPSConnectionPool(host='www.ipox.com', port=443)",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ir scientific inc,2020-04-03 00:00:00,No,OT-101,"TGF-β, Transforming Growth Factor Beta",oncology,cytokine,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,unique inorganic polymers,https://ca.linkedin.com/company/ir-scientific
maplight therapeutics inc,2025-10-10 20:19:34,Yes,ML-007C-MA; ML-007; ML-007C/PAC,"M1/M4, Muscarinic Acetylcholine Receptors",CNS; neuropsychiatric disorders,gpcr,Phase 2,Yes,"ML-007C-MA, our novel M1/M4 muscarinic agonist",https://www.prnewswire.com/news-releases/maplight-therapeutics-announces-372-5-million-series-d-financing-302514844.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
catalyst pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,AGAMREE; FIRDAPSE; FYCOMPA,"DMD, Duchenne Muscular Dystrophy; LEMS, Lambert-Eaton Myasthenic Syndrome; Epilepsy",rare diseases; neuromuscular diseases; neurological diseases; epilepsy,other,Approved,No,,,No,,,No,,,Yes,antibody testing and treatment,https://catalystpharma.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
opus genetics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.ncbiotech.org', port",No,OPGx-BEST1,"BEST1, Bestrophin-1",rare diseases; ophthalmology,ion channels,Phase 1/2,Yes,small molecule therapies for other ophthalmic disorders,https://www.linkedin.com/company/opus-genetics,No,,,No,,,No,,,No,,,No,,,No,,,Yes,AAV-based gene therapies targeting inherited retinal diseases,https://www.linkedin.com/company/opus-genetics,No,,,No,,,No,,
opus genetics incorporation,"Error: Connection failed - HTTPSConnectionPool(host='www.ncbiotech.org', port",No,OPGx-BEST1; OPGx-LCA5; Phentolamine Ophthalmic Solution 0.75%,"BEST1, Bestrophin-1; Disease Name",rare diseases; ophthalmology,other,Phase 1/2; Phase 3; Approved,Yes,small molecule therapies for other ophthalmic disorders,https://www.linkedin.com/company/opus-genetics,No,,,No,,,No,,,No,,,No,,,No,,,Yes,AAV-based gene therapies targeting inherited retinal diseases,https://www.linkedin.com/company/opus-genetics,No,,,No,,,No,,
akebia therapeutics inc,2025-08-28 18:09:06,Yes,Vadadustat; Auryxia,"HIF, Hypoxia-Inducible Factor; Anemia in Chronic Kidney Disease",renal diseases; metabolic diseases; rare diseases,other,Phase 3,Yes,HIF-PH inhibitors in preclinical development,https://www.home.saxo/markets/stocks/akba-xnas,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ophirex inc,2025-10-07 17:42:51,No,varespladib; varespladib methyl,"sPLA2, Secretory Phospholipase A2",poisoning; infectious diseases,enzyme,Phase 2,Yes,oral snakebite treatment,https://www.linkedin.com/company/ophirex,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
portage biotech inc,2025-10-03 00:00:00,Yes,PORT-7; PORT-6,"A2B, Adenosine A2B receptor; A2A, Adenosine A2A receptor",oncology,gpcr,Preclinical,Yes,selective adenosine A2B receptor inhibitor,https://www.stocktitan.net/news/PRTG/,No,,,No,,,Yes,anti-PD1 antibody treatment,https://www.stocktitan.net/news/PRTG/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,combination of selective A2A and A2B antagonists,https://www.stocktitan.net/news/PRTG/
milestone pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Iberdomide; Mezigdomide,"CRBN, Cereblon",oncology,enzyme,Phase 3,Yes,small molecule drugs,https://www.linkedin.com/company/milestone-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cg oncology inc,2024-05-03 11:25:00,No,cretostimogene grenadenorepvec,"Disease Name, Intermediate-risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)",oncology,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,oncolytic virus,https://www.biopharmadive.com/news/cg-oncology-cretostimogene-phase-3-data/715109/
lumos pharma inc,Error: Connection failed - HTTPSConnectionPool(host='www.pharmaceutical-techn,Yes,LUM-201,Not specified,rare diseases; pediatric growth hormone deficiency,other,Phase 3,Yes,"LUM-201, an oral growth hormone stimulating therapeutic",https://www.linkedin.com/company/lumos-pharma,No,,,Yes,protein-based therapeutics for rare diseases,http://investors.linkp.com/management,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"cell genesys, inc. (inactive)","Error: Connection failed - HTTPSConnectionPool(host='www.genengnews.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pt daewoong infion,No timestamp found,Yes,DWP213388; Semaglutide,"BTK, Bruton's Tyrosine Kinase; ITK, Interleukin-2-inducible T-cell kinase; GLP-1, Glucagon-like Peptide-1",autoimmune diseases; metabolic diseases,kinases; cytokine; other,Phase 1,No,,,No,,,Yes,"erythropoietin alpha (Epodion), EGF (epidermal growth factor), hGH (human growth hormone)",https://gosset.ai/companies/daewoong-infion/,No,,,No,,,No,,,No,,,Yes,"stem cells, regenerative medicine",https://daewoongpharm.id/about-dpi/global-network,No,,,No,,,No,,
opna bio sa,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,"FMRP, Fragile X Mental Retardation Protein",oncology,other,Discovery,Yes,CBP/EP300 bromodomain inhibitor,https://www.linkedin.com/company/opna-bio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ap biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.apbioinc.com', port=",No,AP402; AP601,"p95HER2, Shortened HER2 receptor; CD137, Tumor Necrosis Factor Receptor Superfamily Member 9; CD73, 5'-Nucleotidase",oncology,immune checkpoint; enzyme; immune checkpoint,Preclinical,No,,,No,,,No,,,Yes,Bispecific Antibody,https://tw.linkedin.com/company/ap-biosciences-bispecific-antibodies,No,,,No,,,No,,,No,,,No,,,No,,,No,,
fore biotherapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,plixorafenib,https://www.linkedin.com/company/forebiotherapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aronora inc,"Error: Connection failed - HTTPSConnectionPool(host='www.sbir.gov', port=443)",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bonesupport ab,2025-10-17 15:00:09,No,CERAMENT BVF; CERAMENT G; CERAMENT V,Not specified,orthobiologics,Not specified,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,drug-eluting bioceramic products,https://www.linkedin.com/company/bonesupport-ab
viralytics pty ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.merck.com', port=443",Yes,CLD-201; pelareorep; cretostimogene grenadenorepvec; Olvi-Vec; TILT-123; ICVB-1042; VCN-01; BT-001; CAN-2409,Soft Tissue Sarcoma; Pancreatic Ductal Adenocarcinoma; Gastrointestinal Cancers; Bladder Cancer; Small-Cell Lung Cancer; Ovarian Cancer; Retinoblastoma; Solid Tumors; Prostate Cancer,oncology,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CAR-Ts and other cell therapies,https://www.immvirx.com/about-us/,No,,,No,,,Yes,oncolytic viruses,https://www.immvirx.com/about-us/
viralytics pty ltd (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.merck.com', port=443",Yes,CG0070; cretostimogene grenadenorepvec,"PD-L1, Programmed Death-Ligand 1",oncology,immune checkpoint,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,Yes,bio-selected RNA viruses,https://www.immvirx.com/immvirx-reports-on-operations-for-fy22/,Yes,CAR-T cell therapies,https://www.immvirx.com/immvirx-reports-on-operations-for-fy22/,No,,,No,,,Yes,oncolytic viruses,https://www.immvirx.com/immvirx-reports-on-operations-for-fy22/
arrys therapeutics inc,2018-12-18 00:00:00,No,OT-101,"TGF-β, Transforming Growth Factor Beta",oncology; inflammatory diseases,cytokine,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cvie therapeutics company ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,Istaroxime; CVie-216,"SERCA2a, Sarcoplasmic Reticulum Ca2+-ATPase",cardiovascular,enzyme,Phase 2; Preclinical,Yes,preclinical SERCA2a activators for heart failure,https://www.marketscreener.com/quote/stock/WINDTREE-THERAPEUTICS-INC-54601701/news/Windtree-Therapeutics-Inc-acquired-50-42-stake-in-CVie-Therapeutics-Company-Limited-for-approxima-34472687/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tolremo therapeutics ag,"Error: Connection failed - HTTPSConnectionPool(host='techparkbasel.ch', port=",Yes,TT125-802,"CBP/p300, CREB-binding protein/E1A-associated protein p300",oncology,other,Phase 1,Yes,small molecule inhibitor,https://ch.linkedin.com/company/tolremo-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
coave therapeutics,2021-07-21 02:00:00,Yes,Reqorsa; quaratusugene ozeplasmid; GPX-002,"ALK-EML4, Anaplastic Lymphoma Kinase-Echinoderm Microtubule-associated Protein-like 4; TUSC2, Tumor Suppressor Candidate 2; Pdx1, Pancreatic and Duodenal Homeobox 1; MafA, V-maf musculoaponeurotic fibrosarcoma oncogene homolog A",oncology; diabetes,kinases; other,Preclinical,No,,,Yes,"conjugation of targeting ligands, such as small molecules, peptides, or antibody fragments",https://www.globenewswire.com/news-release/2025/04/23/3066174/0/en/Coave-Therapeutics-Expands-into-the-US-with-Strategic-Appointment-of-Romain-Pettenaro-as-VP-of-Business-Development.html,No,,,Yes,"conjugation of targeting ligands, such as small molecules, peptides, or antibody fragments",https://www.globenewswire.com/news-release/2025/04/23/3066174/0/en/Coave-Therapeutics-Expands-into-the-US-with-Strategic-Appointment-of-Romain-Pettenaro-as-VP-of-Business-Development.html,No,,,No,,,No,,,Yes,developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases,https://www.prnewswire.com/news-releases/coave-therapeutics-closes-eur33-million-39-million-series-b-financing-to-develop-its-gene-therapy-pipeline-and-next-generation-vectors-based-on-its-aav-ligand-conjugate-platform-868708634.html,No,,,No,,,Yes,suprachoroidal capsid and suprachoroidal route of administration,https://fr.linkedin.com/company/coavetx
orphomed inc,"Error: Connection failed - HTTPSConnectionPool(host='drug-dev.com', port=443)",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
asarina pharma ab,"Error: Connection failed - HTTPSConnectionPool(host='www.relmada.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
spine biopharma llc,"Error: Connection failed - HTTPSConnectionPool(host='www.healio.com', port=44",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,SB-01 – A first-in-class investigational DDD treatment,https://www.linkedin.com/company/spine-biopharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,regenerative and restorative technologies,https://www.linkedin.com/company/spine-biopharma
ocelot bio inc,2023-08-12 00:00:00,No,Belapectin; PHIN-214; RTX001; LPCN 1148,Metabolic Dysfunction-Associated Steatohepatitis (MASH); Vasopressin 1a receptor; Macrophage replacements,liver diseases; metabolic diseases,other; gpcr; other,Phase 2; Phase 1; Phase 2; Phase 2,No,,,Yes,therapeutic peptide,https://www.linkedin.com/company/ocelot-bio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rani therapeutics llc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,RT-114; PG-102,"GLP-1, Glucagon-like Peptide-1; GLP-2, Glucagon-like Peptide-2",obesity,gpcr,Phase 1,No,,,Yes,"The Rani platform is capable of delivering orally any payload, including proteins, peptides, and antibodies",https://www.ranitherapeutics.com/,Yes,"The Rani platform is capable of delivering orally any payload, including proteins, peptides, and antibodies",https://www.ranitherapeutics.com/,Yes,"The Rani platform is capable of delivering orally any payload, including proteins, peptides, and antibodies",https://www.ranitherapeutics.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
east coast institute for research inc,"Error: Connection failed - HTTPSConnectionPool(host='providenthp.com', port=4",No,Not specified,Type 2 Diabetes; Weight Loss; Alzheimer's Disease; Depression; Anxiety; PTSD; ADHD,metabolic diseases; neurology; psychiatry,Not specified,Phase 2; Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Vaccines, COPD, Osteoarthritis, and more",https://www.linkedin.com/company/east-coast-institute-for-research,No,,,No,,
callisto pharmaceuticals inc (inactive),2008-07-22 11:55:02,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,SP–304 (previously referred to as Guanilib) is an analog (synthetic molecule) of uroguanylin,https://www.eleconomista.es/empresas-finanzas/noticias/667261/07/08/Callisto-Pharmaceuticals-Announces-30-Million-Financing-by-Its-Synergy-Pharmaceuticals-Subsidiary-and-Related-Transactions-Leaving-Callisto-with-a-68-Stake-in-Synergy.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
lophora aps,"Error: Connection failed - HTTPSConnectionPool(host='www.lophora.com', port=4",Yes,LPH-5; Psilocin; BPL-003,Not specified,CNS; depression; anxiety; post-traumatic stress disorder; substance abuse,Not specified,Preclinical; Phase 1; Phase 2,Yes,development of proprietary NCEs for treatment-resistant depression,https://www.beckleypsytech.com/posts/beckley-psytech-bolsters-pipeline-of-next-generation-psychedelic-medicines-with-research-collaboration-and-strengthening-of-relationship-with-lophora-aps,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"developing novel, next-generation, neuroactive medicines to treat neurological and psychiatric disorders",https://www.linkedin.com/company/lophora/
mapreg sas,2008-02-05 00:00:00,Yes,MAP4343,Not specified,CNS; neurotraumatic injuries; depression; spinal cord injuries,Not specified,Phase 2,Yes,neurosteroid derivatives,https://sciencebusiness.net/news/71059/Paris%3A-Investors-sought-for-Mapreg%E2%80%99s-nerve-repair,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
iveena delivery systems inc,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,IVMED-85,"LOX, Lysyl Oxidase",ophthalmology,enzyme,Phase 2,Yes,"IVMED-85 is a new chemical entity (NCE), preservative-free prescription eye drop",https://www.linkedin.com/company/iveena,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cyclacel pharmaceuticals inc,2025-06-20 20:30:00,No,Not specified,Not specified,oncology; hematology,Not specified,Not specified,Yes,"developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology",https://www.globenewswire.com/news-release/2025/06/20/3102932/10564/en/Cyclacel-Pharmaceuticals-Announces-3-Million-Private-Placement-Offering-of-Convertible-Preferred-Stock.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
abl bio inc,2025-09-01 01:56:31,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,bispecific antibody therapeutics,https://www.linkedin.com/company/ablbio/,Yes,antibody-drug conjugates (ADCs),https://www.linkedin.com/company/ablbio/,No,,,Yes,"polynucleotide or oligonucleotides, such as siRNA and ASOs",https://www.prnewswire.com/news-releases/abl-bio-announces-grabody-b-brain-delivery-platform-license-agreement-with-gsk-to-develop-novel-medicines-for-neurodegenerative-diseases-302421544.html,No,,,No,,,No,,,Yes,Blood-Brain Barrier (BBB) shuttle platform,https://www.linkedin.com/company/ablbio/
apim therapeutics as,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,ATX-101,"PCNA, Proliferating Cell Nuclear Antigen",oncology,other,Phase 2,No,,,Yes,ATX-101 is a first-in-class peptide targeting PCNA (Proliferating Cell Nuclear Antigen),https://www.prnewswire.com/news-releases/nordic-nanovector-and-apim-therapeutics-announce-merger-agreement-301673852.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
miralogx llc,2023-11-20 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,Ketamir-2 is a unique and patent-pending compound,https://www.nasdaq.com/articles/mira-pharma-partners-with-miralogx-for-licensing-agreement-for-ketamir-2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sernova biotherapeutics inc,2025-07-09 08:30:00,No,Cell Pouch,Type 1 Diabetes Mellitus,endocrine disorders; regenerative medicine,other,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,stem cell-derived cell therapies,https://www.cnbc.com/quotes/SVA-CA,No,,,No,,,Yes,bio-hybrid organs,https://www.cnbc.com/quotes/SVA-CA
targeted therapy technologies llc,"Error: Connection failed - HTTPSConnectionPool(host='taggs.hhs.gov', port=443",Yes,Trodelvy; Domvanalimab; Zimberelimab,"Trop-2, Trophoblast Cell Surface Antigen 2; TIGIT, T-cell Immunoreceptor with Ig and ITIM Domains; PD-1, Programmed Cell Death Protein-1",oncology,enzyme; immune checkpoint; immune checkpoint,Phase 3; Phase 2; Phase 2,Yes,Episcleral Topotecan was designed for sustained delivery of topotecan hydrochloride,https://3tophthalmics.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"proprietary technology can deliver a number of therapeutic agents to treat neoplastic, inflammatory, neovascular and neurodegenerative ocular diseases",https://3tophthalmics.com/
avotres inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,AVT001; AVT-Dx001; AVT002,Q/E CD8+ Treg pathway,autoimmune diseases; immuno-oncology; transplantation,immune checkpoint,Phase 3; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Novel Autologous Dendritic Cell Therapy AVT001,https://pubmed.ncbi.nlm.nih.gov/38916421/,No,,,No,,,No,,
verismo therapeutics,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,SynKIR-310; SynKIR-110,CD19,oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,chimeric antigen receptor T-cell (CAR-T) therapy based on the company's killer immunoglobulin-like receptor (KIR)-CAR platform,https://www.cgtlive.com/view/verismo-therapeutics-trial-car-t-synkir-310-doses-patient-follicular-lymphoma,No,,,No,,,No,,
verismo therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.crunchbase.com', por",Yes,SynKIR-310; SynKIR-110,CD19; Mesothelin,oncology; hematologic malignancies; solid tumors,immune checkpoint; other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"CAR-T therapy, KIR-CAR, SynKIR™-T cells, T-cell-based cellular immunotherapy, NK cell therapies",https://www.linkedin.com/company/verismo-therapeutics,No,,,No,,,No,,
alethia biotherapeutics inc,2019-07-06 00:00:00,No,Sotevtamab; Nelitolimod; PDC*Neo,"sCLU, Secreted Clusterin; TLR9, Toll-Like Receptor 9",oncology,other; immune checkpoint,Preclinical,No,,,No,,,No,,,Yes,Immunotherapeutics against disease-specific targets,https://ca.linkedin.com/company/alethia-biotherapeutics-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,
spybiotech ltd,No timestamp found,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,SpyTag/SpyCatcher protein superglue platform,https://www.linkedin.com/company/spybiotech,No,,,No,,,No,,,No,,,No,,,Yes,develop vaccines against infectious disease and cancer worldwide,https://www.linkedin.com/company/spybiotech,No,,,Yes,adenovirus platform,https://www.linkedin.com/company/spybiotech
cyprium therapeutics inc,Error: Connection failed - HTTPSConnectionPool(host='www.fortressbiotech.com',No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zealand pharma as,2025-09-25 08:14:58,No,Petrelintide; Dapiglutide; Survodutide; ZP6590; Dasiglucagon; Glepaglutide; ZP9830; ZP10068,"Amylin; GLP-1, Glucagon-Like Peptide-1; GLP-2, Glucagon-Like Peptide-2; Glucagon; GIP, Glucose-Dependent Insulinotropic Polypeptide; Kv1.3, Voltage-Gated Potassium Channel Subunit Kv1.3; Complement C3",obesity; rare diseases; chronic inflammation,other; gpcr; gpcr; gpcr; gpcr; ion channels; other,Phase 1; Preclinical; Preclinical; Preclinical; Preclinical; Preclinical; Preclinical; Preclinical,Yes,ZP9830: A potent and selective blocker of the Kv1.3 ion channel,https://www.zealandpharma.com/,Yes,Over 25 years pioneering peptide therapeutics,https://www.zealandpharma.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
myovant sciences gmbh,2023-03-10 00:00:00,No,Relugolix; RVT-602,"GnRH, Gonadotropin-Releasing Hormone Receptor; Kisspeptin Receptor",oncology; women's health; reproductive health,gpcr; other,Approved; Phase 3,Yes,"relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist",https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-collaboration-develop,Yes,"MVT-602, an oligopeptide kisspeptin-1 receptor agonist",https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-collaboration-develop,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
yicheng kangtai (xiamen) biotechnology co ltd,No timestamp found,No,ACP-204,"5-HT2A, 5-Hydroxytryptamine Receptor Subtype 2A",neuropsychiatric symptoms,gpcr,Phase 3,No,,,No,,,Yes,"Biotime Enzyme Biotechnology Co., Ltd. was established",https://www.xiamenbiotime.com/about-us_d1,Yes,SARS-CoV-2 Neutralizing Antibody Rapid Test,https://www.xiamenbiotime.com/about-us_d1,No,,,No,,,Yes,Detection Kit For Monkeypox Virus (Real-Time PCR),https://www.xiamenbiotime.com/about-us_d1,No,,,Yes,COVID-19 Solution SARS-CoV-2 Antigen Rapid Test,https://www.xiamenbiotime.com/about-us_d1,No,,,No,,
lamassu bio inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,RABI-767,"Disease Name, Acute Pancreatitis",metabolic diseases; veterinary medicine,other,Phase 2,Yes,"novel therapy SA53, a genetically targeted therapy that targets the MDM2 protein",https://www.linkedin.com/company/lamassu-biotech,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cymabay therapeutics inc,2024-02-12 00:00:00,No,Seladelpar,"PPARδ, Peroxisome Proliferator-Activated Receptor Delta",Rare diseases; Liver diseases; Autoimmune diseases,Nuclear receptors,Approved,Yes,"Seladelpar is a potent, selective, orally active PPARδ agonist",https://www.linkedin.com/company/cymabay-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
unity biotechnology inc,2025-05-05 14:09:01,No,UBX1325; UBB 2048; UBX2050,"BCL-xL, B-cell lymphoma-extra large; Tie2, Tyrosine kinase with immunoglobulin-like and EGF-like domains 2; VEGF, Vascular Endothelial Growth Factor",ophthalmology; vascular diseases; neurological diseases,enzyme; kinases; other,Phase 2,Yes,senolytic therapeutic candidate,https://www.linkedin.com/company/unity-biotechnology,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gensight biologics sa,2025-10-07 06:30:20,No,GS010; GS030-Dp; GS030-Md,Leber Hereditary Optic Neuropathy; Retinitis Pigmentosa,rare diseases; ophthalmology,other,Phase III; Phase I/II,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapy-based approach,https://www.linkedin.com/company/gensight-biologics-sa/,No,,,No,,,Yes,optogenetics for retinitis pigmentosa,https://www.linkedin.com/company/gensight-biologics-sa/
peptomyc sl,"Error: Connection failed - HTTPSConnectionPool(host='vhio.net', port=443): Ma",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aprinoia therapeutics inc,2025-05-07 11:28:40,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,Head of Medicinal Chemistry,https://www.linkedin.com/company/aprinoia-therapeutics,No,,,No,,,Yes,advanced antibody technology,https://www.linkedin.com/company/aprinoia-therapeutics,No,,,No,,,No,,,No,,,No,,,Yes,Protein Degradation for CNS Summit,https://www.linkedin.com/company/aprinoia-therapeutics,No,,
spirovant sciences inc,2024-11-14 14:40:58,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,developing novel gene therapies for cystic fibrosis and other pulmonary diseases,https://www.linkedin.com/company/spirovant,No,,,No,,,No,,
aethlon medical inc,2025-07-15 17:51:11,Yes,Hemopurifier,Not specified,oncology; infectious diseases,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation",https://www.cnbc.com/quotes/AEMD
rediscovery life sciences,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
advenchen laboratories llc,2010-06-20 00:00:00,Yes,Rivoceranib; AL3818; AL8326; AL2846; AL58805,"VEGFr, Vascular Endothelial Growth Factor Receptor; FGFr, Fibroblast Growth Factor Receptor; AuroraB, Aurora Kinase B; c-Met, Hepatocyte Growth Factor Receptor; mTor, Mechanistic Target of Rapamycin; pi3k, Phosphoinositide 3-kinase",oncology,kinases,Phase 3,Yes,small molecule cancer drug discovery programs,https://advenchen.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
minerva biotechnologies corp,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,CNS,Not specified,Not specified,Yes,a small molecule therapeutic which are both for the treatment of cancer metastasis,https://www.linkedin.com/company/minerva-biotechnologies,No,,,No,,,Yes,a straight antibody therapeutic,https://www.linkedin.com/company/minerva-biotechnologies,No,,,No,,,No,,,Yes,"huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor",https://www.linkedin.com/company/minerva-biotechnologies,No,,,No,,,No,,
simmaron research inc,Error: Connection failed - HTTPSConnectionPool(host='www.simmaronresearch.com,No,Rapamycin,"mTORC1, Mechanistic Target of Rapamycin Complex 1",CNS; infectious diseases,enzyme,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
virogenics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.salk.edu', port=443)",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
meryx inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
proniras corp,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,novel small-molecule therapeutics,https://www.linkedin.com/company/proniras-corporation,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
genera research ltd,"Error: Connection failed - HTTPSConnectionPool(host='genera-research.com', po",No,Reqorsa; GPX-002,"ALK-EML4, Anaplastic Lymphoma Kinase-Echinoderm Microtubule-associated Protein-like 4; TUSC2, Tumor Suppressor Candidate 2; Pdx1; MafA",oncology; diabetes,other; other; other; other,Preclinical,No,,,No,,,Yes,production of high-quality therapeutic proteins using recombinant DNA technology,https://eupry.com/cases/genera-research/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
china biologic products holdings inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,"placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia",https://www.jitta.com/stock/NASDAQ:CBPO,Yes,human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia,https://www.jitta.com/stock/NASDAQ:CBPO,Yes,"human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency",https://www.jitta.com/stock/NASDAQ:CBPO,No,,,No,,,No,,,No,,,Yes,human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus,https://www.jitta.com/stock/NASDAQ:CBPO,No,,,No,,
tempest therapeutics inc,2025-06-11 00:00:00,Yes,Amezalpat; TPST-1495,"PPARα, Peroxisome Proliferator-Activated Receptor Alpha; EP2/4, Prostaglandin Receptor",oncology; rare diseases,nuclear receptors; gpcr,Phase 3; Phase 2,Yes,advancing a diverse portfolio of small molecule product candidates,https://www.linkedin.com/company/tempesttx,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
lemonex inc,2025-10-17 14:48:25,Yes,LEM-S401; DegradaBALL,Not specified,infectious diseases; immunology; oncology,other,Phase 1,No,,,Yes,custom-made modified silica nanoparticle and graphene oxide tailored with specified peptides,https://www.linkedin.com/company/lemonex-inc-,No,,,No,,,No,,,No,,,Yes,siRNA transfection reagent 'Fluorofect' was developed which showed the excellent efficiency of siRNA transfection exhibiting gene knockdown efficiency,https://www.linkedin.com/company/lemonex-inc-,Yes,optimized for the development of gene therapies and immuno-oncology drugs,https://cepi.net/cepi-partners-lemonex-advance-mrna-vaccine-delivery-against-future-pandemic-threats,Yes,"advance their mRNA drug delivery technology, DegradaBALL®, which has the potential to both minimise post-mRNA vaccination side effects and improve access to future mRNA vaccines",https://cepi.net/cepi-partners-lemonex-advance-mrna-vaccine-delivery-against-future-pandemic-threats,No,,,Yes,nano-drug delivery technologies have attracted a lot of attention; DegradaBALL® is the most advanced nanotechnology-based drug delivery system,https://cepi.net/cepi-partners-lemonex-advance-mrna-vaccine-delivery-against-future-pandemic-threats
g2e co ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
eisbach bio gmbh,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,EIS-12656,"ALC1, Chromatin Remodeling Helicase CHD1L",oncology,enzyme,Phase 1/2,Yes,developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes,https://de.linkedin.com/company/eisbach,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vcn biosciences sl,"Error: Connection failed - HTTPSConnectionPool(host='therivabio.com', port=44",No,VCN-01,Not specified,oncology; rare diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,oncolytic adenoviruses,https://www.prnewswire.com/news-releases/synthetic-biologics-announces-vcn-biosciences-vcn-01-receives-orphan-drug-designation-for-retinoblastoma-from-the-us-fda-301477312.html
phoenix molecular designs,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,Yes,PCS6422; OP-1250; Capivasertib,Not specified,oncology,Not specified,Phase 3; Phase 2,Yes,developing small-molecule kinase inhibitors as a targeted therapy for cancer,https://www.linkedin.com/company/phoenixmoleculardesigns,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neurokine therapeutics,"Error: Connection failed - HTTPSConnectionPool(host='www.inknowvation.com', p",No,Mira-55; INM-901; CRB-913; IGC-AD1; BRC-002,"CB1, Cannabinoid Type-1 Receptor; Disease Name, Alzheimer's Disease; Disease Name, Complex Regional Pain Syndrome",CNS; neurodegenerative diseases; pain management,gpcr; other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sonire therapeutics inc,2024-11-03 05:33:24,No,Suizenji,"Disease Name, Pancreatic Cancer",oncology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,high-intensity focused ultrasound (HIFU) treatment system,https://www.linkedin.com/company/sonire-therapeutics-inc/
neuropore therapies inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,NPT1220-478,Not specified,CNS,Not specified,Not specified,Yes,novel small molecule therapeutics,https://www.linkedin.com/company/neuropore-therapies-inc.,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ocuterra therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Nesvategrast; OTT166,Integrin,retinal disease; diabetic retinopathy,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
centrexion therapeutics corp,2020-11-29 00:00:00,No,Not specified,Not specified,pain; immunology,Not specified,Not specified,Yes,CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist,https://www.marketscreener.com/quote/stock/CENTREXION-THERAPEUTICS-C-47134020/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
snipr biome aps,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CRISPR-based medicines,https://www.linkedin.com/company/sniprbiome/,Yes,CRISPR and Gene Therapy of the Microbiome,https://www.linkedin.com/company/sniprbiome/,No,,,No,,,Yes,CRISPR-armed phages as therapies against anti-microbial resistant (AMR) bacteria,https://www.linkedin.com/company/sniprbiome/
patara pharma inc,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
brain trust bio,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Aducanumab; Pimavanserin; Suvorexant,"Amyloid, Amyloid Beta; Disease Name; Disease Name",CNS; neuropsychiatric symptoms,other; Not specified; Not specified,Phase 3; Approved; Approved,Yes,IT-Riluzole (the only drug demonstrated to prolong survival in ALS),https://www.linkedin.com/company/brain-trust-bio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Intrathecal Drug Delivery Method,https://www.linkedin.com/company/brain-trust-bio
pdl biopharma inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
epidestiny inc,"Error: Connection failed - HTTPSConnectionPool(host='otm.uic.edu', port=443):",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kailera therapeutics inc,2024-10-01 11:00:05,No,KAI-9531; KAI-7535; KAI-4729,"GLP-1, Glucagon-Like Peptide-1; GIP, Glucose-Dependent Insulinotropic Polypeptide; Glucagon receptor",metabolic diseases; obesity,gpcr,Phase 3,Yes,"KAI-7535, a clinical-stage oral small molecule GLP-1 receptor agonist",https://www.globenewswire.com/news-release/2024/10/01/2955962/0/en/Kailera-Therapeutics-Launches-with-400-Million-Series-A-Financing-to-Advance-Portfolio-of-Next-Generation-Therapies-for-Obesity-and-Related-Conditions.html,Yes,GLP-1/GIP receptor dual agonist,https://www.globenewswire.com/news-release/2024/10/01/2955962/0/en/Kailera-Therapeutics-Launches-with-400-Million-Series-A-Financing-to-Advance-Portfolio-of-Next-Generation-Therapies-for-Obesity-and-Related-Conditions.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
apollo therapeutics ltd,2025-10-10 11:00:10,Yes,Camoteskimab,"IL-18, Interleukin-18",immunology; dermatology,cytokine,Phase 2,Yes,small molecules,https://uk.linkedin.com/company/apollo-therapeutics,No,,,No,,,Yes,monoclonal antibodies,https://uk.linkedin.com/company/apollo-therapeutics,Yes,ADC approaches,https://uk.linkedin.com/company/apollo-therapeutics,No,,,No,,,No,,,No,,,No,,,Yes,radioligand therapeutics,https://uk.linkedin.com/company/apollo-therapeutics
medannex ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,MDX-124,Annexin-A1,oncology; autoimmune diseases,other,Phase 1,No,,,No,,,No,,,Yes,monoclonal antibody therapeutic (MDX-124),https://uk.linkedin.com/company/medannex-limited,No,,,No,,,No,,,No,,,No,,,No,,,No,,
g1 therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,GB491; GB261; GB263T; GB268; GBD218; GBD201; GBD209; GB226; GB492,"CDK4/6, Cyclin-Dependent Kinase 4/6; CD20/CD3; EGFR, Epidermal Growth Factor Receptor; cMET, Mesenchymal-Epithelial Transition Factor; PD-1, Programmed Cell Death Protein 1; CTLA-4, Cytotoxic T-Lymphocyte-Associated Protein 4; VEGF, Vascular Endothelial Growth Factor; BCMA, B-Cell Maturation Antigen; GPRC5D, G Protein-Coupled Receptor Class C Group 5 Member D; CCR8, Chemokine Receptor 8",oncology; autoimmune diseases,kinases; immune checkpoint; other,Phase 3; Phase 1; Phase 2; Approved,Yes,"discovery, development, and commercialization of small molecule therapeutics",https://stockanalysis.com/stocks/gthx/,No,,,No,,,No,,,Yes,TROP2 Antibody-Drug Conjugate (ADC),https://stockanalysis.com/stocks/gthx/,No,,,No,,,No,,,No,,,No,,,No,,
aurealis oy,2025-10-14 07:30:04,Yes,AUP-16; AUP-55,"FGF-2, Fibroblast Growth Factor 2; IL-4, Interleukin-4; CSF-1, Colony Stimulating Factor 1",chronic wounds; oncology; inflammation,cytokine,Phase 2,No,,,No,,,Yes,"human FGF-2, IL-4, and CSF-1 produced locally",https://fi.linkedin.com/company/aurealis-ltd,No,,,No,,,No,,,No,,,Yes,multi-target cell and gene therapy platform,https://fi.linkedin.com/company/aurealis-ltd,No,,,No,,,Yes,Oncolytic Bacteria lead candidate AUP-55,https://fi.linkedin.com/company/aurealis-ltd
aurealis therapeutics ag,2025-10-14 07:30:04,Yes,AUP-16; AUP1602-C; AUP-55,"FGF-2, Fibroblast Growth Factor 2; IL-4, Interleukin 4; CSF-1, Colony Stimulating Factor 1",chronic wounds; oncology,cytokine,Phase 2,No,,,No,,,Yes,"human FGF-2, IL-4, and CSF-1 produced locally by a BSL-1 engineered Lactococcus cremoris vector",https://fi.linkedin.com/company/aurealis-ltd,No,,,No,,,No,,,No,,,Yes,"multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria",https://fi.linkedin.com/company/aurealis-ltd,No,,,No,,,Yes,Oncolytic Bacteria lead candidate AUP-55,https://fi.linkedin.com/company/aurealis-ltd
ikena oncology inc,2023-06-15 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,small molecule drug design,https://www.linkedin.com/company/ikenaoncology,No,,,No,,,Yes,"humanized, subcutaneously administered, non-depleting IgG1 monoclonal antibody targeting OX40",https://www.globenewswire.com/news-release/2025/07/15/3116027/0/en/Ikena-Oncology-Announces-Stockholder-Approval-of-Merger-with-Inmagene-Biopharmaceuticals.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vigil neuroscience inc,2025-08-06 13:25:16,No,VG-3927; VGL101,"TREM2, Triggering Receptor Expressed on Myeloid Cells 2",neurology; neurodegenerative diseases; rare diseases,other,Phase 2; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vaxart inc,2025-10-16 20:53:12,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,oral vaccine pills,https://www.linkedin.com/company/vaxart,No,,,No,,
ashibio inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,two of our first-in-class antibody programs,https://www.linkedin.com/company/ashibio,No,,,No,,,No,,,No,,,No,,,No,,,No,,
replicate bioscience inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,RBI-4000,IL-1 receptor agonist; IL-18 binding protein,infectious diseases; immunology,cytokine,Phase 1,No,,,No,,,Yes,Replicate works with industry leaders to create fit-for-purpose srRNA that enables patients' cells to naturally generate their own therapeutic proteins,https://www.prnewswire.com/news-releases/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes-302540245.html,No,,,No,,,No,,,Yes,Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA (srRNA) technology,https://www.linkedin.com/company/replicate-bioscience-inc,No,,,Yes,Replicate’s most advanced therapeutic protein asset targets IL-1 receptor agonist and IL18 binding protein for dual-blockade of cytokines downstream of inflammasome activation,https://www.prnewswire.com/news-releases/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes-302540245.html,No,,,Yes,Replicate has an extensive toolbox of proprietary srRNA technology that enables customization of their protein expression profiles,https://www.prnewswire.com/news-releases/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes-302540245.html
hanbio therapeutics ltd,2022-01-28 22:37:00,Yes,SSGJ-707,"PD-1, Programmed Death-1; VEGF, Vascular Endothelial Growth Factor",oncology,immune checkpoint; cytokine,Phase 3,No,,,No,,,Yes,Protein Sciences,https://www.prnewswire.com/news-releases/hanbio-therapeutics-announces-the-completion-of-a-us40-million-series-a-financing-led-by-orbimed-and-hankang-capital-301471066.html,Yes,innovative antibodies and other biologics products,https://www.prnewswire.com/news-releases/hanbio-therapeutics-announces-the-completion-of-a-us40-million-series-a-financing-led-by-orbimed-and-hankang-capital-301471066.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
anacardio ab,2025-10-02 10:39:26,No,AC01,"GHSR1a, Ghrelin Receptor",cardiovascular,gpcr,Phase 2,Yes,oral ghrelin mimetic small-molecule,https://se.linkedin.com/company/anacardio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
river 3 renal corp,"Error: Connection failed - HTTPSConnectionPool(host='www.baincapital.com', po",No,R3R01,Not specified,rare diseases; chronic kidney diseases,Not specified,Phase 2,Yes,"R3R01, a molecule intended to reduce the accumulation of toxic lipids in podocytes",https://alportsyndrome.org/for-patients/clinical-trials/current-past-clinical-trials/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
olatec therapeutics llc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,Yes,Dapansutrile; OPN-031,"NLRP3, NLR Family Pyrin Domain Containing 3",immunology; cardiovascular; neurodegenerative diseases; diabetes; oncology,enzyme,Phase 2,Yes,"innovative, oral inflammation therapeutics",https://www.linkedin.com/company/olatec,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,NLRP3 inflammasome inhibitor,https://www.linkedin.com/company/olatec
kanyos bio inc,Error: can't compare offset-naive and offset-aware dateti,No,KAN-101,Gliadin,autoimmune diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tasly biopharmaceuticals co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.sutrobio.com', port=",No,BAT8006; Prourokinase recombinant,"FRα, Folate Receptor α; Fibrin",oncology; cardiovascular,other; enzyme,Phase II; Phase III,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vega therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='star-therapeutics.com', ",Yes,VGA039,Protein S,rare blood disorders; bleeding disorders,enzyme,Phase 1,No,,,No,,,No,,,Yes,monoclonal antibody therapy with a novel mechanism of action that regulates Protein S,https://www.linkedin.com/company/vega-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
heartseed inc,"Error: Connection failed - HTTPSConnectionPool(host='www.bio.org', port=443):",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
step pharma,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,"CTPS1, Cytidine Nucleotide Triphosphate Synthase 1",autoimmune diseases,enzyme,Preclinical,Yes,Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases,https://www.linkedin.com/company/step-pharma/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
moonbiotech,"Error: Connection failed - HTTPSConnectionPool(host='www.echemi.com', port=44",No,3BP-6146; NTA-476,"TROP-2, Trophoblast Cell-Surface Antigen 2; PSMA, Prostate-Specific Membrane Antigen; uPAR, Urokinase-type Plasminogen Activator Receptor",oncology,other,Preclinical; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aro biotherapeutics co,No timestamp found,Yes,ABX1100,"GYS1, Glycogen Synthase 1",rare diseases; metabolic diseases,enzyme,Phase 1,No,,,No,,,Yes,protein technology called Centyrins,https://www.linkedin.com/company/aro-biotherapeutics,Yes,Bispecifics,https://www.linkedin.com/company/aro-biotherapeutics,Yes,Centyrin-RNA drug conjugates,https://www.arobiotx.com/,No,,,Yes,siRNA,https://www.linkedin.com/company/aro-biotherapeutics,No,,,No,,,No,,,Yes,Targeted Nanoparticles,https://www.linkedin.com/company/aro-biotherapeutics
toscana life sciences foundation,Error: Connection failed - HTTPSConnectionPool(host='www.toscanalifesciences.,No,Not specified,Not specified,oncology,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
legochem biosciences inc,2024-02-15 00:00:00,Yes,LCB71; LCB97,"ROR1, Receptor Tyrosine Kinase-Like Orphan Receptor 1; L1CAM, L1 Cell Adhesion Molecule",oncology,kinases,Preclinical,No,,,No,,,Yes,Protein-Drug Conjugates (PDCs),https://www.linkedin.com/company/legochem-biosciences-inc-/,No,,,Yes,Antibody-Drug Conjugates (ADCs),https://www.linkedin.com/company/legochem-biosciences-inc-/,No,,,No,,,No,,,No,,,No,,,No,,
ligachem biosciences inc,2024-02-15 00:00:00,Yes,Not specified,Not specified,oncology,other,Not specified,No,,,No,,,Yes,Protein-Drug Conjugates (PDCs),https://www.linkedin.com/company/legochem-biosciences-inc-/,No,,,Yes,Antibody-Drug Conjugates (ADCs),https://www.linkedin.com/company/legochem-biosciences-inc-/,No,,,No,,,No,,,No,,,No,,,No,,
shanghai argo pharmaceutical co ltd,2023-12-01 00:00:00,Yes,BW-00112; BW-40202,"ANGPTL3, Angiopoietin-like 3; CFB, Complement Factor B",cardiovascular; rare diseases,enzyme; other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,Yes,siRNA therapeutics,https://www.prnewswire.com/news-releases/argo-biopharma-announces-multi-asset-license-and-option-agreements-with-novartis-for-novel-molecules-for-cardiovascular-diseases-302544452.html,No,,,No,,,No,,,No,,
solu therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",Yes,STX-0712; STX-0812; STX-0640,"CCR2, GPCR Chemokine Receptor 2; Pathogenic Monocytes; Mast Cells",oncology; immunology; inflammatory diseases,gpcr; other; other,Phase 1; Preclinical; Preclinical,Yes,therapies that combine the target-binding capability of small molecules with the therapeutic power of biologics,https://www.prnewswire.com/news-releases/solu-therapeutics-closes-41m-series-a-financing-and-announces-first-patient-dosed-in-phase-1-clinical-trial-of-stx-0712-in-patients-with-cmml-and-other-advanced-hematologic-malignancies-302423841.html,No,,,No,,,Yes,therapies that combine the target-binding capability of small molecules with the therapeutic power of biologics,https://www.prnewswire.com/news-releases/solu-therapeutics-closes-41m-series-a-financing-and-announces-first-patient-dosed-in-phase-1-clinical-trial-of-stx-0712-in-patients-with-cmml-and-other-advanced-hematologic-malignancies-302423841.html,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms,https://www.prnewswire.com/news-releases/solu-therapeutics-closes-41m-series-a-financing-and-announces-first-patient-dosed-in-phase-1-clinical-trial-of-stx-0712-in-patients-with-cmml-and-other-advanced-hematologic-malignancies-302423841.html
sapience therapeutics inc,2022-05-31 08:14:25,Yes,Lucicebtide; ST316; ST101,"C/EBPβ, CCAAT/enhancer-binding protein beta; β-catenin",oncology; gastrointestinal cancers; glioblastoma; colorectal cancer,other; enzyme,Phase 2; Phase 1,No,,,Yes,peptide therapeutics,https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-41-million-series-b-financing-to-advance-pipeline-of-peptide-therapeutics-targeting-protein-protein-interactions-301557720.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zhuhai beihai biotech co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,BH011,Not specified,oncology,Not specified,Phase I/II,Yes,Albumin Solubilized Docetaxel Injection,https://pharma.economictimes.indiatimes.com/news/pharma-industry/zydus-obtains-zhuhai-beihai-biotech-cancer-drug-us-commercial-rights/118247794,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
iliad biotechnologies llc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,advancing the next generation pertussis vaccine for the prevention of whooping cough,https://www.linkedin.com/company/iliad-biotechnologies-llc,No,,,No,,
bugworks research india pvt ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,BWC0977,Not specified,infectious diseases; oncology,Not specified,Phase 1,Yes,"targeted small molecules for the treatment of multidrug-resistant microbial infections and hypoxic, immunosuppressed, refractory solid tumors",https://bugworksresearch.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
suzhou corning jerry biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.gcbiotek.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
oncoimmune inc,"Error: Connection failed - HTTPSConnectionPool(host='www.merck.com', port=443",Yes,ONC-392,"CTLA-4, Cytotoxic T-Lymphocyte-Associated Protein 4",oncology,immune checkpoint,Phase 3,Yes,developing novel formulations of small molecular drug for the selective targeting leukemia stem cells (LSCs) for the treatment of Acute myeloid leukemia (AML),https://www.pfizer.com/news/press-release/press-release-detail/oncoimmune-announces-option-and-license-agreement-pfizer,No,,,No,,,Yes,"ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody",https://www.pfizer.com/news/press-release/press-release-detail/oncoimmune-announces-option-and-license-agreement-pfizer,No,,,No,,,No,,,No,,,No,,,No,,,No,,
180 life sciences corp,2025-08-04 22:30:00,No,Adalimumab; HMGB1 mAbs,"TNF, Tumor Necrosis Factor; HMGB1, High Mobility Group Box 1 Protein",inflammation; fibrosis,cytokine; other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
areteia therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.baincapital.com', po",No,Dexpramipexole,Eosinophils,Respiratory; immunology,Other,Phase 3,Yes,"dexpramipexole, a first-in-class oral drug",https://areteiatx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
homology medicines inc,2024-03-25 16:15:00,No,HMI-103; HMI-102; GTx-mAb,Phenylketonuria; Hunter syndrome; Metachromatic leukodystrophy; Paroxysmal nocturnal hemoglobinuria,rare diseases,Not specified,Phase 1; Preclinical,No,,,No,,,No,,,Yes,fully human anti-IL-7Rα antibody,https://www.prnewswire.com/news-releases/q32-bio-announces-closing-of-merger-with-homology-medicines-and-concurrent-private-placement-of-42-million-302098557.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
corat therapeutics gmbh,2021-07-08 12:09:00,No,P2C-1F11; BD-368-2; P2B-2F6; COV2-2196; COV2-2130; S2M11; Vh–Fc ab8; 4A8; C002; JS016; LY3832479; LY-CoV016; TY027; BRII-196; BRII-198,"RBD, Receptor Binding Domain; S-protein, Spike Glycoprotein; NTD, N-terminal Domain",infectious diseases,other,Preclinical; Phase 2; Phase 3,No,,,No,,,No,,,Yes,phage-display derived fully human antibodies,https://www.linkedin.com/company/corat-therapeutics/,No,,,No,,,No,,,No,,,Yes,passive vaccines to treat and to protect against COVID-19,https://www.linkedin.com/company/corat-therapeutics/,No,,,No,,
shanghai allink biotherapeutics co ltd,2024-11-28 08:06:36,Yes,ALK201; ALK202,Not specified,oncology; immunology,Not specified,Phase 1,No,,,No,,,No,,,Yes,bispecific antibodies,https://cn.linkedin.com/company/allinkbio,Yes,Antibody-Drug Conjugates (ADCs),https://cn.linkedin.com/company/allinkbio,No,,,No,,,No,,,No,,,No,,,No,,
storm therapeutics ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,Yes,STC-15,"METTL3, Methyltransferase-like 3",oncology,enzyme,Phase 1,Yes,small-molecule drug candidates,https://uk.linkedin.com/company/storm-therapeutics-limited,No,,,No,,,No,,,No,,,No,,,Yes,RNA modifying enzymes (RME),https://www.news-medical.net/suppliers/STORM-Therapeutics-LTD.aspx,No,,,No,,,No,,,No,,
lanova medicines ltd,Error: Connection failed - HTTPSConnectionPool(host='www.lanovamedicines.com',No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,discovery and development of novel biologic drugs for cancer treatment,https://www.linkedin.com/company/lanova-medicines/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neuraltus pharmaceuticals inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,NP001,Inflammation,CNS; rare diseases,other,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
engene holdings inc,2025-10-13 20:36:31,No,detalimogene; detalimogene voraplasmid,"Disease Name, Non-Muscle Invasive Bladder Cancer (NMIBC)",oncology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,Yes,non-viral gene therapy,https://www.linkedin.com/company/engene,Yes,gene-based immunotherapy,https://www.linkedin.com/company/engene,No,,,No,,,No,,
engene inc,2025-10-13 20:36:31,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,Yes,non-viral gene therapy,https://www.linkedin.com/company/engene,Yes,gene-based immunotherapy,https://www.linkedin.com/company/engene,No,,,No,,,No,,
istari oncology inc,2021-05-22 00:00:00,No,lerapolturev,"PD-1, Programmed Cell Death Protein 1",oncology,immune checkpoint,Phase 2,No,,,No,,,No,,,Yes,monoclonal development,https://www.linkedin.com/company/istari-oncology,No,,,No,,,No,,,No,,,No,,,No,,,Yes,novel immuno-oncology and immunotherapy platforms,https://www.linkedin.com/company/istari-oncology
redx pharma limited,2025-09-29 07:33:10,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"novel, small molecule, highly targeted therapeutics",https://uk.linkedin.com/company/redx-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
redx pharma plc,2025-09-29 07:33:10,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"novel, small molecule, highly targeted therapeutics",https://uk.linkedin.com/company/redx-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
staten biotechnology bv,Error: Connection failed - HTTPSConnectionPool(host='european-biotechnology.c,Yes,WELIREG,"HIF-2α, Hypoxia-Inducible Factor-2 Alpha",rare diseases; oncology,other,Approved,No,,,No,,,No,,,Yes,"humanized, monoclonal antibody",https://www.globenewswire.com/news-release/2018/12/17/1732214/0/en/Staten-Biotechnology-B-V-and-Novo-Nordisk-A-S-announce-collaboration-to-develop-novel-treatment-for-dyslipidaemia.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nano intelligent biomedical engineering corp,"Error: Connection failed - HTTPSConnectionPool(host='www.bioworld.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,peptide-based drug,https://www.linkedin.com/posts/crohn%27s-%26-colitis-foundation-of-america_scientists-at-nano-intelligent-biomedical-activity-7130221117713059840-Gcrb,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
samumed pacific pty ltd,Error: Connection failed - HTTPSConnectionPool(host='www.sandiegouniontribune,Yes,SM04646; Lorecivivint; Cirtuvivint,"Wnt, Wnt Signaling Pathway; CLK/DYRK, CDC2-like Kinase/Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase",pulmonology; musculoskeletal; oncology; neurology,other; kinases,Phase 1; Phase 3; IND Enabling,Yes,small molecule inhibitor (SM04646) of the Wnt pathway,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369623&isReview=true,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biogenerix ag (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Obefazimod; Zunsemetinib; ATI-450; BIIB800; TS152; SM03; SHR0302; RC18; Otilimab; ABBV-154; Branebrutinib,"TNF-alpha, Tumor Necrosis Factor-alpha; CD22, CD22 Antigen; JAK1, Janus Kinase 1; BAFF, B-cell Activating Factor; GM-CSF, Granulocyte-Macrophage Colony-Stimulating Factor; GR, Glucocorticoid Receptor; BTK, Agammaglobulinaemia Tyrosine Kinase",rheumatoid arthritis; autoimmune diseases; oncology,cytokine; enzyme; other; immune checkpoint; kinases,Phase II; Phase III; Preclinical; Preregistration,No,,,No,,,Yes,next-generation therapeutic proteins,https://www.missionir.com/small-cap-news/neose-technologies-inc-ntec-announces-sale-of-assets-to-novo-nordisk-and-biogenerix-ag-for-43-million/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
xenikos bv,"Error: Connection failed - HTTPSConnectionPool(host='www.veloxis.com', port=4",Yes,romosozumab; risankizumab; polatuzumab vedotin; brolucizumab; crizanlizumab,"Sclerostin; IL-23 p19; CD79b; VEGF; CD62, P-selectin",osteoporosis; dermatology; oncology; ophthalmology; hematology,other; cytokine; other; other; other,Approved,No,,,No,,,No,,,Yes,monoclonal antibodies that target CD3 and CD7 molecules on immune cells,https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-announces-dosing-of-the-first-patient-by-partner-xenikos-in-the-global-phase-3-study-evaluating-t-guard-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-sr-agvhd-301576083.html,Yes,toxin-conjugated monoclonal antibodies,https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-announces-dosing-of-the-first-patient-by-partner-xenikos-in-the-global-phase-3-study-evaluating-t-guard-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-sr-agvhd-301576083.html,No,,,No,,,Yes,Following allogeneic hematopoietic stem cell transplantation (allo-HSCT),https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-announces-dosing-of-the-first-patient-by-partner-xenikos-in-the-global-phase-3-study-evaluating-t-guard-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-sr-agvhd-301576083.html,No,,,No,,,No,,
prilenia therapeutics development ltd,2025-10-13 20:26:56,No,Pridopidine,"HTT, Huntingtin Protein",CNS; rare diseases,other,Not specified,Yes,"Pridopidine, a first-in-class oral drug candidate",https://www.linkedin.com/company/prilenia,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cerevel therapeutics holdings inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Emraclidine; Darigabat; Tavapadon; CVL-871; CVL-354; CVL-047,"M4, Muscarinic Acetylcholine Receptor M4; GABAA, Gamma-Aminobutyric Acid Type A Receptor; D1/D5, Dopamine Receptors D1 and D5; KOR, Kappa Opioid Receptor; PDE4, Phosphodiesterase 4",CNS; schizophrenia; anxiety; epilepsy; Parkinson's disease; dementia-related apathy; major depressive disorder; substance use disorder,gpcr; gpcr; gpcr; gpcr; enzyme,Phase 2; Phase 1; Phase 3; Phase 2a; Preclinical; Preclinical,Yes,"Emraclidine, a potential best-in-class, next-generation antipsychotic, is a positive allosteric modulator (PAM) of the muscarinic M4 receptor",https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-cerevel-therapeutics-302212336.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cerevel therapeutics llc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Emraclidine; Tavapadon; CVL-354; Darigabat,"M4, Muscarinic M4 receptor; D1/D5, Dopamine D1/D5 receptor; KOR, Kappa Opioid Receptor; GABA A receptor",CNS; schizophrenia; Parkinson's disease; epilepsy; panic disorder; Alzheimer's disease psychosis,gpcr; gpcr; other; gpcr,Phase 3; Phase 3; Phase 1; Phase 2,Yes,clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline,https://news.abbvie.com/2023-12-06-AbbVie-to-Acquire-Cerevel-Therapeutics-in-Transformative-Transaction-to-Strengthen-Neuroscience-Pipeline,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ligand pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,ZELSUVMI,"Disease Name, Molluscum contagiosum",infectious diseases; dermatology,other,Approved,Yes,Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.,https://www.linkedin.com/company/ligand-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.,https://www.linkedin.com/company/ligand-pharmaceuticals
celecor therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
brim biotechnology inc,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,BRM424; BRM421; BRM411; BRM412,Neurotrophic Keratitis; Dry Eye Disease; Glaucoma; Ocular Angiogenesis,ophthalmology; rare diseases,other,Phase 3; Phase 2; Phase 1/2b,No,,,Yes,novel peptide treatments,https://www.linkedin.com/company/brimbiotech,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
flexion therapeutics inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.pharmtech.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
elusys therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='elusys.com', port=443): ",No,Obiltoxaximab,"B. anthrasis PA, Bacillus anthracis Protective Antigen",infectious diseases,enzyme,Approved,No,,,No,,,No,,,Yes,anthrax antitoxin ANTHIM® (obiltoxaximab),https://www.linkedin.com/company/elusys-therapeutics-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,
t3 pharmaceuticals ag,"Error: Connection failed - HTTPSConnectionPool(host='baselarea.swiss', port=4",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,efficient protein delivery technology,https://www.linkedin.com/company/t3pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,bacterial cancer therapy,https://www.linkedin.com/company/t3pharma
kaerus bioscience ltd,2025-09-08 10:19:58,Yes,KER-0193,"BK, Large-Conductance Calcium-Activated Potassium Channels",neurology,ion channels,Phase 2,Yes,"KER-0193 is a novel, orally-bioavailable small molecule",https://www.linkedin.com/company/kaerusbio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cytokinetics inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kubota vision inc,2025-10-18 15:45:47,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,wearable device for myopia control using Kubota Glass technology,https://www.nbr.org/people/ryo-kubota/
biocryst pharmaceuticals inc,2025-10-14 11:03:40,Yes,Navenibart; Orladeyo; STAR-0310,Plasma Kallikrein; OX40,rare diseases; allergic diseases; immunologic diseases,enzyme; other,Phase 3; Marketed; Preclinical,Yes,oral small-molecule therapeutics,https://www.linkedin.com/company/biocryst-pharmaceuticals,No,,,Yes,protein therapeutics,https://www.linkedin.com/company/biocryst-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
constellation pharmaceuticals inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,Pelabresib; CPI-0209,"BET, Bromodomain and Extra-Terminal motif; EZH2, Enhancer of Zeste Homolog 2",oncology; hematological malignancies; solid tumors,other; enzyme,Phase 3; Phase 2,Yes,develops molecule therapeutics,https://www.bloomberg.com/profile/company/CNST:US,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
achieve life sciences inc,2025-10-17 11:36:29,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"Cytisinicline is a naturally occurring, plant-based alkaloid.",https://www.marketscreener.com/news/achieve-life-sciences-says-it-gets-fda-commissioner-s-national-priority-voucher-for-cytisinicline-ce7d5addda8af124,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
coimmune inc,2021-12-15 08:02:00,No,TRACK-NK™; Cyto-102,"PD-L1, Programmed Death-Ligand 1; IL-15, Interleukin-15; CAR, Chimeric Antigen Receptor; BiKE, Bispecific Killer Engager",oncology,immune checkpoint; cytokine; other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"cell-based therapeutics, CAR-CIK technology, cellular immunotherapies",https://www.globenewswire.com/search/organization/CoIMMUNE,No,,,No,,,No,,
northern biologics inc,No timestamp found,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,antibody-based therapeutics,https://www.versantventures.com/portfolio/northern-biologics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cytoki pharma aps,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,CK-0045,"IL-22, Interleukin-22",metabolic diseases; inflammatory bowel disease,cytokine,Phase 2,No,,,No,,,Yes,lipidated IL-22 analogue,https://www.prnewswire.com/news-releases/cytoki-pharma-announces-first-patient-dosed-in-phase-2-study-of-ck-0045-in-obesity-and-type-2-diabetes-302294879.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
mitobridge inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,MA-0211,Duchenne Muscular Dystrophy,genetic disorders,Not specified,Phase 1,Yes,discovering and developing small molecule therapeutics,https://www.massbio.org/members/mitobridge-inc/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,target protein stabilizers or degraders,https://www.generian.com/generian-achieves-first-milestones-in-mitobridge-collaboration/,No,,
carthera sas,"Error: Connection failed - HTTPSConnectionPool(host='www.bioworld.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,carboplatin,https://fr.linkedin.com/company/carthera,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"SonoCloud technology temporarily opens the blood-brain barrier, enabling chemotherapy to reach tumors",https://fr.linkedin.com/company/carthera
reva medical inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,MOTIV; TyroSphere; Fantom Encore,Below-the-Knee Peripheral Artery Disease; Hypervascular Tumors; Coronary Artery Disease,cardiovascular; oncology,other,Approved; Preclinical; Marketed,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,bioresorbable polymer technologies for vascular applications,https://www.revamedical.com/
neotx therapeutics ltd,2020-03-19 00:00:00,No,S-588410; Telomelysin; LVGN-6051; AN-0025,Not specified,oncology,Not specified,Phase 3; Phase 2; Phase 1; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
spinifex pharmaceuticals pty ltd (inactive),2018-06-29 21:37:56,Yes,EMA401,"AT2R, Angiotensin II Type 2 Receptor",CNS; neuropathic pain,gpcr,Phase 2,Yes,"EMA401, a novel angiotensin II type 2 (AT2) receptor antagonist",https://www.prnewswire.com/news-releases/spinifex-pharmaceuticals-raises-us45m-in-series-c-financing-254816981.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
turning point therapeutics inc,2020-11-26 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,structure-based drug design company for the discovery and development of precision medicines for cancer,https://www.nextechinvest.com/clients/turning-point-therapeutics-inc/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pharmaessentia corp,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,Ropeginterferon alfa-2b; PEG-P-INF alpha-2b (P1101),Not specified,hematology; oncology,cytokine,Approved,No,,,No,,,Yes,"new biologics in hematology, oncology, and immunology",https://www.linkedin.com/company/pharmaessentia-corporation,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
chengdu jinkai biotechnology co ltd,2015-01-05 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sonalasense inc,"Error: Connection failed - HTTPSConnectionPool(host='www.fusfoundation.org', ",Yes,SONALA-001,"Protoporphyrin IX, Precursor of Heme",oncology; CNS; blood cancers,enzyme,Phase 2,Yes,aminolevulinic acid (a drug),https://www.linkedin.com/company/sonalasense,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,sonodynamic therapy (SDT),https://www.linkedin.com/company/sonalasense
viva vision biotech,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,VVN461; VVN001; VVN1901; VVN481; VVN432,"JAK1/TYK2, Janus Kinase 1/Tyrosine Kinase 2",ocular diseases; inflammation,kinases,Phase 2,Yes,dual JAK1/TYK2 inhibitor,https://www.prnewswire.com/news-releases/vivavision-announces-positive-comments-from-fda-for-the-type-c-meeting-regarding-vvn461ld-for-post-operative-infalmmation--agreeing-the-phase-2-trial-to-be-served-as-one-of-the-two-pivotal-studies-302476201.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rgenta therapeutics inc,2024-12-04 08:01:45,Yes,RGT-61159; RDrug,"MYB, Myeloblastosis Proto-Oncogene; FXN, Frataxin",oncology; neurological disorders,other,Phase 1,Yes,"developing a pipeline of oral, small-molecule RNA-targeting medicines",https://www.linkedin.com/company/rgenta-therapeutics-inc,No,,,No,,,No,,,No,,,No,,,Yes,RNA-targeting medicines,https://www.linkedin.com/company/rgenta-therapeutics-inc,No,,,No,,,Yes,design small-molecule glues to modulate the interactions,https://www.linkedin.com/company/rgenta-therapeutics-inc,No,,
university of sciences techniques and technologies of bamako-mali-bamako,No timestamp found,No,Artefenomel; Cipargamin; DM1157; DSM265; M5717; Meplazumab; MMV390048; MMV688533; SAR441121; (+)-SJ000557733; Tafenoquine; ZY-19489; Artefenomel-ferroquine; Artefenomel-piperaquine; Ganaplacide; Imatinib-DHA-piperaquine; Methylene blue; Ruxolitinib-artemether-lumefantrine,"PfATP4, Plasmodium falciparum P-type ATPase; Disease Name, Malaria",infectious diseases,enzyme; other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ocular therapeutix inc,2025-10-18 14:18:41,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,Tyrosine Kinase Inhibitors,https://www.linkedin.com/company/ocular-therapeutix-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Ocular Drug Delivery, Sustained Delivery",https://www.linkedin.com/company/ocular-therapeutix-inc
dragonfly therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,DF6215; DF9001,"IL-2R alpha, Interleukin-2 Receptor Alpha; EGFR, Epidermal Growth Factor Receptor",oncology,cytokine; other,Phase 1,No,,,No,,,Yes,engineered IL-2 cytokine,https://www.dragonflytx.com/,Yes,multispecific antibody technology,https://www.linkedin.com/company/dragonfly-therapeutics-inc./,No,,,No,,,No,,,Yes,natural killer cell-based therapies,https://www.dragonflytx.com/,No,,,No,,,Yes,TriNKET® immune engagers,https://www.dragonflytx.com/
tetralogic pharmaceuticals corp,2014-07-24 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,birinapant and suberohydroxamic acid (4-methoxycarbonyl) phenyl ester (SHAPE),https://www.linkedin.com/company/tetralogic-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biolingus ag,2023-06-30 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"oral formulations not only for peptides, but also small molecules",https://www.swissbiotech.org/listing/biolingus/,Yes,oral (sublingual) delivery of peptides,https://www.swissbiotech.org/listing/biolingus/,Yes,oral (sublingual) delivery of peptides and proteins,https://www.swissbiotech.org/listing/biolingus/,Yes,domain antibodies,https://www.swissbiotech.org/listing/biolingus/,No,,,No,,,Yes,nucleotides,https://www.swissbiotech.org/listing/biolingus/,No,,,No,,,No,,,Yes,novel protein scaffolds,https://www.swissbiotech.org/listing/biolingus/
iksuda therapeutics ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,IKS04; IKS014; IKS03,"CA242; HER2, Human Epidermal Growth Factor Receptor 2; CD19, Cluster of Differentiation 19",oncology,other; other; other,Preclinical; Phase 1; Preclinical,No,,,No,,,No,,,Yes,Antibodies,https://uk.linkedin.com/company/iksudatherapeutics,Yes,Antibody-Drug Conjugates (ADCs),https://www.bioindustry.org/member/iksuda-therapeutics-ltd/,No,,,No,,,No,,,No,,,No,,,No,,
dantari inc,Error: can't compare offset-naive and offset-aware dateti,Yes,DAN-222,"HER2, Human Epidermal Growth Factor Receptor 2",oncology,enzyme,Phase 1,Yes,chemotherapeutic agents,https://westlakebio.com/westlake-backed-dantari-launches-with-47-million-series-a/,No,,,No,,,Yes,antibody-drug conjugates (ADCs),https://www.biopharmadive.com/news/dantari-launch-cancer-drug-conjugates/638266/,Yes,antibody-drug conjugates (ADCs),https://westlakebio.com/westlake-backed-dantari-launches-with-47-million-series-a/,No,,,No,,,No,,,No,,,No,,,Yes,nanoparticles for drug delivery,https://www.biopharmadive.com/news/dantari-launch-cancer-drug-conjugates/638266/
ractigen therapeutics inc,2024-04-16 15:54:11,No,RAG-01; RAG-17; RAG-21; RAG-18,"p21, Tumor Suppressor Gene; SOD1, Superoxide Dismutase 1; FUS, Fused in Sarcoma; UTRN, Utrophin",oncology; CNS; rare diseases; genetic disorders,enzyme; other; other; other,Phase 1; Phase 1; Preclinical; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNAa (RNA activation) is a platform technology to selectively turn genes on by using short duplex RNA known as small activating RNA (saRNA),https://www.ractigen.com/,No,,,No,,,No,,,No,,
cugene inc,2022-05-16 00:00:00,Yes,GT-02287,"GCase, Glucocerebrosidase",neurology; metabolic diseases,enzyme,Phase 1,No,,,No,,,Yes,engineered IL-2 mutein,https://news.abbvie.com/2022-05-16-AbbVie-and-Cugene-Announce-Collaboration-in-Autoimmune-Diseases,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,precision immune therapeutics,https://www.massbio.org/members/cugene-inc/
dare bioscience inc,No timestamp found,No,Sildenafil Cream; Ovaprene; DARE-HRT1; DARE-HPV; Casea S; DARE-LARC1; XACIATO,Female Sexual Arousal Disorder; Non-Hormonal Contraception; Menopausal Hormone Therapy; HPV-related Cervical Disease; Long-Acting Reversible Contraception; Bacterial Vaginosis,sexual health; contraception; menopause; infectious diseases; reproductive health,other,Approved; Phase 1; Phase 2; Preclinical,Yes,"topical formulation of sildenafil, the active ingredient in the blockbuster product Viagra®",https://www.linkedin.com/company/dare-bioscience,Yes,"modulation of release rates across a wide array of molecules, hormones, peptides and proteins",https://www.linkedin.com/company/dare-bioscience,Yes,"modulation of release rates across a wide array of molecules, hormones, peptides and proteins",https://www.linkedin.com/company/dare-bioscience,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"DARE-IDDS, our groundbreaking drug delivery platform designed to address significant unmet needs in women’s health and beyond",https://www.linkedin.com/company/dare-bioscience
wuhan heyuan biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.yicaiglobal.com', po",No,Not specified,Not specified,oncology,Not specified,Not specified,No,,,No,,,Yes,plant-derived recombinant human serum albumin (HSA),https://www.linkedin.com/posts/lafaelt-electric-co-ltd_harmonic-staticvargenerator-powerfactorcorrection-activity-7366011693371461633-PO84,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
genta incorporated (inactive),"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,GT-02287,"GCase, Glucocerebrosidase",neurodegeneration; lysosomal storage disorders,enzyme,Phase 1,Yes,"tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel",https://www.nbcnews.com/id/wbna42194617,No,,,No,,,No,,,No,,,No,,,Yes,Genasense Injection is a modified DNA-based antisense drug,https://www.nbcnews.com/id/wbna42194617,No,,,No,,,No,,,No,,
xenetic biosciences inc,2025-10-16 12:52:59,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"small molecule and biotherapeutics R&D across oncology, immuno-oncology and inflammation",https://www.linkedin.com/company/xenetic-biosciences-inc-,No,,,Yes,recombinant human DNase I technology,https://www.linkedin.com/company/xenetic-biosciences-inc-,Yes,personalized CAR T platform technology engineered to target patient-specific tumor neoantigens,https://www.linkedin.com/company/xenetic-biosciences-inc-,No,,,No,,,No,,,Yes,personalized CAR T platform technology engineered to target patient-specific tumor neoantigens,https://www.linkedin.com/company/xenetic-biosciences-inc-,No,,,No,,,Yes,"PolyXen™, its proprietary drug delivery platform",https://www.linkedin.com/company/xenetic-biosciences-inc-
petra pharma corp,"Error: Connection failed - HTTPSConnectionPool(host='www.acceleratorlsp.com',",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"niagen bioscience, inc.","Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pimera inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,PMR-116; Atebimetinib,"Pol I, RNA Polymerase I; MEK, Mitogen-Activated Protein Kinase",oncology,enzyme; kinases,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,PMR-116 targets MYC-driven cancers by inhibiting an enzyme to disrupt ribosomal biogenesis,https://www.prnewswire.com/news-releases/pimera-therapeutics-announces-grant-award-from-medical-research-future-fund-mrff-for-expansion-of-phase-1ab-study-of-pmr-116-for-myc-driven-cancers-302484521.html
tetraphase pharmaceuticals inc,2017-05-01 00:00:00,Yes,TP-6076; TP-271,Not specified,infectious diseases,enzyme,Phase 1,Yes,novel tetracyclines for serious and life-threatening conditions,https://www.flagshippioneering.com/companies/tetraphase-pharmaceuticals-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
propanc biopharma inc,2025-10-07 12:50:56,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
enhancedbio usa inc,Error: Connection failed - HTTPSConnectionPool(host='www.louisianacancercente,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
calithera biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,CB-839; INCB001158,Glutaminase; Arginase,oncology; immuno-oncology; metabolic diseases,enzyme,Phase 2; Terminated,Yes,oral therapeutics,https://www.linkedin.com/company/calithera-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
irlab therapeutics ab,2025-10-17 16:36:33,Yes,IRL757; P003; IRL942; mesdopetam; pirepemat,"D3R, Dopamine D3 Receptor",CNS; neurology; Parkinson's disease,gpcr,Phase 2,Yes,IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders.,https://se.linkedin.com/company/irlab-therapeutics-ab,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
mimivax llc,2025-10-17 10:33:55,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
stem cell medicine ltd,"Error: Connection failed - HTTPSConnectionPool(host='il.linkedin.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biokier inc,"Error: Connection failed - HTTPSConnectionPool(host='www.sbir.gov', port=443)",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vectus biosystems ltd,2016-02-23 00:00:00,Yes,VB4-P5,Kidney Disease,renal diseases,other,Preclinical,Yes,"Funds from the IPO were predominantly used to develop the Company’s lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure.",https://au.linkedin.com/company/vectus-biosystems,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vivoryon therapeutics nv,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,varoglutamstat; VY2149; NCE,Not specified,chronic kidney disease; diabetic kidney disease; Alzheimer's disease,Not specified,Not specified,Yes,small molecule-based medicines,https://de.linkedin.com/company/vivoryon,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shire-nps pharmaceuticals inc,2018-06-28 14:52:49,No,SHP654; BAX 888; Gattex; Revestive; Natpara; Natpar; NPSP795,"FVIII, Factor VIII; GLP-2, Glucagon-like Peptide-2; PTH, Parathyroid Hormone",rare diseases; hematology; gastrointestinal disorders; endocrine disorders,enzyme; cytokine; other,Phase 1; Phase 2; Approved,Yes,"NPS Pharma is also investigating NPSP795, a small molecule antagonist of the calcium-sensing receptor",https://www.prnewswire.com/news-releases/plshire-to-acquire-nps-pharma-as-further-step-in-building-a-leading-biotech-288188461.html,No,,,Yes,"NATPARA/NATPAR (rhPTH [1-84]), if approved, would be the only bioengineered hormone replacement therapy for use in the treatment of HPT",https://www.prnewswire.com/news-releases/plshire-to-acquire-nps-pharma-as-further-step-in-building-a-leading-biotech-288188461.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ariad pharmaceuticals inc,2025-03-17 13:35:43,Yes,Iclusig; Brigatinib,"BCR-ABL, Breakpoint Cluster Region-Abelson Tyrosine Kinase",oncology,kinases,Approved; Phase 3,Yes,ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.,https://www.takeda.com/newsroom/newsreleases/2017/takeda-to-acquire-ariad-pharmaceuticals-inc/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ensysce biosciences inc,2025-10-16 14:20:03,No,PF614-MPAR,Not specified,pain management,Not specified,Phase 1,Yes,"abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform",https://www.linkedin.com/company/ensyscebio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tuhura biosciences inc,2025-07-03 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,VISTA inhibiting monoclonal antibody (mAb),https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update-302530551.html,Yes,bi-specific antibody drug conjugates,https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update-302530551.html,No,,,No,,,No,,,No,,,No,,,Yes,Delta Opioid Receptor technology targeting Myeloid Derived Suppressor Cells,https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update-302530551.html
protalix biotherapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
birchbiomed inc,2016-06-20 00:00:00,No,FS2,Keloid Scars,dermatology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immunogenx llc,"Error: Connection failed - HTTPSConnectionPool(host='www.sbir.gov', port=443)",No,latiglutenase; capeserod; adrulipase,Celiac Disease; Gastroparesis; Exocrine Pancreatic Insufficiency,gastrointestinal diseases; cystic fibrosis; chronic pancreatitis,enzyme; gpcr; enzyme,Phase 3; Not specified; Not specified,Yes,"Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy",https://www.marketscreener.com/quote/stock/ENTERO-THERAPEUTICS-INC-30506551/news/First-Wave-BioPharma-Inc-completed-the-acquisition-of-ImmunogenX-LLC-for-57-9-million-46198078/,No,,,Yes,"adrulipase, a recombinant lipase enzyme",https://www.marketscreener.com/quote/stock/ENTERO-THERAPEUTICS-INC-30506551/news/First-Wave-BioPharma-Inc-completed-the-acquisition-of-ImmunogenX-LLC-for-57-9-million-46198078/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immunogenics llc,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
global blood therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.pfizer.com', port=44",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"GBT developed Oxbryta ® (voxelotor), a first-in-class medicine that directly targets the root cause of SCD.",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance,No,,,No,,,Yes,"GBT’s promising pipeline also includes inclacumab, a fully human monoclonal antibody targeting P-selectin.",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance,No,,,No,,,No,,,No,,,No,,,No,,,No,,
city of hope,2025-10-18 19:02:02,Yes,Prizloncabtagene Autoleucel; Orca-T,"CD19/CD20; GVHD, Graft-Versus-Host Disease",oncology; hematologic malignancies,immune checkpoint; other,Phase 3,No,,,No,,,No,,,Yes,monoclonal antibodies,https://www.cancer.gov/research/infrastructure/cancer-centers/find/beckmancityofhope,Yes,antibody-drug conjugates,https://www.linkedin.com/company/city-of-hope,No,,,No,,,No,,,No,,,No,,,No,,
geneuro sa,2025-02-11 09:37:13,No,GNK 301,Not specified,CNS,Not specified,Not specified,No,,,No,,,No,,,Yes,GeNeuro develops antibodies to neutralize patient-produced pathogenic proteins,https://www.swissbiotech.org/listing/geneuro-sa/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
genkyotex sa,2020-03-06 00:00:00,No,setanaxib; Nefecon; TARPEYO,"NOX1, NADPH Oxidase 1; NOX4, NADPH Oxidase 4",rare diseases; inflammation; fibrosis; oncology; renal diseases; hepatic diseases,enzyme,Phase 3; Approved; Marketed,Yes,"setanaxib, is a first-in-class NOX inhibitor",https://www.linkedin.com/company/genkyotex-s.a/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ampo biotechnology inc,"Error: Connection failed - HTTPSConnectionPool(host='www.sbir.gov', port=443)",Yes,Not specified,Not specified,oncology; infectious diseases,Not specified,Phase 3,No,,,No,,,Yes,Dok-7 protein is central to the development and maintenance of the neuromuscular junction,https://amplobiotechnology.com/,No,,,No,,,No,,,No,,,Yes,AMP-101 AAV-Dok7 gene therapy; AMP-201 AAV-Collagen-Q gene therapy,https://amplobiotechnology.com/,No,,,No,,,No,,
starpharma holdings ltd,2025-09-30 00:08:58,Yes,DEP-SN38,Not specified,oncology,Not specified,Phase 1,No,,,No,,,No,,,Yes,DEP® ADC Platform improving antibody-drug conjugates to deliver safer and more effective cancer therapies,https://au.linkedin.com/company/starpharma,Yes,DEP® ADC Platform improving antibody-drug conjugates to deliver safer and more effective cancer therapies,https://au.linkedin.com/company/starpharma,No,,,No,,,No,,,No,,,No,,,Yes,development of dendrimers; DEP® drug delivery; dendrimer-drug conjugate incorporating a radiopharmaceutical molecule,https://au.linkedin.com/company/starpharma
organicell regenerative medicine inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.a,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,stem cells and exosome products,https://www.zeoscientifix.com/,No,,,No,,,Yes,exosome-based therapeutics,https://www.zeoscientifix.com/
indaptus therapeutics inc,2025-08-13 12:34:00,Yes,Decoy20,"TLR, Toll-like Receptor; STING, Stimulator of Interferon Genes; NLR, Nucleotide Oligomerization Domain-like Receptor",oncology; infectious diseases,immune checkpoint; other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,bacteria’s natural ability to activate both innate and adaptive cellular immune pathways,https://www.linkedin.com/company/indaptus-therapeutics-inc
delpor inc,2025-01-09 06:12:48,No,Brilaroxazine; Ulotaront; Emraclidine; CY6463; Olanzapine LAI; Iclepertin,"TAAR1, Trace Amine-Associated Receptor 1; 5-HT1A, Serotonin Receptor; M4, Muscarinic Acetylcholine Receptor; sGC, Soluble Guanylate Cyclase; GlyT1, Glycine Transporter 1",CNS; psychiatric disorders,gpcr; enzyme; other,Phase 3; Phase 2; Phase 1,Yes,sustained release of proteins and peptides as well as small molecules,https://www.kairosventures.com/delpor/,Yes,sustained release of proteins and peptides,https://www.kairosventures.com/delpor/,Yes,sustained release of proteins,https://www.kairosventures.com/delpor/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"implantable drugs, including Delpor’s implant devices",https://www.kairosventures.com/delpor/
alexion pharmaceuticals inc,2025-10-17 13:00:02,No,Not specified,"TTR, Transthyretin",rare diseases; cardiovascular,enzyme,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cellectar biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.cellectar.com', port",Yes,CLR 125; CLR 121225; CLR 121125; iopofosine I 131,Solid Tumors; Triple-Negative Breast Cancer; Pancreatic Cancer; Multiple Myeloma; Central Nervous System Lymphoma; Waldenstrom Macroglobulinemia,oncology,other,Phase 1,Yes,"lead asset iopofosine I 131, a small-molecule PDC",https://www.linkedin.com/company/cellectar-biosciences-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Phospholipid Drug Conjugate™ (PDC) delivery platform,https://www.linkedin.com/company/cellectar-biosciences-inc
resolve therapeutics llc (inactive),Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,Yes,RSLV-132; RSLV-145,Extracellular RNA; Extracellular DNA; Neutrophil Extracellular Traps,immunology; autoimmune diseases,enzyme,Phase 2,No,,,No,,,Yes,"Our fully-human biologic drug platform combines RNases and DNases with an antibody Fc to remove extracellular nucleic acids including RNA, DNA and neutrophil extracellular traps (NETs)",https://www.resolvetherapeutics.com/,Yes,Our fully-human biologic drug platform combines RNases and DNases with an antibody Fc,https://www.resolvetherapeutics.com/,No,,,Yes,Our fully-human biologic drug platform combines RNases and DNases with an antibody Fc,https://www.resolvetherapeutics.com/,Yes,"Our fully-human biologic drug platform combines RNases and DNases to remove extracellular nucleic acids including RNA, DNA",https://www.resolvetherapeutics.com/,No,,,No,,,No,,,No,,
curasen therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.alzdiscovery.org', p",Yes,CuraAX; CST-3056; CST-103; CST-107; CST-2032,"α1A-AR, Alpha-1A Adrenoceptor; β2-AR, Beta-2 Adrenoceptor",CNS; neurodegenerative diseases; psychiatric diseases,gpcr,Phase 1; Phase 2b,Yes,"first new chemical entity, CST-2032",https://www.linkedin.com/company/curasen,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
moleculin biotech inc,2025-10-15 13:12:35,No,Annamycin; WP1066; WP1122,"Disease Name, Acute Myeloid Leukemia; Disease Name, Soft Tissue Sarcoma; p-STAT3, Signal Transducer and Activator of Transcription 3; Pathogenic Viruses",oncology; infectious diseases,other; other; other,Phase 3,Yes,Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms,https://www.linkedin.com/company/moleculin-llc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pulmotect inc,"Error: Connection failed - HTTPSConnectionPool(host='ktla.com', port=443): Ma",Yes,PUL-042,Not specified,infectious diseases,Not specified,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Harnessing the Power of the Innate Immune System,https://www.linkedin.com/company/pulmotect-inc.
teclison ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Tirapazamine,Disease Name,oncology,Not specified,Phase 1,Yes,hypoxia-activating agent,https://www.linkedin.com/company/teclison,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
quanta therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,QTX3034; QTX3544; QTX3046,"KRAS G12D, Kirsten Rat Sarcoma Viral Oncogene Homolog G12D; KRAS G12V, Kirsten Rat Sarcoma Viral Oncogene Homolog G12V",oncology,kinases,Phase 1,Yes,novel small molecule cancer medicines targeting previously undruggable KRAS mutations,https://www.globenewswire.com/news-release/2025/07/23/3120181/0/en/Quanta-Announces-Leadership-Team-Appointment-and-Highlights-Clinical-Program-Progress.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Second Harmonic Generation (SHG) optical technology to identify allosteric modulators of protein complexes,https://www.globenewswire.com/news-release/2025/07/23/3120181/0/en/Quanta-Announces-Leadership-Team-Appointment-and-Highlights-Clinical-Program-Progress.html
neurosense therapeutics ltd,2025-09-04 08:49:00,No,PrimeC,Not specified,CNS; neurodegenerative diseases,Not specified,Phase 2,Yes,"PrimeC is a patented, extended-release oral formulation: a unique fixed-dose combination of two FDA-approved drugs",https://www.linkedin.com/company/neurosense-therapeutics,No,,,No,,,No,,,No,,,No,,,Yes,exploring the emerging role of microRNAs as therapeutic targets and biomarkers,https://www.linkedin.com/company/neurosense-therapeutics,No,,,No,,,No,,,No,,
mary crowley cancer research center,Error: Connection failed - HTTPSConnectionPool(host='www.crystalcharityball.o,Yes,Ulevostinag; Pembrolizumab,"STING, Stimulator of Interferon Genes; PD-1, Programmed Cell Death Protein 1",oncology,cytokine; immune checkpoint,Phase 2,Yes,BBO-10203 is a first-in-class orally bioavailable RAS:PI3Ka breaker,https://www.linkedin.com/company/mary-crowley-cancer-research-centers,No,,,No,,,No,,,No,,,No,,,No,,,Yes,PERSONALIZED gene and immune based therapies,https://www.linkedin.com/company/mary-crowley-cancer-research-centers,No,,,No,,,No,,
the walter and eliza hall institute of medical research,2025-10-16 00:52:26,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CAR T cell therapies and other immune-based strategies for aggressive paediatric and adult brain tumours,https://au.linkedin.com/company/wehi_research,No,,,No,,,No,,
immunoflex therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,OT-101,"TGF-β, Transforming Growth Factor Beta",oncology; inflammatory diseases,cytokine,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,We bridge the health gap when vaccines are not available or not fully effective.,https://ca.linkedin.com/company/immunoflex,No,,,No,,
mikrobiomik healthcare company sl,2025-07-03 00:00:00,No,Not specified,Not specified,infectious diseases,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
opsidio llc,2017-10-25 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,novel biologic therapeutics,https://www.linkedin.com/company/opsidio-llc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
caelum biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tetra therapeutics,Error: Connection failed - HTTPSConnectionPool(host='www.michiganbusiness.org,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
athenex inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='buffalonews.com', port=4",No,HLX10; Camrelizumab; Catumaxomab; Abemaciclib; Amivantamab; RAPA-201; HC 5404 FU,"PD-1, Programmed Cell Death-1; CLDN18.2, Claudin 18.2; HER2, Human Epidermal Growth Factor Receptor 2; ARID1a, AT-Rich Interaction Domain 1A",oncology,immune checkpoint; other; kinases; other,Phase 3; Phase 3; Phase 3; Phase 2; Phase 2; Phase 2; Phase 1,Yes,small molecule or Orascovery business,https://www.wgrz.com/article/money/business/athenex-assets-sold-in-bankruptcy-auction-top-executives-dismissed/71-9cbc0f76-6419-4d03-bb6b-1c482de85ac6,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
obseva sa,2018-07-14 00:00:00,No,Linzagolix,"GnRH, Gonadotropin-Releasing Hormone receptor",women's health; uterine fibroids; endometriosis,gpcr,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
celcuity inc,2025-10-18 14:14:28,No,Gedatolisib,"PAM, PI3K/AKT/mTOR Pathway",oncology,kinases,Phase 3,Yes,"gedatolisib, a potent pan-PI3K and mTOR inhibitor",https://www.celcuity.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vera therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Atacicept,"APRIL, A Proliferation-Inducing Ligand; BLyS, B Lymphocyte Stimulator",rare diseases; nephrology; autoimmune diseases,cytokine,Phase 3,No,,,No,,,Yes,Atacicept is an investigational recombinant fusion protein,https://www.globenewswire.com/news-release/2025/,Yes,"MAU868, a monoclonal antibody designed to neutralize infection with BK virus",https://www.globenewswire.com/news-release/2025/,No,,,Yes,"Atacicept, a fusion protein self-administered as a subcutaneous injection",https://www.globenewswire.com/news-release/2025/,No,,,No,,,No,,,No,,,No,,
proteus digital health inc (inactive),2020-06-16 15:19:38,No,Abilify MyCite; aripiprazole,Not specified,psychiatric disorders,Not specified,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"ingestible sensors that communicate when medicines are taken, plus a wearable patch that monitors the response",https://www.cnbc.com/2020/06/15/proteus-digital-health-once-worth-1point5-billion-files-for-chapter-11.html
lyell immunopharma inc,2025-09-29 15:55:01,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,next-generation CAR T-cell therapies,https://www.linkedin.com/company/lyell,No,,,No,,,No,,
poseida therapeutics inc,2025-01-08 15:32:07,Yes,P-BCMA-ALLO1; P-CD19CD20-ALLO1,"BCMA, B-Cell Maturation Antigen; CD19, Cluster of Differentiation 19; CD20, Cluster of Differentiation 20",oncology; hematologic malignancies,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,Yes,nanoparticle gene delivery technologies,https://poseida.com/,Yes,allogeneic CAR-T therapies with an early memory phenotype,https://poseida.com/,No,,,No,,,Yes,nanoparticle gene delivery technologies,https://poseida.com/
sangamo therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,SB-525,"Factor VIII, Coagulation Factor VIII",rare diseases; hematology,enzyme,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene-based therapeutic development,https://www.linkedin.com/company/sangamo-therapeutics,No,,,No,,,Yes,engineered zinc fingers,https://www.linkedin.com/company/sangamo-therapeutics
eden biologics inc,"Error: Connection failed - HTTPSConnectionPool(host='bora-corp.com', port=443",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,Developing & Manufacturing high quality biologics,https://www.linkedin.com/company/eden-biologics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
oncoquest inc,No timestamp found,No,IMNN-001; Elahere; Stenoparib; Oregovomab,"FRα, Folate Receptor Alpha; CA-125, Cancer Antigen 125; PARP 1 and 2, Poly ADP-Ribose Polymerases; Tankyrase 1 and 2, Telomerase Maintenance Enzymes",oncology,immune checkpoint; other; enzyme,Phase 3; Phase 2,No,,,No,,,No,,,Yes,cancer immunotherapy company,https://www.newswire.ca/news/oncoquest-inc./,No,,,No,,,No,,,No,,,No,,,No,,,No,,
metacrine inc,2019-10-18 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"proprietary library of over 2,500 FXR compounds",https://www.linkedin.com/company/metacrine-inc.,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vir biotechnology inc,2025-10-17 15:55:07,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,next-generation antibody platform,https://www.linkedin.com/company/vir-biotechnology-inc.,No,,,No,,,No,,,No,,,No,,,No,,,Yes,dual-masked T-cell engagers #TCEs,https://www.linkedin.com/company/vir-biotechnology-inc.
ascentage pharma group international,2025-10-17 00:00:00,Yes,Olverembatinib; Lisaftoclax; APG-2449; APG-5918; AS03157,"BCR-ABL, Breakpoint Cluster Region-Abelson Tyrosine Kinase; BCL-2, B-cell Lymphoma 2; FAK, Focal Adhesion Kinase; ALK, Anaplastic Lymphoma Kinase; ROS1, ROS Proto-Oncogene 1; EED, Embryonic Ectoderm Development Protein; IAP, Inhibitor of Apoptosis Proteins",oncology; hematological malignancies,kinases; enzyme; other,Preclinical,Yes,small molecule therapies,https://www.linkedin.com/company/ascentage-pharma-group-corporation,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
acumen pharmaceuticals inc,2025-10-16 14:30:08,Yes,sabirnetug; ACU193,"AβO, Amyloid Beta Oligomers",CNS; neurodegenerative diseases,other,Phase 2,No,,,No,,,No,,,Yes,monoclonal antibody that selectively targets toxic soluble AβOs,https://acumenpharm.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cti biopharma corp,2021-09-25 00:00:00,No,Pacritinib; PIXUVRI,"JAK2, Janus Kinase 2; FLT3, Fms-like Tyrosine Kinase 3; IRAK1, Interleukin-1 Receptor-Associated Kinase 1; CSF1R, Colony Stimulating Factor 1 Receptor",oncology; hematology,kinases,Phase 3,Yes,investigational oral kinase inhibitor,https://stockanalysis.com/stocks/ctic/company/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
poxel sa,2025-06-20 13:56:36,Yes,Imeglimin; PXL770,Mitochondrial Dysfunction,metabolic diseases,other,Phase 2,Yes,"Imeglimin, PXL770, PXL065",https://www.linkedin.com/company/poxel,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cybin inc,2025-10-16 13:07:08,Yes,CYB003; CYB004; CYB005,"5-HT2A, Serotonin 2A Receptor",Major Depressive Disorder; Generalized Anxiety Disorder; CNS Disorders,gpcr,Phase 3; Phase 2; Preclinical,Yes,"innovative molecules, optimized delivery",https://ca.linkedin.com/company/cybin,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"psychedelic therapeutics, tryptamine-based therapies",https://cybin.com/
cybin therapeutics inc,2025-10-16 13:07:08,Yes,CYB003; CYB004; CYB005,"5-HT2A, Serotonin 2A receptor",CNS; mental health disorders; major depressive disorder; generalized anxiety disorder,gpcr,Phase 3,Yes,novel molecules with controllable drug delivery systems through our proprietary deuterated process,https://cybin.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"psychedelic therapeutics space with innovative molecules, optimized delivery, and a best-in-class intellectual property portfolio",https://ca.linkedin.com/company/cybin
coherus biosciences inc,2025-10-16 19:38:45,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,"CHS-114, our highly selective cytolytic anti-CCR8 mAb",https://www.linkedin.com/company/coherus-oncology,No,,,No,,,No,,,No,,,No,,,No,,,No,,
coherus oncology inc,2025-10-16 19:38:45,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,CHS-114 is a highly selective cytolytic CCR8 antibody,https://www.globenewswire.com/news-release/2025/05/30/3091025/33333/en/Coherus-Completes-Strategic-Transformation-to-Coherus-Oncology-Focusing-Exclusively-on-Innovative-Cancer-Therapeutics.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
